patents

advertisement
5/2005
‫התשס"ה‬/'‫י"א‬
‫רשומות‬
ISRAEL STATE RECORDS
‫כ"ו באב התשס"ה‬
August 31, 2005
‫יומן הפטנטים והמדגמים‬
PATENTS AND DESIGNS JOURNAL
PATENTS
Applications accepted
Patents granted
Patents renewed
Patents not in force due to
non-payment of renewal fees
Patents renewed for 20 years
Patents expired
Patent extension
‫עמוד‬
Page
940
000
000
000
000
000
000
‫פטנטים‬
‫בקשות שקובלו‬
‫פטנטים שניתנו‬
‫פטנטים שחודשו‬
‫פטנטים שתוקפם פקעו בגלל אי תשלום‬
‫אגרת חידוש‬
‫פטנטים שחודשו לעשרים שנה‬
‫פטנטים שפג תוקפם‬
‫ארכת פטנט‬
Changes in particulars entered
in register
Notices
000
000
‫שינויים בפרטים רשומים‬
‫בפנקס‬
‫הודעות‬
Country codes
Indices of applications accepted
000
i
‫קודים למדינות‬
‫מפתחות לבקשות שקובלו‬
DESIGNS
Designs registered
Designs renewed
Designs void
000
000
000
‫מדגמים‬
‫מדגמים שנרשמו‬
‫מדגמים שחודשו‬
‫מדגמים שבוטלו‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
938
‫ידיעות כלליות‬
:‫ וכו' בענייני פטנטים ומדגמים יש לשלוח אל‬,‫ מסמכים‬,‫מכתבים‬
‫ ירושלים‬,4 ‫ רח' הסדנא‬,‫רשם הפטנטים והמדגמים‬
‫ ירושלים והיא פתוחה לציבור בימי חול‬,‫ תלפיות‬,4 ‫לשכת הפטנטים נמצאת ברח' הסדנא‬
.12:30 -‫ ו‬8:30 ‫שאינם ערבי שבת או מועד בין השעות‬
‫ שקלים בעד כל‬2.50 ‫לשכת הפטנטים מספקת תצלומים של פירוטים ושרטוטים במחיר של‬
.‫עמוד או חלק ממנו‬
'‫אגרות ללשכת הפטנטים מתקבלות אך ורק על ידי תשלום לחשבון הלשכה בבנק הדואר מס‬
‫ יש להציג קבלת בנק הדואר ללשכה יחד עם הבקשה לפעולה שעבורה האגרה‬.0-24145-2
.‫שולמה‬
GENERAL INFORMATION
Letters, documents, etc. concerning Patents and Designs should be addressed to:
The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem
The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on
weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.
The Patent Office supplies photocopies of specifications and drawings at the rate of NIS 2.50
per page or part thereof.
Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the
Office, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together
with the application for the action for which the fee has been paid.
Copyright by the State of Israel. No
Extracts may be published except with the
permission of the Patent Office.
‫זכות היוצרים בתקצירים אלה שמורה‬
‫ אין להעתיק מתקצירים‬,‫למדינת ישראל‬
.‫אלה אלא ברשות לשכת הפטנטים‬
Price per single issue (incl. VAT) : NIS 96.
.₪ 96 ).‫מ‬.‫ע‬.‫ לכל חוברת בודדת (כולל מ‬:‫מחיר‬
Annual subscription (incl. VAT):
NIS 1,152.
Available at the Distribution Service of
Government Publications, 29 B-Street,
Hakirya, Tel-Aviv.
939
.₪ 1,152 ).‫מ‬.‫ע‬.‫דמי חתימה לשנה (כולל מ‬
:‫אפשר להשיג אצל‬
'‫ רחוב ב‬,‫שרות ההפצה של פרסומי הממשלה‬
.‫אביב‬-‫ תל‬,‫ הקריה‬,29 '‫מס‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
NOTICE UNDER SECTION 26 OF THE
PATENTS LAW, 5727-1967
The applications, particulars of which are set
out below, have been accepted pursuant to
Section 17 of the Patents Law. Any person
wishing to oppose the grant of a patent on any
of the applications published here, may,
within three months from the date of this
journal, give to the Commissioner of Patents
notice under Section 30 of the Patents Law, in
the manner prescribed in regulations 57 et seq
of the Patents Regulations, 5728-1968
Particulars of the applications, where
applicable, are given in the following order:
[11] [21] Number of application
[54] Title of invention
[22] Application date
[31] [32] [33] Number and date of foreign
application – convention country.
*[51] Int.Cl.
[61] Application for patent of addition
[62] Divisional application
[71] Applicant
[72] Inventor
[87] International Publication Number
[74] Address for service
[57] Abridgement of invention (in the
language in which the specification is
drawn up)
*Note: As from Patents and Designs Journal
No.4/00, patent applications are classified
according to the Seventh Edition of the
International Patent Classification (1999)
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫ לחוק הפטנטים‬26 ‫הודעה לפי סעיף‬
1976 – ‫תשכ"ז‬
‫הבקשות שפרטיהן מתפרסמים להלן קובלו‬
‫ כל המעונין‬.‫ לחוק הפטנטים‬17 ‫לפי סעיף‬
‫להתנגד למתן פטנט על פי בקשה מהבקשות‬
‫ תוך שלושה חדשים‬,‫המתפרסמות רשאי‬
‫ להגיש לרשם הפטנטים‬,‫מתאריך יומן זה‬
‫ לחוק‬30 ‫הודעת התנגדות לפי סעיף‬
‫ ואילך‬57 ‫הפטנטים בדרך הקבועה בתקנה‬
.1968 – ‫ תשכ"ח‬,‫לתקנות הפטנטים‬
‫פרטי הבקשות במידה ויישימים מובאים לפי‬
:‫סדר זה‬
‫מספר הבקשה‬
‫שם האמצאה‬
‫תאריך הבקשה‬
‫מספר ותאריך של בקשות החוץ – מדינת‬
‫האגוד‬
‫*סיווג בינלאומי – מהדורה שביעית‬
‫בקשה לפטנט מוסף‬
‫בקשת חלוקה‬
‫המבקש‬
‫הממציא‬
‫מס' פרסום של בקשה הבינלאומית‬
‫מען למסירת מסמכים‬
)‫תקציר האמצאה (בשפה בה ערוך הפירוט‬
'‫ החל מיומן הפטנטים והמדגמים מס‬:‫*הערה‬
‫ ניתן ציון לבקשות פטנטים הסיווג לפי‬4/00
‫המהדורה השביעית של הסיווג הבינלאומי‬
)1999 ‫של פטנטים (משנה‬
940
[11] [21] 97602
‫ייצור חברים פעילים ביולוגית ורקומביננטים‬
‫של משפחת חלבונים הנוירוטרופיים‬
NGF/BDNF
[54]
PRODUCTION OF
BIOLOGICALLY ACTIVE,
RECOMBINANT MEMBERS OF
THE NGF/BDNF FAMILY OF
NEUROTROPHIC PROTEINS
[22]
[31]
19.3.1991
505441
[32] 6.4.1990
[33] US
547750
2.7.1990
"
594126
9.10.1990
"
Int. Cl.7 C12N 15/12; C07K 14/48; C12P 21/02; A61K 38/18
Amgen Inc., Thousand Oaks, Calif.,
U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[51]
[71]
[74]
[57] A method for producing the mature
biologically active form of a human
neurotrophic protein in a prokaryotic cell
expression system, wherein said
neurotrophic protein is selected from the
NGF/BDNF family of neurotrophic factors
said method comprises:
(i) inserting the gene coding for said
mature protein into a vector;
(ii) expressing said gene to form a
biologically inactive form of said protein;
and
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
(iii) refolding and renaturing said
biologically inactive form in a reaction
medium created by the steps comprised of:
disrupting all intramolecular and intermolecular disulfide bonds in a solution of
said neurotrophic protein by adding a
denaturant and a reducing agent to said
solution and forming free thiols; oxidizing
said free thiols with a disulfide containing
compound to form mixed disulfide bonds
without removing the reducing agent; and
diluting said solution in the presence of a
thiol containing compound.
__________
941
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 106949
[54]
DEVELOPMENT OF
XENOGENEIC CYTOTOXIC T
LYMPHOCYTES IN NONHUMAN MAMMALS
[22]
[31]
[51]
[61]
[71]
8.9.1993
061706
[32] 17.5.1993
Int. Cl.7 A61K 48/00; C12N 5/06
Addition to 93067
Yeda Research and Development
Company Limited, Rehovot
Yair Reisner
XTL Biopharmaceuticals Ltd.,
P.O.B. 370, Rehovot
‫פיתוח של לימפוציטים ציטוטוקסיים זרים‬
‫ביונקים לא אנושיים‬
[33] US
‫ רחובות‬,‫ידע חברה למחקר ופתוח בע"מ‬
‫יאיר רייזנר‬
,‫אקס טי אל ביופרמסיוטיקלס בע"מ‬
‫ רחובות‬,370 .‫ד‬.‫ת‬
[57] Method for providing human or
therapeutic effect against said pathology
other mammalian cytotoxic T lymphocytes
by lysing said pathological cells or tissue,
against a pathogenic antigen comprising:
and wherein said mammal M4, is a
(a) immunizing a chimeric non-human
mammal M1, the hematopoietic cells of
mammal M4 having xenogeneic cytotoxic
which have been substantially destroyed,
T lymphocyte precursor cells or tissue,
said mammal M1 having transplanted
with pathological cells, tissue or
therein cells or tissue from at least two
components thereof presenting an antigen
different sources, at least one of said
capable of eliciting said cytotoxic T cells
sources being hematopoietic cells derived
in recoverable amounts in said mammal
from a mammal M2 having a
M4, and optionally further comprising,
hematopoietic deficiency, and at least a
(b) recovering said cytotoxic T
second of said sources being hematopoietic
lymphocytes from the immunized mammal
cells or tissue from a mammal M3 of a
M4, wherein the recovered cytotoxic T
species other than that of mammals M1
lymphocytes are capable of providing a
and M2.
__________
[72]
[74]
August 31, 2005– ‫כ"ו באב התשס"ה‬
942
[11] [21] 108007
(INF-γ) ‫גמה‬-‫שימוש במעכב אינטרפרון‬
‫בהכנת תרופה לטיפול במחלת דלקת המעי‬
[54]
USE OF AN INTERFERONGAMMA (IFN- γ) INHIBITOR IN
THE PREPARATION OF A
MEDICAMENT FOR
TREATMENT OF
INFLAMMATORY BOWEL
DISEASE
[22]
[31]
[51]
[71]
13.12.1993
997835
[32] 29.12.1992
[33] US
Int. Cl.7 A61K 38/00; A61P 1/00 // C07K 2/00, 14/57, 16/00, 19/00
Genentech, Inc., South San Francisco,
Calif., U.S.A.
S. Horowitz & Co.,
,'‫ הורוביץ ושות‬.‫ש‬
P.O.B. 2499, Tel-Aviv
‫אביב‬-‫ תל‬,2499 .‫ד‬.‫ת‬
[74]
[57] Use of an interferon-gamma (IFN- γ)
inhibits the binding of native IFN- γ to its
inhibitor in the preparation of a
native receptor, substantially as described
medicament for treatment of inflammatory
in the specification.
bowel disease, wherein the inhibitor
__________
[11] [21] 108779
‫פוליריבוזים המסוגל להקנות עמידות‬
‫ וצמחים בעלי עמידות‬,‫ווירלית לצמתים‬
‫המייצרים אותו ריבוזים‬
[54]
POLYRIBOZYME CAPABLE OF
CONFERRING VIRAL
RESISTANCE TO PLANTS, AND
RESISTANT PLANTS
PRODUCING SAID RIBOZYME
[22]
[31]
[51]
[71]
27. 2.1994
9302269
[32] 26. 2.1993
[33] FR
Int. Cl.7 C12N 15/11, 15/33, 9/22, 5/10; A01H 1/00, 3/00, 5/00
Gene Shears Pty. Limited, Canberra,
ACT, Australia
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[74]
[57] Polyribozyme having
endoribonuclease activity and being
capable of inactivating the capsid protein
gene of a virus, wherein said polyribozyme
comprises a plurality of ribozymes, each of
943
which cleaves the said capsid protein gene
or the corresponding transcript of the said
capsid protein gene, or its replication
intermediate of the said capsid protein
gene, each ribozyme comprising a catalytic
August 31, 2005– ‫כ"ו באב התשס"ה‬
portion and hybridizing arms, wherein the
portion of the capsid protein gene.
hybridizing arms are complementary to a
__________
[11] [21] 109382
‫שיטה מחוץ לגוף להכנסתם של גנים‬
‫הטרולוגיים‬
[54]
IN VITRO METHOD FOR
INSERTING A HETEROLOGOUS
GENE
[22]
[31]
21.4.1994
9308271.7
[32] 21. 4.1993
[33] GB
9313323.9
28.6.1993
"
9401011.3
20.1.1994
"
Int. Cl.7 C12N 15/10, 15/12, 5/16; A01K 67/027
The University of Edinburgh,
Edinburgh, Scotland
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[51]
[71]
[74]
[57] In vitro method of inserting a
heterologous gene coding sequence into a
target endogenous gene in a eukaryotic
cellular host cell genome and expressing
said heterologous gene coding sequence,
by transforming the host cell with a vector
comprising a DNA construct, characterized
in that the DNA construct comprises the
sequence:
5' X-A-PA-B-Q-C-Y 3'
in which
X and Y are substantially homologous
with separate sequences from the target
endogenous gene and are of sufficient
length to undergo homologous
recombination with the host cell genome
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
so as to insert the A-P-B-Q-C sequence
into the host cell genome;
P is an internal ribosome entry site (IRES);
Q is the heterologous gene coding
sequence and encodes a first polypeptide
other than a selectable marker and,
optionally, a second polypeptide which is a
selectable marker; and
A, B and C are, separately, optionally
linker sequences, wherein the construct
inserts the heterologous gene coding
sequence into or in place of the target
endogenous gene so that transcription of
the heterologous gene coding sequence is
directed by the host regulatory elements
for the target endogenous gene.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
944
[11] [21] 109991
‫מקטע דנ"א המכיל אגד גנים המקודדים‬
‫לקומפלקס של דהידרוגנזה של חומצות‬
‫קטו בלעות שרשרת מסועפת‬-‫אלפא‬
‫מסטרפטומייסס אוורמטיליס‬
[54]
DNA SEQUENCE COMPRISING
A GENE CLUSTER ENCODING
BRANCHED CHAIN ALPHAKETOACID DEHYDROGENASE
COMPLEX FROM
STREPTOMYCES AVERMITILIS
[22]
[31]
[51]
[71]
[74]
13. 6.1994
168602
[32] 16. 12.1993
[33] US
Int. Cl.7 C12N 15/53, 15/76, 1/21, 9/02; C12P 19/62; // C12N 9/02; C12R 1:465
Pfizer, Inc., New York, N.Y., U.S.A.
Luzzatto & Luzzatto,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352, Beersheba
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] An isolated DNA segment
comprising a gene cluster encoding the
branched alpha-ketoacid dehydrogenase
complex of Streptomyces avermitilis,
wherein said DNA segment comprises the
DNA sequence of SEQ ID No. 1, SEQ ID
No. 2, SEQ ID No. 3, or SEQ ID No. 4.
__________
[11] [21] 110430
[54]
DNA SEQUENCE COMPRISING
A GENE CLUSTER ENCODING
BRANCHED CHAIN ALPHAKETOACID DEHYDROGENASE
COMPLEX FROM
STREPTOMYCES AVERMITILIS
‫מקטע דנ"א המכיל אגד גנים המקודדים של‬
‫קטו בעלות‬-‫הידרוגנזה של חומצות אלפא‬
‫שרשרת מסועפת מסטרפטומייסס‬
‫אוורמטיליס‬
[22]
[31]
[51]
[71]
[74]
25. 7.1994
100518
[32] 30. 7.1993
[33] US
Int. Cl.7 C12N 15/53, 15/76, 1/21, 9/02; C12 P 19/62; // C12N 9/02; C12R 1/465
Pfizer, Inc., New York, N.Y., U.S.A.
Luzzatto & Luzzatto,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352, Beersheba
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] An isolated DNA segment
avermitilis, wherein said DNA segment
comprising the bkd cluster coding for
comprises the DNA sequence of SEQ ID
branched-chain alpha-ketoacid
No. 1, SEQ ID No. 2, SEQ ID No. 3, or
dehydrogenase complex of a Streptomyces
SEQ ID No. 4 or SEQ ID No. 5.
__________
945
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 111482
[54]
[22]
[31]
[51]
[71]
[74]
ASPERGILLUS NIGER
ASPARTIC PROTEASE
1. 11.1994
93810764.6
[32] 3. 11.1993
K61Int. Cl.7 C12N 15/57, 9/60, 1/14
Novartis AG, Basle, Switzerland
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
‫פרוטאזה אספרטית של אספרגילוס נייגר‬
[33] EP
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] An aspergillus niger strain deficient
protease having the same aspartic protease
in an aspergillus niger aspartic protease
activity as the amino acid sequence shown
gene encoding an aspergillus niger aspartic
in SEQ.ID No.2.
__________
[11] [21] 112261
MoMLV ‫ריבוזימים המכוונים לרצף האריזה‬
HIV ‫ של‬TAT ‫ ולרצף‬PSI
[54]
RIBOZYMES TARGETING THE
MoMLV PSI PACKAGING
SEQUENCE AND THE HIV TAT
SEQUENCE
[22]
[31]
5. 1.1995
178082
[32] 5. 1.1994
[33] US
310259
21.9.1994
"
Int. Cl.7 C12N 5/10, 15/86, 15/11
Gene Shears Pty. Limited, Neutral Bay,
NSW, Australia
S. Horowitz & Co.,
P.O.B. 2499, Tel-Aviv
[51]
[71]
[74]
[57] A cell comprising a viral vector
producing a non-naturally occurring RNA
compound which comprises nucleotides
whose sequence defines a catalytic region
and nucleotides whose sequence comprises
sequences complementary to both a first
nucleotide sequence directly 3' and a
second nucleotide sequence 5' of a target
site in a target molecule of a MoMLV or a
,'‫ הורוביץ ושות‬.‫ש‬
‫אביב‬-‫ תל‬,2499 .‫ד‬.‫ת‬
HIV RNA virus, wherein the target site
comprises three nucleotides of which the 5'
nucleotide is selected form the group
consisting of nucleotide numbers 274 and
366 of the MoMLV packaging sequence,
and nucleotide number 5849 of the HIV tat
gene, wherein the non-naturally occurring
RNA compound inactivates the target
molecule in the cell.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
946
[11] [21] 112327
‫ עמידה‬E3 ‫ המקודד לאסטרזה‬DNA ‫רצף‬
‫ עמידה‬E3 ‫ אסטרזה‬,‫לאורגנופוספטים‬
,‫לאורגנופוספטים המקודדת על ידו‬
‫ושימושיהם‬
[54]
DNA SEQUENCE ENCODING AN
ORGANOPHOSPHATERESISTANT E3 ESTERASE, AN
ORGANOPHOSPHATERESISTANT E3 ESTERASE
ENCODED THEREBY AND USES
THEREOF
[22]
[31]
[51]
[71]
12. 1.1995
PM3347
[32] 13. 1.1994
[33] AU
Int. Cl.7 C12N 15/55, 9/16, 1/21; C12Q 1/44, 1/68
Commonwealth Scientific and
Industrial Research Organisation,
Campbell, ACT, Australia
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[74]
[57] An isolated and purified
organophosphate (OP)-resistant E3
esterase having the amino acid sequence
L103con shown in Table 1 as given in the
specification or a homolog thereof,
wherein said OP-resistant E3 esterase has a
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
substitution of the amino acid
corresponding to the glycine residue at
position 137 of the OP-sensitive E3
esterase from Lucilia cuprina having the
amino acid sequence Lc743 shown in
Table 1.
__________
[11] [21] 112329
DNA ‫ רציפי‬,‫איזומרזים של סוכרוזה‬
‫המקודדים עבורם ותהליכים להכנת סוכרים‬
‫ המשתמשים בהם‬,‫שאינם גורמים לעששת‬
[54]
SUCROSE ISOMERASES, DNA
SEQUENCES CODING
THEREFOR AND PROCESSES
FOR THE PREPARATION OF
NON-CARIOGENIC SUGARS
UTILIZING THE SAME
[22]
[31]
13. 1.1995
P4401451.1
[32] 19. 1.1994
[33] DE
P4414185.8
22.4.1994
"
Int. Cl.7 C12N 15/61, 9/90, 15/63, 1/21; C12P 19/24
Sudzucker Aktiengesellschaft,
Mannheim, Germany
[51]
[71]
947
August 31, 2005– ‫כ"ו באב התשס"ה‬
[74]
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[57] DNA sequence characterized in that it
codes for a protein with sucrose isomerase
activity that isomerizes that α-1→β-2
glycosidic linkage between the
monosaccharide units of sucrose to an α-1→6 linkage under the formation of
palantinose or to a α-1-→ α-1 linkage
under the formation of trehalulose, and
comprises:
(a) one of the nucleotide sequences shown
in SEQ ID NO. 1, SEQ ID NO 2, SEQ ID
NO. 3, SEQ ID NO. 9, SEQ ID NO. 11 or
SEQ ID NO. 13, where appropriate
without the signal peptide-coding region,
or
(b) a nucleotide sequence corresponding to
the sequences from (a) within the scope of
the degeneracy of the genetic code.
__________
[11] [21] 114566
‫תכשירים המכילים חומצות גרעין ופולימר‬
‫קטיוני ושימושיהם‬
[54]
COMPOSITIONS CONTAINING
NUCLEIC ACIDS AND
CATIONIC POLYMER AND
THEIR USES
[22]
[31]
[51]
[71]
[74]
12. 7.1995
9408735
[32] 13. 7.1994
[33] FR
Int. Cl.7 C07H 21/00; C08G 73/04; C12N 15/87; A61K 9/127, 47/34, 48/00
Aventis Pharma, Antony, France
Luzzatto & Luzzatto,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352, Beersheba
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] A composition comprising at least
one nucleic acid and a cationic polymer of
the formula:
in which
R is a hydrogen atom or a group of the formula
August 31, 2005– ‫כ"ו באב התשס"ה‬
948
wherein the R group is attached at the
(CH2) end to the N atom in the main
formula;
n is an integer between 2 and 10;
p and q are integers,
wherein the sum of p+q is such that the
average molecular weight of the polymer
is between 100 and 107.
__________
[11] [21] 114655
‫ ביצור תרופה‬GnRH‫שימוש באנטגוניסט ה‬
‫לטיפול במצב התלוי בסטרואיד גונדתי ביונק‬
[54]
USE OF GnRH ANTAGONIST IN
THE MANUFACTURE OF A
MEDICAMENT FOR THE
TREATMENT OF A GONADALSTEROID DEPENDENT
CONDITION IN A MAMMAL
[22]
[31]
18. 7.1995
279593
[32] 22. 7.1994
[33] US
467860
6.6.1995
"
Int. Cl.7 A61K 38/00; A61P 5/24 // C07K 7/23
The Medical College of Hampton
Roads, Norfolk, Va. and Ortho
Pharmaceutical Corporation, Raritan,
N.J., both of U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[51]
[71]
[74]
[57] Use of a GnRH antagonist in the
manufacture of a medicament for the
treatment of a gonadal-steroid dependent
condition in a mammal, wherein said
medicament, when administered in amount
effective to inhibit proliferation of
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
endometrial tissue without substantially
stopping the production of endogenous
estrogen, is effective to reduce the estrogen
supply in said mammal, substantially as
described in the specification.
__________
949
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 115047
‫סוכר של‬-‫תצמידים חיסוניים המכילים רב‬
,‫פנוימוקוקוס ופנוימוליסין רקומבינטי‬
‫חיסונים המכילים תצמידים כאלה ושימוש‬
‫בחיסונים כאלה ביצור תרופות לחיסון כנגד‬
‫דלקות פנוימוקוקוס‬
[54]
IMMUNOGENIC CONJUGATES
COMPRISING PNEUMOCOCCAL
POLYSACCHARIDE AND
RECOMBINANT PNEUMOLYSIN,
VACCINES COMPRISING SUCH
CONJUGATES AND USE OF
SUCH VACCINES IN THE
MANUFACTURE OF
MEDICAMENTS FOR
IMMUNIZING AGAINST
PNEUMOCOCCAL INFECTIONS
[22]
[31]
[51]
[71]
23. 8.1995
295305
[32] 24. 8.1994
[33] US
Int. Cl.7 C07K 19/00, 14/315; A61K 39/09
Wyeth Holdings Corporation, Madison,
N.J., U.S.A.
S. Horowitz & Co.,
P.O.B. 2499, Tel-Aviv
[74]
[57] An immunogenic polysaccharideprotein conjugate comprising (a) an
oxidized polysaccharide derived from the
capsular polysaccharide of streptococcal
pneumoniae (S. pneumoniae), and (b) the
pneumolysin protein of S. pneumoniae
,'‫ הורוביץ ושות‬.‫ש‬
‫אביב‬-‫ תל‬,2499 .‫ד‬.‫ת‬
which is expressed recombinantly, where
said pneumolysin is not toxoided or is not
produced by site-specific mutagenesis
prior to conjugation with said oxidized
polysaccharide.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
950
[11] [21] 115473
‫תכשירי רוקחות ותרכובות לעיכוב שגשוג‬
‫ שימוש של תרכובות כאלה‬,‫תאי גבעול‬
‫ ושיטות במבחנה‬,‫בייצור תרופות לשם זה‬
‫לטפל במוח עצמות ולהכין תאים‬
‫הימטופואטיים לרפואה‬
[54]
PHARMACEUTICAL
COMPOSITIONS AND
COMPOUNDS FOR INHIBITION
OF STEM CELL
PROLIFERATION, USE OF SUCH
COMPOUNDS IN THE
MANUFACTURE OF
MEDICAMENTS FOR THIS
PURPOSE, AND IN VITRO
METHODS FOR TREATING
BONE MARROW AND FOR
PREPARING HEMATOPOIETIC
CELLS FOR THERAPY
[22]
[31]
29. 9.1995
316424
[32] 30. 9.1994
[33] US
535882
28.9.1995
"
Int. Cl.7 A61K 38/02, 38/04, 38/12, 38/41, 38/42; A61P 35/00, 35/02, 37/00; C07K
2/00, 7/08, 7/64, 14/47, 14/795, 14/805
Addition to 109177
Pro-Neuron, Inc., Gaithersburg, Md.,
U.S.A.
Jeremy M. Ben-David & Co. Ltd.,
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
P.O.B. 45087, Jerusalem
‫ ירושלים‬,45087 .‫ד‬.‫ת‬
[51]
[61]
[71]
[74]
[57] Pharmaceutical composition, for use
in the inhibition of stem cell proliferation,
which comprises at least one
pharmaceutically acceptable diluent,
preservative, solubilizer, emulsifier,
adjuvant, and/or carrier, and at least one
active ingredient selected from substances
(i), (ii), (iii) and (iv):
(i) at least one compound possessing a
combination of the properties: (a) specific
activity (IC50) ≤20 ng/ml in a murine CFUS assay; (b) a molecular weight from
951
14,000 daltons to 17,000 daltons by SDSpolyacrylamide gel electrophoresis;
(c) activity sensitive to degradation by
trypsin; (d) more hydrophobicity than
either MP1α or TGFβ and separable from
both by reverse phase chromatography; (e)
biological activity retained after heating
one hour at 37oC, 55oC or 75oC in aqueous
solution; (f) biological activity retained
after precipitation with 1% hydrochloric
acid in acetone; and (g) a capacity to
August 31, 2005– ‫כ"ו באב התשס"ה‬
achieve inhibition in an in vitro
proliferation assay after a short preincubation period;
(ii) at least one member of the group
consisting of hemoglobin, a polypeptide
selected from the α-, β-, γ-, δ-, ε- and ζchains of hemoglobin, and a dimer
comprising two polypeptides selected from
the α-, β-, γ-, δ-, ε- and ζ- chains of
hemoglobin;
(iii) at least one member of the group
consisting of:
a peptide having the sequence Phe-Pro-
having the sequence Asp-Ala-Leu-ThrAsn-Ala-Val-Ala-His-Val-Asp-Asp-MetPro-Asn-Ala-Leu-Ser-Ala;
(iv) at least one member of the group
consisting of hemorphin peptides having
the sequence:
Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-ArgPhe,
Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg,
Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln,
Leu-Val-Val-Tyr-Pro-Trp-Thr,
Leu-Val-Val-Tyr-Pro-Trp,
Leu-Val-Val-Tyr-Pro,
Val-Val-Tyr-Pro-Trp-Thr-Gln,
Tyr-Pro-Trp-Thr-Gln-Arg-Phe,
Tyr-Pro-Trp-Thr-Gln-Arg,
Tyr-Pro-Trp-Thr-Gln, and
Tyr-Pro-Trp-Thr.
His-Phe-Asp-Leu-Ser-His-Gly-SerAla-Gln-Val;
a cyclic peptide having the sequence CysPhe-Pro-His-Phe-Asp-Leu-Ser-His-GlySer-Ala-Gln-Val-Cys where the two Cys
residues form a disulfide bond; a peptide
__________
[11] [21] 116026
‫ של‬SH3-‫פפטידים המתחברים לאיזור ה‬
‫ רצפי נוקליאוטידים המקדדים‬,GAP ‫החלבון‬
‫ הכנתם ושמושיהם‬,‫להם‬
[54]
PEPTIDES CAPABLE OF
LINKING TO THE SH3 DOMAIN
OF GAP, NUCLEOTIDE
SEQUENCES ENCODING THE
SAME, THEIR PREPARATION
AND USES
[22]
[31]
16. 11.1995
9413955
[32] 22. 11.1994
[33] FR
9505753
16.5.1995
"
Int. Cl.7 C12N 15/12; C07K 14/47; A61K 38/17; A61P 35/00; C12Q 1/68
Rhone Poulenc Rorer S.A., Antony,
France
Luzzatto & Luzzatto,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352, Beersheba
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[51]
[71]
[74]
[57] Polypeptide capable of interacting
with the SH3 domain of the GTP aseactivating protein (GAP protein) which
polypeptide comprises an amino acid
sequence selected from the sequence
shown in SEQ ID No. 1, SEQ ID No. 2,
SEQ ID No. 3, SEQ ID No. 4, SEQ ID No.
5 and SEQ ID No. 9; or a derivative
thereof that is capable of interacting with
the SH3 domain of the GAP protein.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
952
[11] [21] 117645
‫דם‬-‫נוגדי גורם גדילה של תאי דופן של כלי‬
‫לשימוש כתרופה לטיפול בהתנוונות של‬
‫עור הקשורה לזקנה‬-‫כתמי‬
[54]
VASCULAR ENDOTHELIAL
CELL GROWTH FACTOR
ANTAGONISTS FOR USE AS
MEDICAMENTS IN THE
TREATMENT OF AGE-RELATED
MACULAR DEGENERATION
[22]
[31]
[51]
[71]
25. 3.1996
413305
[32] 30. 3.1995
[33] US
Int. Cl.7 A61K 38/18, 39/395; A61P 37/02
Genentech, Inc., South San Francisco,
Calif., U.S.A.
S. Horowitz & Co.,
P.O.B. 2499, Tel-Aviv
[74]
[57] Therapeutically effective amount of
hVEGF antagonist for use as a
,'‫ הורוביץ ושות‬.‫ש‬
‫אביב‬-‫ תל‬,2499 .‫ד‬.‫ת‬
medicament in the treatment of age-related
macular degeneration.
__________
[11] [21] 118890
‫ שיטה‬,‫ מוטאנטיות‬CTLA4 ‫מולקולות‬
‫להכנתן ושימושים בהן‬
[54]
CTLA4 MUTANT MOLECULES,
METHOD FOR THEIR
PREPARATION AND USES
THEREOF
[22]
[31]
[51]
[71]
18. 7.1996
505058
[32] 21. 7.1995
[33] US
Int. Cl.7 C07K 14/705; C12N 15/12, 15/85, 5/10; A61K 38/17; A61P 37/00, 37/06
Bristol-Myers Squibb Company, New
York, N.Y., U.S.A.
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[74]
953
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] CTLA4 mutant molecule reactive
with the CD80 antigen, wherein in an
extracellular domain of CTLA4 the first
tyrosine in the amino acid motif MYPPPY
is replaced by an amino acid other that
tyrosine or alanine.
__________
[11] [21] 119422
‫שיטה והתקן לפענוח אות מוצפן‬
[54]
METHOD AND APPARATUS FOR
DECODING AN ENCODED
SIGNAL
[22]
[31]
[51]
[71]
14. 10.1996
581696
[32] 29. 12.1995
[33] US
Int. Cl.7 H04B 7/216; H04L 27/06; H03D 1/00
Motorola, Inc., Schaumburg, Ill.,
U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] An apparatus for decoding an
encoded signal, the encoded signal having
been interleaved by a transmitter, the
apparatus comprising:
(a) a receiver (156) for receiving the
encoded signal and processing the encoded
signal into a form suitable for
deinterleaving;
(b) a deinterleaver (210) coupled to the
receiver, for producing a set of loglikelihood values;
August 31, 2005– ‫כ"ו באב התשס"ה‬
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
(c) a conditional soft decision metric
generator (310) for generating a set of
conditional soft decision metrics from the
set of log-likelihood values;
(d) a bit metric generator (315) for
generating bit metrics from the set of
conditional soft decision metrics based
upon a hard coded symbol value; and
(e) means (320, 325) for decoding the bit
metrics to produce an estimate (in 330) of
the signal before encoding.
954
__________
[11] [21] 119721
[54]
METHOD AND SYSTEM FOR
MONITORING THE
PHYSIOLOGICAL CONDITION
OF A PATIENT
[22]
[51]
[71]
[72]
[74]
29. 11.1996
Int. Cl.7 A61B 5/0205
Mindlife Ltd., Jerusalem
S. Pelz
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[57] A method of monitoring the
physiological condition of a patient's body,
comprising the steps of:
obtaining signals representing the
mechanical activity and movement of the
body from two or more detecting and
sensing means not secured to the body and
spaced apart from each other; removing
signals associated with the movements of
the body from the obtained signals;
separating signals possibly associated with
cardiac and/or respiratory activity from the
955
‫שיטה ומערכת לבקרת מצב פיזיולוגי של‬
‫חולה‬
‫ ירושלים‬,‫מיינדלייף בע"מ‬
‫ פלץ‬.‫ש‬
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
obtained signals; determining propagation
rates of the pulse waves of cardiac and
respiration activities by determining the
shift of the obtained cardiac and
respiration signals; comparing the signals
representing propagation rates with
propagation rate signals obtained from an
earlier measurement of the same body;
removing signals which are not
characteristic of the wave propagation
rates of said body; determining the cardiac
and respiratory rhythm parameters from
August 31, 2005– ‫כ"ו באב התשס"ה‬
the remaining signals; comparing said
storing, displaying and comparing the
parameters with parameters obtained from
separated parameters with parameters
an earlier measurement of the same body,
obtained from said earlier measurements,
as well as with predetermined parameters;
and generating an alarm when one of the
separating and removing parameters which
parameters exceeds a preset range.
differ from said predetermined parameters;
__________
[11] [21] 119840
‫שיטה לניקוי הורמון פאראתירואיד של בני‬
‫אדם‬
[54]
METHOD FOR PURIFYING
HUMAN PARATHYROID
HORMONE
[22]
[31]
[51]
[62]
[71]
11. 5.1992
707114
[32] 23.5.1991
[33] US
Int. Cl.7 C07K 14/635
Divison from 101829
NPS Allelix Corp., Mississauga, Ont.,
Canada
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A method for purifying human
high performance liquid chromatography
parathyroid hormone, which comprises the
in the presence of a cationic ion-pairing
step of fractionating a partially purified
agent.
human PTH preparation by reversed phase
__________
[11] [21] 119938
‫פפטידים המעוררים תנגודת חיסונית להלם‬
‫טוקסי המושרה ע"י אקסוטוקסינים‬
‫ ע"י‬T ‫פירוגניים או סותרים שפעול של תאי‬
‫טוקסינים שכאלה‬
[54]
PEPTIDES CAPABLE OF
ELICITING PROTECTIVE
IMMUNITY AGAINST TOXIC
SHOCK INDUCED BY
PYROGENIC EXOTOXINS OR
OF ANTAGONIZING TOXINMEDIATED ACTIVATION OF T
CELLS
[22]
[51]
[71]
30.12.1996
Int. Cl.7 C07K 14/31, 14/315; 61K 38/16, 39/085; A61P 43/ 00
Yissum Research Development
‫יישום חברה לפיתוח המחקר של‬
company of the Hebrew University of
‫ ירושלים‬,‫האוניברסיטה העברית בירושלים‬
Jerusalem, Jerusalem
Raymond Kaempfer and Gila Arad
‫ריימונד קמפפר וגילה ערד‬
Luzzatto & Luzzatto,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352, Beersheba
[72]
[74]
August 31, 2005– ‫כ"ו באב התשס"ה‬
956
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] Peptide comprising an amino acid
sequence substantially homologous to the
amino acid sequence of a fragment of a
pyrogenic exotoxin, and derivatives of said
peptide, wherein said peptide or derivative
thereof is capable of at least one of
eliciting protective immunity against toxic
shock induced by a pyrogenic exotoxin or
by a mixture of pyrogenic exotoxins and of
antagonizing toxin-mediated activation of
T cells, which fragment of said pyrogenic
exotoxin forms therein a central turn
starting within a β-strand and connecting
it, via an additional short β-strand to an αhelix and does not bind T cell receptor
(TCR) or MHC class II molecules,
provided that said peptide does not have
the amino acid sequence corresponding to
amino acid residues 152-161 of SEB.
__________
[11] [21] 120184
‫תכשירי רוקחות המכילים נגזרות טעונות‬
‫יציבות של אגוניסטים או אנטאגוניסטים של‬
‫סטרואידים למניעת אנגיוגנזה‬
[54]
PHARMACEUTICAL
COMPOSITIONS COMPRISING
PERMANENTLY CHARGED
DERIVATIVES OF STEROID
AGONISTS OR ANTAGONISTS
FOR PREVENTING
ANGIOGENESIS
[22]
[51]
[71]
[72]
[74]
9. 2.1997
Int. Cl.7 C07C 215/28, 217/30, 317/14; A61K 31/095, 31/13 A61P 43/ 00
Pharmos Ltd., Rehovot
‫ רחובות‬,‫פארמוס בע"מ‬
Anat Beigon and Marcus E. Brewster
‫ ברוסטר‬.‫ענת ביאגון ומרכוס א‬
Dr. Cynthia Webb,
,‫ד"ר סינתיה וב‬
P.O.B 2189, Rehovot
‫ רחובות‬,2189 .‫ד‬.‫ת‬
[57] A pharmaceutical composition for
treating or reducing angiogenesis
comprising as an active ingredient a
957
therapeutically effective quantity of a
compound of the formula
August 31, 2005– ‫כ"ו באב התשס"ה‬
wherein:
Y is any non-toxic pharmaceutically
acceptable anion;
DRUG is a radical selected from the group
consisting of a steroid agonist or
antagonist, a mixed agonist-antagonist, and
a partial agonist and does not include a
triphenyl ethyl or triphenyl ethylene
moiety in which the ethyl or ethylene
moieties are not additionally substituted;
X is a direct bond or a radical selected
from the group consisting of -O-; -NH-; NR-, wherein R is an alkyl or aryl with
less than ten carbons; -PO3-; -S-; -SO-; and
–SO2-;
R1 and R2 are the same or different and
may be a radical selected from the group
consisting of H, an alkyl of 1-10 carbon
atoms, an arylalkyl of 7-16 carbons, and an
aryl; R3, R4 and R5 are independently a
radical selected from the group consisting
of a branched or unbranched, cyclic or
noncyclic alkyl of 1-10 carbon atoms; an
alkyl of up to 10 carbon atoms substituted
by carboxy, hydroxy, alkoxy, halo, or nitro
group; a branched or unbranched, cyclic or
noncyclic arylalkyl of 7-16 carbon atoms;
and an aryl; and n is 0-12.
__________
[11] [21] 121329
[54]
[22]
[31]
[51]
[71]
[74]
PHARMACEUTICAL
‫תכשיר רוקחות לטיפול בסרטן הכולל‬
COMPOSITION FOR THE
‫ ופפטידים אחרים‬2‫סומטוסתטין‬
TREATMENT OF CANCER
COMPRISING SOMATOSTATIN2
AND OTHER PEPTIDES
17. 7.1997
727679
[32] 8. 10.1996
[33] US
Int. Cl.7 A61K 38/31, 38/10, 38/22; A61P 35/00 // C07K 14/655, 14/575, 7/ 08
National Institute of Immunology, New
Delhi, India
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] Pharmaceutical composition
comprising: a therapeutically effective
combination of peptide somatostatin2
(SOM2) and at least four of peptides:
Vasoactive Intestinal Peptide1, 2,3 (VIP1),
(VIP2), (VIP3), Somatostatin1 (SOM1),
bombesin antagonist1 (BOM1), and
substance P antagonist1 (SP1).
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
958
[11] [21] 122783
[54]
[22]
[31]
[87]
[51]
[71]
[74]
CELL ADHESION INHIBITORS
‫מעכבי הדבקות תאים ותכשירי רוקחות‬
AND PHARMACEUTICAL
‫המכילים אותם‬
COMPOSITIONS CONTAINING
THE SAME
11. 7.1996
498237
[32] 11. 7.1995
[33] US
WO 97/03094
Int. Cl.7 C07K 5/06, 5/08, 5/10, 7/06, 14/78; A61K 38/04, 38/39; A61P 3/10, 19/02,
31/00, 37/06, 37/08
Biogen Idec MA Inc., Cambridge,
Mass., U.S.A.
Wolff, Bregman and Goller,
,‫ ברגמן וגולר‬,‫וולף‬
P.O.B. 1352, Jerusalem
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[57] Cell adhesion inhibitory compound
of the formula
Z-(Y1)-(Y2)-(Y3)n-X (I)
and pharmaceutically acceptable
derivatives thereof; wherein: Z is selected
from the group consisting of aliphatic acyl
substituted with N-arylamido;
heterocycloyl; alkylsulfonyl; substituted
aralkylcarbonyl; heterocycloalkylcarbonyl;
cycloalkylcarbonyl fused with aryl;
heterocycloalkyloxycarbonyl;
alkylaminocarbonyl; arylaminocarbonyl
and aralkylaminocarbonyl optionally
substituted with bis (alkylsulfonyl) amino,
alkoxycarbonylamino or alkenyl;
alkylsulfonyl; aralkylsulfonyl;
arylsulfonyl; cycloalkylsulfonyl optionally
fused with aryl; heterocyclylsulfonyl;
heterocyclylalkylsulfonyl;
aryloxycarbonyl; cycloalkyloxycarbonyl;
heterocycloxycarbonyl;
heterocyclylalkoxycarbonyl; mono-or dialkylaminocarbonyl optionally substituted
with aryl; (alkyl) (aralkyl)aminocarbonyl;
mono- or diaralkylaminocarbonyl; monoor di-arylaminocarbonyl; (aryl) (alkyl)
aminocarbonyl; mono – or
dicycloalkylaminocarbonyl;
heterocyclylaminocarbonyl;
heterocyclylalkylaminocarbonyl; (alkyl)
(heterocyclyl) aminocarbonyl; (alkyl)
959
heterocyclylalkyl) aminocarbonyl;
(aralkyl) (heterocyclyl) aminocarbonyl;
(aralkyl) (heterocyclylalkyl)
aminocarbonyl; alkenoyl optionally
substituted with aryl; alkenylsulfonyl
optionally substituted with aryl; alkynoyl
optionally substituted with aryl;
alkynylsulfonyl optionally substituted with
aryl; cycloalkenylcarbonyl;
cycloalkenylsulfonyl;
cycloalkylalkylsulfonyl; arylaroyl,
biarylsulfonyl; alkoxysulfonyl;
aralkoxysulfonyl; alkylaminosulfonyl;
aryloxysulfonyl; arylaminosulfonyl; Narylurea-subsituted alkanoyl; N-arylureasubstituted alkylsulfonyl; cycloalkenylsubstituted carbonyl; cycloalkenylsubsituted sulfonyl; alkenoxycarbonyl
optionally substituted with aryl;
alkenoxysulfonyl optionally substituted
with aryl; alkynoxycarbonyl optionally
substituted with aryl; alkynoxysulfonyl
optionally substituted with aryl; alkenyl-or
alkynylaminocarbonyl optionally
substituted with aryl; alkenyl or alkynylaminosulfonyl optionally substituted with
aryl; acylamino-substituted alkanoyl;
acylaminosubstituted alkylsulfonyl;
aminocarbonyl-substituted alkanoyl;
carbamoyl-substituted alkanoyl;
carbamoylsubstituted alkylsulfonyl;
August 31, 2005– ‫כ"ו באב התשס"ה‬
heterocyclylaminosulfonyl; carboxyalkylsubstituted aralkoyl; carboxyalkylsubstituted aralkylsulfonyl;
oxocarbocyclyl-fused aroyl;
oxocarbocyclyl-fused arylsulfonyl;
heterocyclylalkanoyl; N', N'-alkyl,
arylhydrazinocarbonyl; aryloxy-substituted
alkanoyl and heterocyclylalkylsulfonyl,
Y1 is –N(R1)-C(R2)(A1)-C(O)-;
Y2 is –N(R1)-C(R2)(A2)-C(O)-;
each Y3 is independently represented by
the formula –N(R1)-C(R2)(A3)-C(O)-; each
R1 is independently selected from the
group consisting of hydrogen, alkyl, and
aralkyl; alkenyl; alkynyl; cycloalkyl;
cycloalkenyl; cycloalkylalkyl; aryl;
aminoalkyl; mono- or di-alkyl-substituted
aminoalkyl; mono-or di-aralkyl-subsituted
aminoalkyl; hydroxyalkyl; alkoxyalkyl;
mercaptoalkyl; and thioalkoxyalkyl;
A1 is selected from the group consisting of
amino acid side chains and corresponding
protected derivatives; cycloalkyl; and alkyl
optionally substituted with amino,
acylamino, amino-substituted acylamino,
alkoxycarbonylamino, aryl, cycloalkyl,
carboxy, alkoxy, aralkyloxy,
alkoxycarbonyl, aralkoxycarbonyl,
aminocarbonyl, alkylaminocarbonyl,
dialkylaminocarbonyl, (alkyl) (aralkyl)
aminocarbonyl, aralkylaminocarbonyl,
diaralkylaminocarbonyl, hydroxyl,
carboxyalkylaminocarbonyl,
hydroxylaminocarbonyl, mercapto,
thioalkoxy or heterocycle;
A2 is selected from the group consisting of
acidic functional groups and alkyl
optionally substituted with an acidic
functional group, protected acidic
functional group or aryl; each A3 is
independently selected from the group
consisting of amino acid side chains and
corresponding protected derivatives; aryl;
cycloalkyl; and alkyl optionally substituted
with amino, acylamino, aminosubstituted
acylamino, aryl, cycloalkyl, carboxy,
alkoxy, aralkyloxy, alkoxcarbonyl,
aralkoxycarbonyl, aminocarbonyl,
August 31, 2005– ‫כ"ו באב התשס"ה‬
alkylaminocarbonyl,
dialkylaminocarbonyl, (alkyl) (aralkyl)
aminocarbonyl, aralkylaminocarbonyl,
diaralkylaminocarbonyl, hydroxyl,
carboxyalkylaminocarbonyl,
hydroxylaminocarbonyl, mercapto,
thioalkoxy or heterocycle; provided that R1
and any of A1, A2, and A3 can be taken
together with the atoms to which they are
each attached to form a 3- to 6- membered
ring heterocycle; each R2 is independently
selected from the group consisting of
hydrogen and alkyl;
N is an integer from 0 to 8; and
X is selected from the group consisting of
alkoxy; aryloxy; aralkyloxy; hydroxyl;
amino; dialkylamino; cycloalkylamino;
dicyloalkylamino; cycloalkylalkylamino;
(alkyl) (aryl) amino; (mono- or biscarboxylic acid) – substituted alkylamine,
alkylamino optionally substituted with
hydroxy, aminocarbonyl, Nalkylaminocarbonyl, carboxy or
alkoxycarbonyl, aralkylamino optionally
substituted with carboxy; diaralkylamino;
arylamino; heterocycle;
heterocyclylamino; and heterocyclylsubstituted alkylamino; further provided
that the compound of formula l is
expressly not N-carboxymethyl-N(phenylacetyl-L-leucyl-L-aspartyl-L
phenylalanyl-L-prolyl) piperazine (i.e.,
when Z=phenylacetyl, Y1=L, Y2=D,
Y3=F/P, n=2, and X=4carboxymethylpiperazinyl) and expressly
not phenylacetylL leucyl-L-aspartyl-Lphenylalanyl-D-proline amide (i.e., when
Z=phenylacetyl, Y1=L, Y2=D, Y3=F/P,
n=2, and X=NH2); and with the proviso
that Z is not benzyl, phenylacetyl,
pyridinylcarbonyl, pyridinylacetyl,
anilinocarbonyl, 3-quinolinoyl,
pyrazolylcarbonyl, tryptophyl, and 3, 4dihydroxybenzoyl when Y2 is D, Y3 is V,
I, F, P, W, Y, or L, and n is 1; and when Y2
is D and n is 0. (The terms L, D, F, P, W,
V, I, Y are defined in the specification)
960
__________
[11] [21] 123131
‫הרכבים הכוללים אוליגוסכרידים שאינם‬
‫ניתנים לעיכול להפחתת משך זמן השלשול‬
[54]
COMPOSITIONS CONTAINING
INDIGESTIBLE
OLIGOSACCHARIDES FOR
REDUCING THE DURATION OF
DIARRHEA
[22]
[31]
2. 7.1996
60/001036
[32] 11. 7.1995
[33] US
653084
11.6.1996
"
WO 97/02829
Int. Cl.7 A61K 31/7016; A61P 1/12 // C07H 3/00
Abbott Laboratories, Abbott Park, Ill.,
U.S.A.
Dr. Shlomo Cohen & Co.,
P.O.B. 11490, Tel-Aviv
[87]
[51]
[71]
[74]
,'‫ד"ר שלמה כהן ושות‬
‫אביב‬-‫ תל‬,11490 .‫ד‬.‫ת‬
indigestible oligosaccharide selected from
the group consisting of
fructooligosaccharides, fructosans,
oxylooligosaccharides and
galactooligosaccharides, in which said
[57] A composition useful for reducing
indigestible oligosaccharide includes lthe duration of diarrhea in humans, said
kestose, nystose, and 1F-β-fructorfuranosyl
composition comprising at least one
nystose.
__________
[11] [21] 123370
[54]
CONDITIONAL ACCESS DEVICE
AND PROCESS
[22]
[31]
19. 2.1998
PCT/FR 96/01269
[32] 8. 8.1996
9509952
21.8.1995
9513038
3.11.1995
Int. Cl.7 G06F 1/00//G07F 7/10
Cornel Sirbu, Guy Ancourt, France
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[51]
[71]
[74]
961
‫תהליך ומכשיר גישה מותנה‬
[33] WO
FR
"
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] A conditional access device intended
to be used in connection with an electronic
host equipment, formed by a pointing
pheripheral including at least one
microcircuit card coupler, characterized in
that it further includes means for acquiring
personal informative data specific to a
user, representative of a confidential code
of the user and in that said personal
informative data are locally compared with
informative data stored in the microcircuit
card in order to provide an authorization
information datum of the user or not,
transmitted to the host electronic
equipment without having said personal
informative data pass through the host
electronic equipment.
__________
[11] [21] 123642
-‫תכשירי רוקחות המכילים פגוציטים חד‬
‫גרעיניים לעידוד יצירה מחודשת של‬
‫אקסונים‬
[54]
PHARMACEUTICAL
COMPOSITIONS COMPRISING
MONONUCLEAR PHAGOCYTES
TO PROMOTE AXONAL
REGENERATION
[22]
[31]
12. 9.1996
528845
[32] 15. 9.1995
[33] US
695351
9.8.1996
FR
Int. Cl.7 C12N 5/06,5/08; A61K 35/12, 35/30, 48/00; A61P 25/00
[51]
August 31, 2005– ‫כ"ו באב התשס"ה‬
962
[71]
[72]
[74]
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
Yeda Research and Development Co.
Ltd., Rehovot
Michal Eisenbach-Schwartz, Orly
Spiegler and David L. Hirschberg
‫ דוד‬,‫ אורלי שפיגלר‬,‫שוורץ‬-‫מיכל אייזנבך‬
‫הירשברג‬
,‫עמי‬-‫פאולינה בן‬
,'‫עמי ושות‬-‫בן‬
‫ רחובות‬,94 .‫ד‬.‫ת‬
Paulina Ben-Ami,
Ben-Ami & Associates,
P.O.B. 94, Rehovot
[57] Pharmaceutical composition
comprising non-stimulated allogeneic
mononuclear phagocytes, or allogeneic
mononuclear phagocytes that have been
stimulated together with at least one
stimulatory tissue, with stimulatory cells,
with medium conditioned by at least one
stimulatory tissue or with stimulatory cells,
or with medium to which at least one
stimulatory biologically active agent has
been added, said stimulatory tissue, cells
or biologically active agent being capable
of enhancing the capacity of the
nononuclear phagocytes to promote axonal
regeneration, and a pharmaceutically
acceptable carrier.
__________
[11] [21] 123995
[54]
PEPTIDE DERIVATIVES, THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM
[22]
[31]
[51]
[62]
[71]
[74]
12. 5.1994
9301916-4
[32] 3. 6.1993
Int. Cl.7 C07K 5/12; A61K 47/42 A61P 43/00
Division from 109634
AstraZeneca AB, Sodertalje, Sweden
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
‫ הכנתן ותכשירי‬,‫תולדות של פפטידים‬
‫רוקחות המכילות אותן‬
[33] SE
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
[57] Trypsin-Like serine protease
inhibiting compounds of the formula
963
August 31, 2005– ‫כ"ו באב התשס"ה‬
wherein:
A1 represents a structural fragment of the
formula
wherein:
k is an integer 0, 1, 2, 3 or 4;
m is an integer 1, 2, 3, or 4;
q is an integer 0, 1, 2, or 3;
R1 represents R11OOC-alkyl-, where the
alkyl group has 1 to 4 carbon atoms and is
possibly substituted in the position which
is alpha to the carbonyl group, and the
alpha subsitutent is a group R17-(CH2)p-,
wherein p is 0, 1 or 2 and R17 is COOR12,
CONHR12, where R12 is H, an alkyl group
having 1 to 4 carbon atoms or a benzyl
group, and R11 is H or an alkyl group
having 1 to 6 carbon atoms, or a benzyl
group, or
R1 represents Ph (4-COOR12) – CH2-,
where R12 is as defined above, or
R1 represents R13-NH-CO-alkyl-, where
the alkyl group has 1 to 4 carbona toms
and is possibly substituted alpha to the
carbonyl with an alkyl group having 1 to 4
carbon atoms and where R13 is H or an
alkyl group having 1 to 4 carbon atoms or
–CH2COOR12, where R12 is as defined
above, or
R1 represents R12OOC-CH2-OOC-alkyl-,
where the alkyl group has 1 to 4 carbon
atoms and is possibly substituted alpha to
the carbonyl with an alkyl group having 1
to 4 carbon atoms and where R12 is as
defined above, or
R1 represents R14S2-, Ph (4-COOR12)-SO2-,
Ph (3-COOR12)- SO2-, Ph (2-COOR12) –
SO2- where R12 is as defined above and R14
is an alkyl group having 1-4 carbon atoms,
or
R1 represents –CO-R15, wherein R15 is an
alkyl group having 1-4 carbon atoms, or
R1 represents –CO-OR15, where R15 is as
defined above, or
R1 represents –CO- (CH2)p-COOR12,
where R12 is as defined above and p is an
integer 0, 1 or 2, or
R2 represents H or an alkyl group having 1
to 4 carbon atoms or R21OOC-alkyl-,
where the alkyl group has 1 to 4 carbon
atoms and where R21 is H or an alkyl group
having 1 to 4 carbon atoms or a benzyl
group;
R3 represents an alkyl group having 1-4
carbon atoms, and the alkyl group may or
may not carry one or more fluorine atoms,
or
R3 represents a cyclopentyl, cyclohexyl- or
a phenyl group which may or may not be
substituted with an alkyl group having 1 to
4 carbonatoms, or
R3 represents a phenyl group substituted
with a OR31 group, where R31 is H or an
alkyl group having 1 to 4 carbon atoms
and k is 0, 1, or
August 31, 2005– ‫כ"ו באב התשס"ה‬
964
R3 represents a 1-naphthyl or 2-naphthyl
group and k is 0, 1, or
R3 represents a cis- or trans-decalin group
and k is 0, 1, or
R3 represents 4-pyridyl, 3-pyrrolidyl or 3indolyl which may or may not be
substituted with a OR31 group, where R31 is
as defined above and k is 0, 1, or
R3 represents Si(Me)3 or CH(R32)2,
wherein R32 is a cyclohexyl- or a phenyl
group;
R4 represents H, an alkyl group having 1 to
4 carbon atoms, a cyclohexyl or phenyl
group; A2 represents a structural fragment
of the formula
wherein:
p is an integer 0, 1 or 2;
m is an integer 1, 2, 3 or 4;
Y represents a methylene group, or
Y represents an ethylene group and the
resulting 5-membered ring may or may not
carry one or two fluorine atoms, a hydroxy
group or an oxo group in position 4, or
may or may not be unsaturated, or
Y represents –CH2-O-, -CH2-S-,
-CH2-SO-, with the heteroatom
functionality in position 4, or
Y represents a n-propylene group and the
resulting 6-membered ring may or may not
carry in position 5 one fluorine atom, a
hydroxy group or an oxo group, carry two
fluorine atoms in one of positions 4 or 5 or
be unsaturated in position 4 and 5, or carry
in position 4 an alkyl group with 1 to 4
carbon atoms, or
Y represents –CH2-O-CH2-, -CH2-S-CH2-,
-CH2-SO-CH2-, or
Y represents –CH2-CH2-CH2-CH2-;
R3 is as defined above;
R5 represents H or an alkyl group having 1
to 4 carbon atoms, or
R5 represents –(CH2)p-COOR51, where p is
0, 1 or 2 and R51 is H or an alkyl group
having 1 to 4 carbon atoms;
n is an integer 0, 1, 2, 3 or 4;
B represents a structural fragment of the
formula
wherein:
R is an integer 0 or1;
X1 represents CH2 or NH or is absent;
X2 represents CH2, NH or C=NH;
X3 represents NH, C=NH, N-C(NH)-NH2,
CH-C(NH)-NH2, CH-NH-C(NH)-NH2 or
CH-CH2-C(NH)-NH2;
X4 represents CH2 or NH;
X5 represents C(NH)-NH2 or NH-C(NH)NH2;
X6 represents CH or N;
R6 is H or an alkyl group having 1 -4
carbon atoms;
D is Z or (Z)2;
965
August 31, 2005– ‫כ"ו באב התשס"ה‬
Z is a benzyloxy carbonyl group;
either the compound as such or
stereoisomers thereof or in the form of a
physiologically acceptable salt.
__________
[11] [21] 124043
[54]
COMPOSITION CONTAINING A
MONOCLONAL
IMMUNOGLOBULIN THE
SEQUENCE OF WHICH IS
SUBSTANTIALLY IDENTICAL
TO HUMAN IMMUNOGLOBULIN
AND WHICH HAS UNDERGONE
SOMATICAL MUTATION
[22]
[31]
[87]
[51]
[71]
10. 10.1996
544404
[32] 10. 10.1995
WO 97/13852
Int. Cl.7 C07K 16/00, 16/28; C12N 5/20
Genpharm International, Inc., San Jose,
Calif., U.S.A.
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[74]
[57] A monoclonal human
immunoglobulin composition free of other
human proteins, comprising a human
sequence IgG having a binding constant of
at least 2X109M-1 for binding to a
predetermined human antigen, wherein
said immunoglobulin consists of:
(a) somatically mutated human sequence
light chain composed of (1) a light chain
variable region having a polypeptide
sequence which is substantially identical to
a polypeptide sequence encoded by a
human VL gene segment and a human JL
segment, and (2) a light chain constant
region having a polypeptide sequence
which is substantially identical to a
polypeptide sequence encoded by a human
CL gene segment; and
‫שבטי שרצפו‬-‫תכשיר של אימונוגלובלין חד‬
‫זהה בעיקרו לאימונוגלובולין של אדם ועבר‬
‫מוטציה סומטית‬
[33] US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
(b) a somatically mutated human sequence
heavy chain composed of a (1) a heavy
chain variable region having a polypeptide
sequence which is substantially identical to
a polypeptide sequence encoded by a
human VH gene segment, a D region, and a
human JH segment, and (2) a constant
region having a polypeptide sequence
which is substantially identical to a
polypeptide sequence encoded by a human
CH gene segment wherein the human
sequence heavy chain and human sequence
light chain are separately encoded by a
human heavy chain transgene and a human
light chain transgene integrated into a
mouse cell genome.
_________
August 31, 2005– ‫כ"ו באב התשס"ה‬
966
[11] [21] 124268
[54]
[22]
[31]
[87]
[51]
[71]
[74]
[57]
HYPOCHOLESTEROLEMIC (1ARYL-2-OXO-3-SUBSTITUTED-4AZETIDINYL)
PHENYLGLUCOPYRANOSE
DERIVATIVES AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
29. 10.1996
60/008185
[32] 31. 10.1995
[33] US
570847
12.12.1995
"
WO 97/16455
Int. Cl.7 C07H 15/26; A61K 31/7052; A61P 3/06, 9/00
Schering Corporation, Kenilworth,
N.J., U.S.A.
Eitan, Pearl, Latzer & Cohen,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
Zedek, 7 Shenkar St., Herzliya
‫ הרצליה‬,7 ‫רח' שנקר‬
A compound of the formula
or a pharmaceutically acceptable salt
thereof, wherein
R26 is H or OG1;
967
-4-‫מותמר‬-3-‫אוקסו‬-2-‫אריל‬-1( ‫תולדות‬
‫אזטידיניל) פנילגלוקופיראנוז‬
‫היפוכלסטרולמיות ותכשירי רוקחות‬
‫המכילים אותן‬
G and G1 are independently selected from
the group consisting of
August 31, 2005– ‫כ"ו באב התשס"ה‬
OH, G is not H;
R, Ra and Rb are independently selected
from the group consisting of H, -OH,
halogeno, -NH2, azido, (C1-C6) alkoxy (C1C6)- alkoxy or –W-R30;
W is independently selected from the
group consisting of –NH-C(O)-, -O-C(O)-,
-O-C(O)-N(R31)-and –O-C(S)-N(R31)-;
R2 and R6 are independently selected from
the group consisting of H, (C1-C6) alkyl,
aryl and aryl (C1-C6) alkyl;
R3, R4, R5, R7, R3a and R4a are
independently selected from the group
consisting of H, (C1-C6) alkyl, aryl (C1-C6)
alkyl, -C(O)(C1-C6) alkyl and –C(O) aryl;
R30 is independently selected from the
group consisting of R32- substituted T, R32subsituted-T-(C1-C6) alkyl, R32-substituted
– (C2-C4) alkenyl, R32- substituted --(C1C6) alkyl, R32-substituted- (C3-C7)
cycloalkyl and R32-substituted- (C3-C7)
cycloakyl (C1-C6) alkyl; R31 is
independently selected from the group
consisting of H and (C1-C4) alkyl;
T is independently selected from the group
consisting of phenyl, furyl, thienyl,
pyrrolyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, benzothiazolyl, thiadiazolyl,
pyrazolyl, imidazolyl and pyridyl; R32 is
independently selected from 1-3
substituents independently selected from
the group consisting of halogeno, (C1-C4)
alkyl, -OH, phenoxy, -CF3, -NO2, (C1-C4)
alkoxy, methylenedioxy, oxo, (C1-C4)
alkylsulfanyl, (C1-C4) alkylsufinyl, (C1-C4)
alkylsulfonyl, -N(CH3)2, -C(O)-NH(C1-C4)
alkyl, -C(O)-N((C1-C4) alkyl)2, -C(O)-(C1C4) alkyl, -C(O)-(C1-C4) alkoxy and
pyrrolidinylcarbonyl; or
R31, the nitrogen to which it is attached
and R30 form a pyrrolidinyl, piperidinyl,
N-methyl-piperazinyl, indolinyl or
morpholinyl group, or a (C1-C4)
alkoxycarbonyl-substituted pyrrolidinyl,
piperidinyl, N-methylpiperazinyl, indolinyl
or morpholinyl group;
Ar1 is aryl or R10-substituted aryl;
Ar2 is aryl or R11-substituted aryl;
Q is a bond or with the 3-position ring
carbon of the azetidinone,
R1 is selected from the group consisting of
-(CH2)q-, wherein q is 2-6, provided that
when Q forms a spiro ring, q can also be
zero or 1;
-(CH2)e-E-(CH2)1, wherein E is –O-, C(O)-, phenylene, -NR22- or –S(O)0-2-, e is
0-5 and r is 0-5, provided that the sum of e
and r is 1-6;
-(C2-C6) alkenylene-; and
-(CH2)f-V-(CH2)g-, wherein V is C3-C6
cycloalkylene, f is 1-5 and g is 0-5,
provided that the sum of f and g is 1-6;
R12 is
August 31, 2005– ‫כ"ו באב התשס"ה‬
968
R13 and R14 are independently selected
from the group consisting of –CH2-, CH(C1-C6 alkyl)-, -C(di-(C1-C6) alkyl), CH=CH- and –C(C1-C6 alkyl)=CH-; or R12
together with an adjacent R13, or R12
together with an adjacent R14, form a –
C=CH- or a –C=C(C1-C6 alkyl)- group;
a and b are independently 0, 1, 2 or 3,
provided both are not zero;
provided that when R13 is-CH=CH- or –C(C1-C6 alkyl) =CH-, a is 1;
provided that when R14 is –CH=CH- or -C(C1-C6 alkyl)=CH-, b is 1;
provided that when a is 2 or 3, the R13's can
be the same or different;
and provided that when b is 2 or 3, the
R14's can be the same or different;
and when Q is a bond, R1 also can be:
M is –O-, -S-, -S(O)- or –S(O)2-;
X, Y and Z are independently selected
from the group consisting of –CH2-, -CH(C1-C6) alkyl- and –C(di--(C1-C6) alkyl);
R10 and R11 are independently selected
from the group consisting of 1-3
substituents independently selected from
the group consisting of -(C1-C6) alkyl, OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)119
19 20
19 20
5OR , -O(CO)NR R , -NR R , 19
20
NR (CO)R ,
-NR19(CO)OR21, -NR19(CO)NR20R25, NR19SO2R21, -COOR19,
-CONR19R20, -COR19,- SO2NR19R20,
S(O)0-2R21,
-O(CH2)1-10 –COOR19, -O(CH2)1-10
CONR19R20, -(C1-C6 alkylene)COOR19, -CH=CH-COOR19, -CF3, -CN, CN, -NO2 and halogen;
R15 and R17 are independently selected
from the group consisting of –OR19, O(CO)R19, -O(CO)OR21 and –
O(CO)NR19R20; R16 and R18 are
independently selected from the group
consisting of H; -(C1-C6) alkyl and aryl; or
R15 and R16 together are =O, or R17 and
R18 together are =O;
d is 1, 2 or 3;
h is 0, 1, 2, 3 or 4;
s is 0 or 1; t is 0 or 1; m, n and p are
independently 0-4; provided that at least
one of s and t is 1, and the sum of m, n, p,
s and t is 1-6;
provided that when p is 0 and t is 1, the
sum of m, s and n is 1-5; and
provided that when p is 0 and s is 1, the
sum of m, t and n is 1-5; v is 0 or 1;
i and k are independently 1-5, provided
that the sum of j, k and v is 1-5;
also be pyridyl, isoxazolyl, furanyl,
pyrrolyl, thienyl, imidazolyl, pyrazolyl,
thiazolyl, pyrazinyl, pyrimidinyl or
pyridazinyl;
R19 and R20 are independently selected
from the group consisting of H, -(C1-C6)
alkyl, aryl and aryl-substituted -(C1-C6)
alkyl;
R21 is -(C1-C6) alkyl, aryl or R24substituted aryl;
R22 is H, -(C1-C6) alkyl, aryl -(C1-C6)
alkyl, -C(O)R19 or –COOR19;
969
August 31, 2005– ‫כ"ו באב התשס"ה‬
R23 and R24 are independently 1-3 groups
independently selected from the group
consisting of H, -(C1-C6) alkyl, -(C1-C6)
alkoxy, -COOH, NO2, -NR19R20, -OH and
halogeno; and
R25 is H, -OH or -(C1-C6) alkoxy.
__________
[11] [21] 124498
[54]
NURSING BOTTLE WITH TWO
PIECE AIR VENTING
STRUCTURE
[22]
[51]
[62]
[71]
14. 5.1998
Int. Cl.7 A61J 9/04
Addition to 123822
New Vent Designs, Inc., Mt. Zion, Ill.,
U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] An improved nursing bottle (100) of
the type having an internal venting
prevent a structure (112, 116, 118) to
vacuum from being formed within the
bottle when inverted, the improvement
comprising:
‫בקבוק לתינוק עם התקן אוורור בעל שני‬
‫חלקים‬
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
a venting structure formed from no more
than two integral pieces, wherein one of
said integral pieces comprises a reservoir
(116).
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
970
[11] [21] 125145
[54]
‫חלקיקים של רקומביננט ויראלי‬-‫פסאודו‬
‫והשימוש בהם כחיסון או נגד גידול סרטני‬
VIRAL RECOMBINANT
PSEUDO-PARTICLES AND
VACCINAL AND ANTITUMORAL APPLICATIONS
[22]
[51]
[71]
30. 8.1996
Int. Cl.7 C12N 15/34, 15/35, 15/40; C07K 14/01, 14/015 A61K 39/295
Institut Pasteur, Paris, France and
Immunologia y Genetica Aplicada
S.A., Madrid, Spain
[74]
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] Recombinant viral pseudo-particles
presence of at least one antigenic
characterized in that they are constituted
determinant comprising a sequence of 8 to
by auto-assembly of at least one viral
25 amino acids, only able to associate with
structural protein, in that they have a size
at least one class I molecule of the major
of between 20 and 60 nm, in that they form
histo-compatibility complex, said
an approximately icosahedral structure,
association being recognized by cytotoxic
and in that said protein is modified by the
CD8+T lymphocytes.
__________
[11] [21] 125734
‫פפטידים אנטיפתוגניים ותכשירים המכילים‬
‫אותם‬
[54]
ANTIPATHOGENIC PEPTIDES
AND COMPOSITIONS
COMPRISING THEM
[22]
[51]
[71]
20. 2.1997
Int. Cl.7 C07K 14/435, 14/46; A61K 38/04, 38/17; A61P 31/00, 3 5/00
Yeda Research and Development Co.
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
Ltd., Rehovot
Yechiel Shai and Ziv Oren
‫יחיאל שי וזיו אורן‬
Paulina Ben-Ami,
,‫עמי‬-‫פאולינה בן‬
Ben-Ami & Associates,
,'‫עמי ושות‬-‫בן‬
P.O.B. 94, Rehovot
‫ רחובות‬,94 .‫ד‬.‫ת‬
[72]
[74]
971
August 31, 2005– ‫כ"ו באב התשס"ה‬
higher than that in which it manifests said
cytolytic activity on pathogenic cells, said
peptide having the following
characteristics:
(a) it is a peptide comprising both L-amino
acid residues and D-amino acid residues;
(b) the peptide has a net positive charge
which is greater than +1; and
(c) the peptide is amphipathic, with the
proviso that said peptide is not D-L5, L19TA2-Par.
[57] Peptide having a selective cytolytic
activity manifested in that it has a cytolytic
activity on pathogenic cells, and it has no
cytolytic effect on red blood cells or has a
cytolytic effect on red blood cells at
concentrations which are substantially
__________
[11] [21] 125789
‫ אנושי‬t-PA ‫שימוש בוריאנט חסר של חלבון‬
‫דם‬-‫להכנת תרופה לטיפול במחלות כלי‬
[54]
USE OF A DELETION VARIANT
HUMAN t-PA PROTEIN IN THE
PREPARATION OF A
MEDICAMENT FOR
TREATMENT OF VASCULAR
DISEASES
[22]
[31]
28. 6.1988
068448
[32] 30. 6.1987
170970
21.3.1988
188237
29.4.1988
Int. Cl.7 A61K 38/49; A61P 7/02; C12N 9/50
Division from 86887
Genentech, Inc., South San Francisco,
Calif., U.S.A.
S. Horowitz & Co.,
P.O.B. 2499, Tel-Aviv
[51]
[62]
[71]
[74]
[57] The use of an amino acid deletion
variant human t-PA protein produced in a
recombinant host cell, and free of
derivatives wherein blocking groups are
included on their protein structure, in the
preparation of a medicament for the
treatment of vascular disease in a patient
for which t-PA plasma half-life longer than
that exhibited by natural t-PA and/or
clearance rates less than the clearance rate
exhibited by natural t-PA is advantageous,
wherein said deletion variant has all or a
August 31, 2005– ‫כ"ו באב התשס"ה‬
[33] US
"
"
,'‫ הורוביץ ושות‬.‫ש‬
‫אביב‬-‫ תל‬,2499 .‫ד‬.‫ת‬
portion of the finger region removed, and
results in said variant human t-PA protein
exhibiting a plasma half-life of at least 12
minutes or at least 2 times longer than that
exhibited by natural t-PA made in the same
host cell and/or clearance rates less than 2
ml/min/kg or half or less the clearance rate
exhibited by natural t-PA protein made in
the same host cell, or the use of an amino
acid deletion variant human t-PA protein
produced in a recombinant host cell, free
of derivatives wherein blocking groups are
972
included on their protein structure, in the
preparation of a medicament for the
treatment of vascular disease in a patient
for which t-PA plasma half-life longer than
that exhibited by natural t-PA and/or
clearance rates less than the clearance rate
exhibited by natural t-PA is advantageous,
wherein said deletion variant has at least a
portion of the kringle 1 domain removed,
and results in said variant human t-PA
protein exhibiting a plasma half-life of at
least 12 minutes or at least 2 times longer
than that exhibited by natural t-PA made in
the same host cell and/or clearance rates
less than 2 ml/min/kg or half or less the
clearance rate exhibited by natural t-PA
protein made in the same host cell, with
the exclusion of variant t-PA consisting of
the entire wild-type amino acid sequence
of t-PA apart from a deletion consisting of
amino acids 92-173, and the N-terminus
upstream of Serl denoted by R, where R is
absent or is selected from the natural signal
sequence of t-PA, Gly-Ala-Arg-, Met-GlyAla-Arg or Met-, and optionally having
Glu at 275 and/or Ile at 277.
__________
[11] [21] 125809
[54]
PROCESS AND
INTERMEDIATES FOR
PRODUCTION OF DONEPEZIL
AND RELATED COMPOUNDS
[22]
[51]
[71]
[74]
17. 8.1998
Int. Cl.7 C07D 211/32, 211/34, 213/50
FineTech Laboratories, Ltd., Haifa
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
‫תהליך וחומרי ביניים להכנת דונפזיל‬
‫ותרכובות דומות‬
‫ חיפה‬,‫פיינטק מעבדות בע"מ‬
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
[57] A process for the preparation of a
compound of the formula
and optical isomers and salts thereof
wherein:
973
R4, R5, R6 and R7 are identical or different
and each represents hydrogen, C1-6 alkyl,
C1-6 alkoxy, or halogen;
August 31, 2005– ‫כ"ו באב התשס"ה‬
R10 is selected from benzyl, C1-6 alkyl, ωaralkyl, acyl and C1-6 alkoxycarbonyl,
which process comprises the following
steps:
(a) reacting a compound of the formula
wherein R8 and R9 are identical or different
and each represents C1-6 alkyl and R4, R5,
R6 and R7 are as defined above with 4-
pyridinecarboxaldehyde in the presence of
base to give a compound of the formula
wherein the dotted lines represent two
possible locations of the double bond
formed in the reaction, R4, R5, R6, R7 and
R8 are as defined above, including
tautomers, stereoisomers or mixtures
thereof as well as acid addition salt
thereof;
(b) catalytic hydrogenation of the
compound or mixture of compounds or
their salts obtained in step (a) to give a
compound of the formula
wherein R4, R5, R7 and R8 are as defined
above, as well as acid addition salt thereof;
(c) reacting the compound obtained in step
(b) above or a salt thereof with a
compound of formula R10X, wherein R10 is
as defined above and X is a leaving group,
to yield a compound of the formula
wherein R4, R5, R6, R7, R8 and R10 are as
defined above, or its salt; following
hydrolysis of the ester group to form the
corresponding carboxylic acid or a salt
thereof;
(d) intramolecular cyclization of the
August 31, 2005– ‫כ"ו באב התשס"ה‬
974
carboxylic acid obtained in step (c) above
or salt thereof to yield the compound [Ib];
(e) optionally converting the resulting
compound of formula [1b] into a
pharmacologically acceptable salt.
Claimed as novel are the compounds of the
formula
wherein R4, R5, R6 and R7 are as above,
and the compounds of the formula (II)
R11 is hydrogen or is selected from benzyl,
including tautomers, steroisomers or
C1-16 alkyl, ω-aralkyl, acyl and C1-6
mixtures thereof as well as acid addition
alkoxycarbonyl,
salts thereof, with the proviso that when
R12 is hydrogen or C1-6 alkyl,
three of R4-R7 are H, the other one is
including optical isomers and salts thereof
halogen or C1-6 alkoxy.
__________
[11] [21] 126107
[54]
LASER RANGING SYSTEM
[22]
[51]
[71]
7. 9.1998
Int. Cl.7 G01C 3/08
Rafael – Armament Development
Authority Ltd., Haifa
[74]
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
[57] A laser ranging system comprising:
(a) a laser pulse emitter (10) for producing
a pulse of light to be reflected by at least
one object at an unknown distance from
said laser emitter;
(b) an imaging and impingement detecting
sensor (12) having a multiplicity of
photoelements for collecting reflected light
from said at least one object and for
determining the intensity of said reflected
975
‫מערכת טווח לייזר‬
,‫רפאל הרשות לפיתוח אמצעי לחימה בע"מ‬
‫חיפה‬
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
light and the time it first impinged on each
of said photoelements; and
(c) a system processor (14) for controlling
said laser pulse emitter and said detecting
amplifier and for receiving output from
said detecting amplifier thereby to produce
at least distance indications for said at least
one object based on the length of time
from emission of said pulse of light to
receipt of its reflection as sensed by each
of said photoelements.
August 31, 2005– ‫כ"ו באב התשס"ה‬
__________
[11] [21] 126497
‫תכשירים להדברה של פטריות מזיקות‬
[54]
COMPOSITIONS FOR
CONTROLLING HARMFUL
FUNGI
[22]
[31]
[87]
[51]
22. 4.1997
19615977.6
[32] 22.4.1996
[33] DE
97/39628
Int. Cl.7 A01N 37/24, 43/40, 43/48, 43/56, 43/78, 43/80 // C07 C 233/54, 233/56,
233/75, 255/50, 323/25; C07D 213/06, 275/02, 277/22, 231/04, 231/06, 261/02, 263/02
BASF Aktiengesellschaft,
Ludwigshafen, Germany
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[71]
[74]
[57] A composition for controlling
harmful fungi, containing in a solid or
liquid carrier
(a) at least one p-hydroxyaniline derivative
of the formula
where
R1 is hydrogen, alkyl, which can be
partially or completely halogenated and/or
can carry one or two of the following
groups: alkoxy, haloalkoxy, alkylthio,
cycloalkyl, cycloalkenyl, it being possible
for the cyclic groups for their part to carry
one, two or three halogen atoms, alkyl
groups and/or alkoxy groups, and aryl
which can be partially or completely
halogenated and/or can carry one, two or
three of the following substituents: nitro,
cyano, alkyl, haloalkyl, alkoxy, haloalkoxy
and alkylthio;
cycloalkyl or cycloalkenyl, it being
possible for these radicals to be partially or
completely halogenated and/or to carry 1,
2, 3, 4 or 5 of the following groups: alkyl,
haloalkyl, alkoxy, haloalkoxy and aryl,
which can be partially or completely
August 31, 2005– ‫כ"ו באב התשס"ה‬
976
halogenated and/or can carry one, two or
three of the following substituents: nitro,
cyano, alkyl, haloalkyl, alkoxy, haloalkoxy
and alkylthio; C6-C15- bicycloalkyl or C6C15-bicycloalkenyl, it being possible for
these radicals to be partially or completely
halogenated and/or to carry 1, 2, 3, 4 or 5
of the following groups: alkyl, haloalkyl,
alkoxy, haloalkoxy and aryl, which can be
partially or completely halogenated and/or
can carry one, two or three of the
following substituents: nitro, cyano, alkyl,
haloalkyl, alkoxy, haloalkoxy and
alkylthio; R2 and R3 independently of one
another are halogen, alkyl, haloalkyl,
alkoxy or haloalkoxy;
Z is H or R4-(CO)-, where
R4 is the following radicals:
alkyl or alkenyl, it being possible for these
groups to be partially or completely
halogenated and/or to carry one of the
following radicals: alkoxy, haloalkoxy,
alkylthio, cycloalkyl, cycloalkenyl or aryl,
it being possible for the aromatic radicals
for their part to carry one, two or three of
the following groups: nitro, cyano,
halogen, alkyl, haloalkyl, alkoxy,
haloalkoxy and alkylthio; cycloalkyl or
cycloalkenyl, it being possible for these
groups to carry one, two or three of the
following radicals: halogen, alkyl,
haloalkyl and alkoxy; aryl, which can be
partially or completely halogenated and/or
can carry one, two or three of the
following radicals: nitro, cyano, alkyl,
haloalkyl, alkoxy, haloalkoxy and
alkylthio; OR5 or NR6R7, where
R5 is alkyl or alkenyl, it being possible for
these groups to be partially or completely
halogenated and/or to carry one of the
following radicals: alkoxy, haloalkoxy,
alkylthio, cycloalkyl, cycloalkenyl or aryl,
it being possible for the aromatic radicals
for their part to carry one, two or three of
the following groups: nitro, cyano,
halogen, alkyl, haloalkyl, alkoxy,
haloalkoxy and alkylthio; or is cycloalkyl
or cycloalkenyl, it being possible for these
groups to carry one, two or three of the
following radicals: halogen, alkyl,
haloalkyl and alkoxy; or is aryl which can
be partially or completely halogenated
and/or can carry one, two or three of the
following radicals: nitro, cyano, alkyl,
haloalkyl, alkoxy, haloalkoxy and
alkylthio; R6 is alkyl or alkenyl, it being
possible for these groups to be partially or
completely halogenated and/or to carry one
of the following radicals: alkylthio,
cycloalkyl, cycloalkenyl or aryl, it being
possible for the aromatic radicals for their
part to carry one, two or three of the
following groups: nitro, cyano, halogen,
alkyl, haloalkyl, alkoxy, haloalkoxy and
alkylthio; cycloalkyl or cycloalkenyl, it
being possible for these groups to carry
one, two or three of the following radicals:
halogen, alkyl, haloalkyl and alkoxy; aryl,
which can be partially or completely
halogenated and/or can carry one, two or
three of the following radicals: nitro,
cyano, alkyl, haloalkyl, alkoxy, haloalkoxy
and alkylthio; and R7 is hydrogen or alkyl,
(b) at least one amide compound of the
formula
A-CO-NR8-R9
where
A is pyridyl, thiazolyl pyrazolyl or
axazolyl, it being possible for these groups
977
to have 1, 2 or 3 subsitutents which are
selected independently of one another from
alkyl, halogen, difluoromethyl and
August 31, 2005– ‫כ"ו באב התשס"ה‬
trifluoromethyl; R8 is a hydrogen atom,
alkyl or alkoxy;
R9 is phenyl, which has a phenyl group in
the 2-position which is substituted by 1 to
5 halogen atoms and/or 1 to 3 groups
which independently of one another are
selected from C1-C4-alkyl, C1-C4haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy,
C1-C4-alkylthio and C1-C4-alkylthio and
C1-C4-haloalkylthio.
__________
[11] [21] 126674
‫שמוש בתרכובות ציקליות והטרוציקליות‬
‫להכנת תכשירי רוקחות המעקבים פעילות‬
‫ תכשירי רוקחות המכילים אותן‬,IMPDH
‫ותולדות תיאזול ואוקסזול שתנן חדשות‬
[54]
USE OF CYCLIC AND
HETEROCYLIC COMPOUNDS
FOR PREPARING
PHARMACEUTICAL
COMPOSITIONS INHIBITING
IMPDH ACTIVITY,
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME AND NOVEL
THIAZOLE AND OXAZOLE
UREA DERIVATIVES
[22]
[31]
21. 4.1997
636361
[32] 23.4.1996
[33] US
801780
14.2.1997
"
832165
2.4.1997
"
WO 97/40028
Int. Cl.7 C07C 275/26, 275/28, 275/42, 307/08, 307/10, 309/25, 309/51, 311/36,
311/37, 317/26, 323/43, 335/14, 335/16; C07D 263/32, 277/22, 307/58, 317/48,
319/18, 413/12, 417/12; C07F 9/09; A61K 31/16, 31/335, 31/42, 31/425; A61P 37/00
Vertex Pharmaceuticals Inc.,
Cambridge, Mass., U.S.A.
Wolff, Bregman and Goller,
,‫ ברגמן וגולר‬,‫וולף‬
P.O.B. 1352, Jerusalem
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[87]
[51]
[71]
[74]
[57] Use of a compound for the
preparation of a pharmaceutical
composition for inhibiting IMPDH activity
in a mammal having the formula:
wherein:
B is a saturated, unsaturated or partially
saturated monocyclic or bicyclic ring
system optionally comprising up to 4
heteroatoms selected from N, O, or S and
selected from the formulae:
August 31, 2005– ‫כ"ו באב התשס"ה‬
978
wherein each X is the number of hydrogen
atoms necessary to complete proper
valence; and B optionally comprises up to
3 substituents, wherein: when one of said
substituents is present, it is selected from
R1, R2, R4 or R5, when two of said
substituents are present, the first is selected
from R1, R2, R4 or R5, and the second is
selected from R1 or R4, and when three of
said substituents are present, the first is
selected from R1, R2, R4 or R5, the second
is selected from R1or R4, and the third is
selected from R1, and
D is selected from C(O), C(S), or S(O)2;
wherein:
each R1 is independently selected from 1,
2-methylenedioxy, 1, 2 – ethylenedioxy,
R6, OR6, or (CH2)n-Y; wherein n is 1 or 2;
and
Y is selected from halogen, CN, NO2, CF3,
OCF3, OH, SR6, S(O)R6, SO2R6, NH2,
NHR6, N(R6)2, NR6R8, COOH, or
COOR6;
each R2 is independently selected from
(C1-C4) – straight or branched alkyl, or
(C2-C4) – straight or branched alkenyl or
alkynyl; and each R2 optionally comprises
up to 2 substituents, wherein: when one of
said substituents is present, it is selected
from R1, R4 or R5,
when two of said substituents are present,
the first is selected from R1, R4 or R5, and
the second is selected from R1, and
each R4 is independently selected from
OC(O)R6, OC(O)R5, OC(O)OR6,
OC(O)OR5, OC(O)N(R6)2, OP(O)(OR6)2,
979
SR6, S(O)R6, S(O)R5, SO2R6, SO2R5,
SO2N(R6)2, SO2NR5R6, SO3R6, C(O)R5,
C(O)OR5, C(O)R6, C(O)OR6,
NHC(O)C(O)R6, NHC(O)C(O)R5,
NHC(O)C(O)OR6, NHC(O)C(N)(R6)2,
C(O)N(R6)2, C(O)N(R6)2,
C(O)N(OR6)R6, C(O)N(OR6)R5,
C(NOR6)R6, CNOR6, NR6C(O)OR5,
NR6C(O)N(R6)2, NR6C(O)NR5R6,
NR6SO2R6, NR6SO2R5,
NR6SO2N(R6)2, NR6SO2NR5R6,
N(OR6)R5, P(O) (OR6)N(R6)2, and
P(O)(OR6)2;
each R5 is a monocyclic or a bicylic ring
system consisting of 5 to 6 members per
ring, wherein said ring system optionally
comprises up to 4 heteroatoms selected
from N, O, or S, and wherein a CH2
adjacent to said N, O or S may be replaced
with C(O); and each R5 optionally
comprises up to 3 substituents, each of
which, if present, is R1;
each R6 is independently selected from
(C1-C4) – straight or branched alkyl, or
(C2-C4) straight or branched alkenyl; and
when R6 is alkyl, R6 comprises a
substituent that is R7; when R6 is alkenyl,
R6 optionally comprises a substituent that
is R7; R7 is a monocyclic or a bicyclic ring
system consisting of 5 to 6 members per
ring, wherein said ring system optionally
comprises up to 4 heteroatoms selected
from N, O, or S, and wherein CH2 adjacent
to said N, O or S may be replaced with
C(O); and each R7 optionally comprises up
to 2 substituents independently chosen
August 31, 2005– ‫כ"ו באב התשס"ה‬
from H, (C1-C4) – straight or branched
alkyl, or (C2-C4) straight or branched
alkenyl, 1, 2-methylenedioxy, 1, 2ethylenedioxy, or (CH2)n-Z;
wherein n is 0, 1 or 2; and
Z is selected from halogen, CN, NO2,
OCF3, OH, S(C1-C4)-alkyl, SO(C1-C4)alkyl, SO2(C1-C4)-alkyl, NH2, NH(C1-C4)-
alkyl, N((C1-C4)-alkyl)2, N ((C1-C4)alkyl)R8, COOH, C(O)O(C1-C4)-alkyl or
O(C1-C4)—alkyl; and
R8 is an amino protecting group; and
wherein any carbon atom in any R2 or R6 is
optionally replaced by O, S, SO, SO2, NH,
or N(C1-C4)-alkyl.
__________
[11] [21] 126853
[54]
N-ACYL SULPHONAMIDES AS
SAFENERS FOR PROTECTING
CROP PLANTS AGAINST
PHYTOTOXIC SIDE EFFECTS
OF HERBICIDES, HERBICIDAL
COMPOSITIONS CONTAINING
THEM AND HERBICIDALLY
ACTIVE SUBSTANCES, SOME
SUCH NOVEL COMPOUNDS
AND PROCESS FOR THEIR
PREPARATION
‫אציל סולפונאמידים כמאבטחים להגנת‬-N
‫צמחי תבואה כנגד תופעות לואי‬
‫ תכשירים‬,‫פיטוטוקסיות של קוטלי עשבים‬
‫קוטלי עשבים המכילים אותם וחומרים‬
‫ מספר תרכובות‬,‫הפעילים כקוטלי עשבים‬
‫חדשות כאלו ותהליך להכנתן‬
[22]
[31]
[51]
6. 5.1997
19621522.6
[32] 29. 5.1996
[33] DE
Int. Cl.7 C07C 311/51, 317/44, 323/50, 325/02, 327/04, 333/08; C07D 203/04, 205/08,
207/26, 211/76, 223/10, 255/02, 307/68, 333/38; C07F 9/38; A01N 41/06, 43/08, 43/10
[87]
WO 97/45016
[71]
Hoechst Schering Agrevo GmbH,
Berlin, Germany
[74]
Eitan, Pearl, Latzer & Cohen,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
Zedek, 7 Shenkar St., Herzliya
‫ הרצליה‬,7 ‫רח' שנקר‬
[57] The use of compounds of the
plants against phytotoxic side effects of
formula (l) or salts thereof in the
herbicide
preparation of safeners for protecting crop
where
R1 is hydrogen, a hydrocarbon radical, a
hydrocarbonoxy radical, a hydrocarbonthio
radical or a heterocyclyl radical, each of
August 31, 2005– ‫כ"ו באב התשס"ה‬
the last mentioned 4 radicals being
unsubsituted or substituted by one or more
identical or different radicals selected from
the group consisting of halogen, cyano,
980
nitro, amino, hydroxyl, carboxyl, formyl,
carboxamide, sulfonamide and radicals of
the formula –Za-Ra,
R2 is hydrogen or (C1-C4)-alkyl, or
R1 and R2 together with the group of the
formula –CO-N- are the radical of a 3-to 8membered saturated or unsaturated ring
and R3, in the event that n=1, or the R3
radicals independently of one another, in
the event that n is greater than 1, is, or are,
in each case halogen, cyano, nitro, amino,
hydroxyl, carboxyl, formyl, CONH2,
SO2NH2 or a radical of the formula –Zb-Rb,
R4 is hydrogen or (C1-C4)-alkyl,
R5, in the event that m=1, or the R5
radicals independently of one another, in
the event that m is greater than 1, is, or are,
in each case halogen, cyano, nitro, amino,
hydroxyl, carboxyl, CHO, CONH2,
SO2NH2 or a radical of the formula –Zc-Rc,
Ra is a hydrocarbon radical or a
heterocyclyl radical, each of the two lastmentioned radicals being unsubstituted or
substituted by one or more identical or
different radicals selected from the group
consisting of halogen, cyano, nitro, amino,
hydroxyl, mono-and di-[(C1-C4)-alkyl]
amino, or is an alkyl radical in which more
than one non-adjacent CH2 group is in each
case replaced by an oxygen atom,
Rb, RC independently of one another are a
hydrocarbon radical or a heterocyclyl
radical, each of the two last-mentioned
radicals being unsubstituted or substituted
by one or more identical or different
radicals selected from the group consisting
of halogen, cyano, nitro, amino, hydroxyl,
phosphoryl, halo-(C1-C4) – alkoxy, monoand di-[(C1-C4)- alkyl]amino, or are an
alkyl radical in which more than one nonadjacent CH2 group is in each case
replaced by an oxygen atom,
Za is a divalent group of the for mula –O-, S-, -CO-, -CS-, -CO-O-,
-CO-S-, -O-CO-, -S-CO-, -SO-, -SO-2-, NR*-, -CO-NR*-, -NR-CO-,
-SO2-NR*- OR –NR*-SO2-, the bond
shown on the right of the divalent group in
981
question being the bond to the radical Ra
and the R* radicals in the last-mentioned 5
radicals independently of one another
being in each case H, (C1-C4)-alkyl or
halo- (C1-C4)- alkyl,
Zb ,Zc independently of one another are a
direct bond or divalent group or the
formula –O-, -S-, -CO-,-CS-, CO-O-, -COS-, -O-CO-, -S-CO-, -SO-, -SO2-, -NR*-, SO2-NR*-or –NR*-CO-, the bonds given
on the right of the divalent group in
question being the bond to the radical Rb
or Rc, and the R* radicals in the lastmentioned 5 radicals independently of one
another in each case being H, (C1-C4)alkyl or halo- (C1-C4) – alkyl,
n is an integer from 0 to 4, and m is an
integer from 0 to 5.
Claimed as novel are the compounds of the
formula (l) or a salt thereof with the
exception of compounds where (a) R2=H,
R3=H, and
(a1) R1=CH3 and
m = 0 or (R5)m=2-, 3- or 4-CH3, 4-C2H5, 4n-C3H7, 4-i-C3H7,
4-OCH3, 4-i-OC3H7, 4-NH2, 4-Cl, 4-NO2,
2, 3-(CH3)2,
2, 4-(CH3)2, 3, 4-(CH3)2, 2,5-(CH3)2, 2,4,5(CH3)3,
2, 4, 6-(CH3)3, 2, 3, 4, 5, 6-(CH3)5, 3-CH34-OCH3, 3-CH3-4SCH3, 2,4-(OCH3)2, 3, 4, 5-(OCH3)3, 2OCH3-4NH2, 2-OCH3-4-NO2
(a2) R1 = H, n-C3H7, n-C6H13, cyclohexyl
or 2-methylphenyl and (R5)m = 2-CH3,
(a3) R1 = n-C5H11 and
m = 0 or (R5)m = 2-CH3, 3-NO2, 4-NO2,
(a4) R1 = n-C9H19 and m= 0,
(a5) R1 = OCH3, (R5)m = 2-i-OC3H7,
(a6) R1 =OC2H5, (R5)m=2-OCH3, 2-COOH,
3, 5-(CH3)2,
(a7) R1 = CH2CH2COOH and
m = 0 or (R5)m=4-i-OC3H7,
(a8) R1 =CH=CHCOOH and (R5)m=2-CH3
or 4-i-OC3H7,
August 31, 2005– ‫כ"ו באב התשס"ה‬
(a9) R1 = 4-methoxyphenyl and (R5)m=4(e) R1 = C6H5, R2, (R3)n, R4 and (R5)m = H;
OCH3,
(f) R1 = CH3, R2, (R3)n and R4 = H, (R5)m =
(a10) R1=4-nitrophenyl and (R5)m=4-NO2,
2-COOH;
(a11) R1 = benzioxol-6-yl
(g) R1 = OC2H5, R2(R3)n and R4 = H, (R5)m
1
(a12) R = 3, 5-dimethyl-1-phenylpyrazol= 2-OH;
4-yl or
(h) R1 and R2 together with the group –
2, 3-dimethyl-1-phenyl-5-oxopyrazol-4-yl
CO-N- they are attached to are N-phthalyl,
and
R3, R4 and (R5)m = H;
5
(R )m=4-i-OC3H7,
(i) R1=CH3, R2, (R3)n and R4 =H, (R5)m =
(a13) R1 = C11H23, CH2Cl, CH2Br, CH2I,
2-OH-4-NH2;
CHCl2, CCl3 or CH2F and
(k) R1 = C6H5-CH=CH, R2(R3)n and R4 =
5
(R )m = 3, 4-(CH3)2; or
H, (R5)m=2-CH3,
1
2
4
(b) R = H, R = H, R =CH3, n=m=o,
(l) R1 = CH3, R2 and (R3)n = H, R4 = CH3,
(c) R1 = CH3, R2 = H, (R3)=a fused
(R5)m-H;
benzene ring in the 2, 3 – position and m =
(m) R1 = 2-(2-COOH-C6H4)-C6H4, R2,
0 or
(R3)n and R4 = H, (R5)m = H or 2-NO21
2
4
3
(d) R = phenyl, R =R =H, (R )n=3(n) R1 = 2-COOH-C6H4, R2 = R4 = H, n=0
phenylcarbonyloxy and m=0;
and m=0.
__________
[11] [21] 127092
[54]
REGULATION OF EXCITABLE
TISSUE CONTROL OF THE
HEART BASED ON
PHYSIOLOGICAL INPUT
[22]
[51]
[71]
16. 11.1998
Int. Cl.7 A61N 1/365
Impulse Dynamics (Israel) Ltd., Tirat
Harcarmel
[74]
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[57] Apparatus for stimulating cardiac
tissue in the body of a patient, comprising:
at least one sensor (40), coupled to the
body which generates signals indicative of
physiological activity; one or more
stimulation electrodes (38), which are
placed in contact with the heart; and an
electrical control unit (44), which receives
and analyzes the signals from the sensor so
as to derive a measure of the physiological
activity and which applies an excitable
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫וויסות של בקרה על רקמה בלב הניתנת‬
‫לגירוי באמצעות קלט פיזיולוגי‬
‫ טירת‬,‫אימפולס דינמיק (ישראל) בע"מ‬
‫הכרמל‬
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
tissue control (ETC) signal to the
stimulation electrodes so as to enhance
contractility of the heart muscle responsive
to the measure, wherein the control unit
assigns the measure to one of a plurality of
predetermined ranges and varies the
application of the ETC signals dependent
on the range, wherein the control unit
holds off application of the signal when the
measure is outside a range between
predetermined lower and upper thresholds.
982
__________
[11] [21] 127374
[54]
SELF PROPELLING MACHINE
FOR PLANT ANTI VIRUS
INOCULATION
[22]
[51]
[71]
2. 12.1998
Int. Cl.7 A01C 23/04
Bio-Oz Advanced Biotechnological
Agriculture Ltd. Yad Mordechay
[72]
Gal Yarden, Eliyahu Lev, Ronen
Chemo and Chaim Livne
G.E. Ehrlich (1995) Ltd.,
28 Bezalel St., Ramat Gan
[74]
[57] A self-propelling machine for
large scale plant inoculation by
insertion of inoculum material into
inner tissues of plants, comprising;
(a) conveying mechanism (2) for
conveying the machine along rows of
plants;
(b) an inoculum solution container (4);
(c) a pressurized-gas source (18);
(d) at least one multi-outlet inoculum
sprayer (7) controlled by a trigger, and
connected by respective pipes (5, 16)
to the inoculum solution container and
to the pressurized-gas source;
(e) a chassis for supporting and
983
‫מכונה הנעה בכוח עצמי לחיסון אנטי וירוס‬
‫לצמחים‬
‫ביו עוז ביוטכנולוגיה מתקדמת בחקלאות‬
‫ יד מרדכי‬,‫בע"מ‬
‫ רונן חמו וחיים ליבנה‬,‫ אליהו לב‬,‫גל ירדן‬
,‫) בע"מ‬1995( ‫ ארליך‬.‫אי‬.‫ג'י‬
‫ רמת גן‬,28‫רח' בצלאל‬
connecting between the machine parts;
wherein once the trigger of the multioutlet inoculum sprayer is turned on,
inoculum solution and pressurized gas
flow simultaneously from the
inoculum solution container and from
the pressurized gas source to the
multi-outlet sprayer through the
respective pipes, and both said flows
are brought within the multi-outlet
sprayer to a plurality of nozzles, and
spray the plants with inoculumsolution carried by jets of pressurized
gas, the pressure of said jets is
sufficient for effective plant
August 31, 2005– ‫כ"ו באב התשס"ה‬
inoculation by insertion of inoculum
material into inner tissues of plants.
__________
[11] [21] 127425
[54]
DEVICE FOR THE
MANUFACTURE OF HYDROGEN
BROMIDE
[22]
[31]
[51]
[61]
[71]
7. 12.1998
9715765
[32] 12. 12.1997
Int. Cl.7 C01B 7/09
Addition to 121142
Elf Atochem S.A., Puteaux (Hauts de
Seine), France
Sylvie Frances, Gilles Drivon and
Philippe Leduc
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[72]
[74]
[57] Device for the manufacture of
hydrogen bromide by direct combustion of
bromine in hydrogen, characterized in that
it successively comprises: a burner (1)
comprising means (2) for introducing the
bromine and/or the oxidant, means (3) for
introducing the hydrogen and means for
placing the said reactants in contact, the
said burner consisting of a vertical
chamber inside which is placed a vertical
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫מתקן לייצור מימן ברומי‬
[33] FR
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
cylindrical tube, the said chamber
comprising successive zones: a cylindrical
zone of height h1 and of diameter D3, a
convergent frustoconical zone of height h2
and of diameters D3 and D4 respectively,
with D3>D4, a cylindrical zone of height
h3 and of diameter D4, and a divergent
frustoconical zone of height h4 and of
diameters D4 and D5 respectively, with D4
‹D5, h2‹h4 and D5 >D3; a combustion
984
chamber (4), means (5) for starting a
flame, means (6) for cooling the
combustion gases, means (7 and 8) for
evacuating the combustion gases, and
safety members (9) and (10).
__________
[11] [21] 127774
‫ – פרוטנייס‬1 – ‫תהליך להפרדת מונע אלפא‬
IV1+IV4 ‫ממשחת נגזרות כהן‬
[54]
PROCESS FOR SEPARATING
ALPHA-1-PROTEINASE
INHIBITOR FROM COHN
FRACTION IV1 + IV4
[22]
[31]
[87]
[51]
[71]
27. 6.1997
673064
[32] 1. 7.1996
WO 98/00154
Int. Cl.7 C07K 1/14, 1/18, 1/30, 1/34, 14/81
Alpha Therapeutic Corporation, Los
Angeles, Calif., U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[74]
[57] Process for purifying alpha-1-PI
comprising: providing an impure protein
fraction comprising alpha-1-PI; suspending
the impure protein fraction comprising
alpha-1-PI in an aqueous solution at a pH
of about 6 for a time sufficient for soluble
985
[33] US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
proteins to dissolve; filtering the
suspension and recovering insoluble
proteins; resuspending the insoluble
protein in an aqueous solution; adding
PEG to the resuspended insoluble protein
to precipitate α-2-globulin; recovering the
August 31, 2005– ‫כ"ו באב התשס"ה‬
supernatant from the PEG precipitation,
wherein the supernatant comprises alpha1-PI; adding ZnCl2 to the supernatant to
precipitate crude alpha-1-PI; recovering
the crude alpha-1-PI; solubilizing the
recovered crude alpha-1-PI; applying the
solubilized crude alpha-1-PI to an anionexchange medium; and recovering a
fraction comprising purified alpha-1-PI
from the anion-exchange medium.
_________
[11] [21] 128036
[54]
[22]
[31]
[87]
[51]
[71]
[74]
DEOXYNOJIRIMYCIN
‫תולדות דאוקסינוז'ירימיצין המכילות קבוצה‬
DERIVATIVES COMPRISING A
‫ תכשירים רפואיים‬,‫טבעתית‬-‫אלכוהולית רב‬
POLYCLIC ALCOHOL GROUP,
,‫המכילים תולדות דאוקסינוז'ירימיצין‬
PHARMACEUTICAL
‫ושימושים שלהם‬
COMPOSITION COMPRISING A
DEOXYNOJIRIMYCIN
DERIVATIVE AND USES
THEREOF
14. 7.1997
96202010.3
[32] 15. 7.1996
[33] EP
WO 98/02161
Int. Cl.7 C07D 211/46; C07J 9/00; C07H 5/06; A61K 31/445, 31/715; A61P 43/00
Universiteit van Amsterdam,
Amsterdam, The Netherlands
Eitan, Pearl, Latzer & Cohen,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
Zedek, 7 Shenkar St., Herzliya
‫ הרצליה‬,7 ‫רח' שנקר‬
[57] Glucosylceramidase inhibiting
deoxynojirimycin derivatives containing a
large hydrophobic moiety linked through a
spacer to the nitrogen atom of
deoxynojirimycin, and salt thereof,
wherein said spacer comprises an alkoxy
polyalkylene and/or polyalkylene chain of
from 3 to 8 carbon atoms and wherein said
hydrophobic moiety comprises a
polycyclic alcohol group containing three
or more rings that each share two or more
carbon atoms with another ring, said
hydrophobic moiety being capable of
inserting in lipid bilayer membranes.
_________
August 31, 2005– ‫כ"ו באב התשס"ה‬
986
[11] [21] 128329
[54]
[22]
[31]
[51]
[71]
[74]
PHARMACEUTICAL
COMPOSITION OF HEDGEHOG
PROTEINS AND USE THEREOF
2. 2.1999
98101893.0
[32] 4. 2.1998
98104416.7
12.3.1998
Int. Cl.7 A61K 47/30, 38/16; A61P 19/00
Curis, Inc., Cambridge, Mass., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
hedgehog ‫תכשיר רוקחות המכיל חלבוני‬
‫ושמוש בו‬
[33] EP
"
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] Pharmaceutical composition of a
hedgehog protein when it binds to the
hedgehog protein which is characterized in
carrier, contains at least 0.1 to 2
that the hedgehog protein is bound to a
negatively-charged residues per monomer
hydrophilic carrier which is biocompatible
under neutral conditions, contains the
wherein the carrier is a polymer which
charge in the form of acidic groups, has an
binds the hedgehog protein as a
average molecular weight of at least
negatively-charged carrier as result of
50,000 Da, and contains no agarose.
ionic interactions, does not denature the
__________
[11] [21] 128411
‫נירוטוין גן ניורולוגי‬
[54]
NEURITIN, A NEUROGENE
[22]
[31]
[87]
[51]
[71]
7. 8.1997
694679
[32] 9. 8.1996
[33] US
WO 98/06843
Int. Cl.7 C12N 15/12, 15/63, 15/70, 15/74, 15/79; C07K 14/435, 14/475
Amgen Inc., Thousand Oaks, Calif.,
‫ רחובות‬,‫ידע חברה למחקר ופתוח בע"מ‬
U.S.A. and Yeda Research &
Development Co. Ltd., Rehovot
Sanford T. Colb & Co.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273, Rehovot
‫ רחובות‬,2273 .‫ד‬.‫ת‬
[74]
[57] An isolated nucleic acid molecule
(c) a nucleic acid molecule encoding the
encoding a polypeptide which promotes
polypeptide of SEQ ID NO:3;
neuritogenesis in hippocampal or cortical
(d) a nucleic acid molecule encoding the
neuronal cultures, wherein the nucleic acid
polypeptide of SEQ ID NO:4; and
molecule is selected from the group of
(e) a nucleic acid molecule that encodes a
nucleic acid molecules consisting of:
polypeptide that is at least 70 percent
(a) the nucleic acid molecule of SEQ ID
identical to the polypeptide of SEQ ID
NO:1;
NO:3 or SEQ ID NO:4.
(b) the nucleic acid molecule of SEQ ID
NO:2;
__________
987
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 128622
‫הרכב הכולל פולי (ארילן אתר) בעל שתל‬
‫ שיטה להכנתו של השתל הארומטי‬,‫ארומטי‬
‫ושיטה לצילוב פולימר ארומטי‬
[54]
COMPOSITION COMPRISING
POLY (ARYLENE ETHER) WITH
AN AROMATIC GRAFT, A
METHOD OF SYNTHESIZING
SAID AROMATIC GRAFT, AND A
METHOD OF CROSSLINKING
AN AROMATIC POLYMER
[22]
[31]
[51]
[71]
19. 2.1999
030039
[32] 25. 2.1998
[33] US
Int. Cl.7 C08G 65/40, 65/48; C08L 71/00; H01L 23/532
Air Products and Chemicals, Inc.,
Allentown, Pa., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A composition comprising a poly
(arylene ether) polymer having a graft
which graft can be thermally induced to
crosslink the polymer, wherein said
polymer having said graft has the
structure:
wherein m = 0 to 1.0; and n=1.0 – m; and
Ar1, Ar2, Ar3 and Ar4 are individually
arylene radicals defined in the
specification and G1-a are individually: H,
or mixtures thereof, wherein Z is the
average number of G radicals which are 1
or 2 per repeating unit of said polymer and
Z is in the range of 0.1 to 4.0, where R1,
R2, R3 and R4 are individually H or alkoxy
radical, wherein the alkoxy radical can
have a normal or branched alkyl radical of
C1-8, and further wherein said poly (arylene
ether) polymer consists essentially of nonfunctional repeating units wherein Ar1,
Ar2, Ar3 and Ar4 are individually arylene
radicals defined in the specification.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
988
[11] [21] 128654
‫אדום‬-‫כיסויים מחזירי אור אינפרה‬
[54]
INFRA-RED REFLECTIVE
COVERINGS
[22]
[31]
30. 7.1997
707997
[32] 20. 9.1996
751288
18.11.1996
WO 98/12494
Int. Cl.7 F41H 3/02
W.L. Gore & Associates, Inc., Newark,
Del., U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[87]
[51]
[71]
[74]
[57] An infra-red reflective material for
covering objects, said material comprising
a microporous, air-permeable, moisture
vapor transmissive, water resistant and
drapeable polymeric membrane (10)
having a top surface (10a), a bottom
surface, and pores (12) therebetween; said
membrane including:
(a) an infra-red reflective metal coating
[33] US
"
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
(13) covering at least one of said
membrane surfaces and exposed subsurface portions thereof; in a manner such
that the coating is disposed only
discontinuously on at least one of said
membrane top surface and exposed subsurface; and
(b) an oleophobic coating (14) covering at
least a portion of said metal coating.
__________
[11] [21] 128829
[54]
SOLID PHASE SYNTHESIS OF
PEPTIDES WITH PRESEQUENCES
[22]
[31]
[87]
[51]
[71]
9. 9.1997
0971/96
[32] 9. 9.1996
WO 98/11125
Int. Cl.7 C07K 1/04
Zealand Pharma A/S, Glostrup,
Denmark
Dr. Yitzhak Hess & Partners,
P.O.B. 6451, Tel-Aviv
[74]
989
‫סינטזה בפזה מוצקה של פפטידים עם‬
‫רצפים מקדימים‬
[33] DK
,‫ד"ר יצחק הס ושותפיו‬
‫אביב‬-‫ תל‬,6451 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] A process for the production of
peptides
X-AA1-AA2 …. AAn-Y
wherein AA is an L- or D-amino acid
residue,
X is hydrogen or an amino protective
group, and
Y is OH, NH2 and n is an integer greater
than 2 by solid phase synthesis wherein the
C-terminal amino acid in the form of an Nα-protected, and if necessary side chain
protected reactive derivative is coupled to
a solid support or a polymer optionally by
means of a linker, subsequently N-αdeprotected, whereafter the subsequent
amino acids forming the peptide sequence
are stepwise coupled or coupled as a
peptide fragment in the form of suitably
protected reactive derivatives or fragments,
wherein the N-α-protective group is
removed following formation of the
desired peptide and the peptide is cleaved
from the solid support, characterized in
that the process further comprises:
selecting a pre-sequence comprising from
3 to 9 residues independently selected
from native amino acids having a side
chain functionality which is protected
during the coupling steps and having a
propensity factor pα>0.57 and a propensity
factor pβ ≤1.10, the C-terminal part of said
peptide comprising the pre-sequence; and
cleaving said pre-sequence from the
formed peptide.
__________
[11] [21] 129555
-N ‫תכשירי רוקחות המכילים תולדות‬
‫(אוקסואציטיל) – חומצת אמינו אמיד‬
‫להמרצת גידול ניוריט‬
[54]
PHARMACEUTICAL
COMPOSITIONS CONTAINING
N-(OXOACETYL)-AMINO ACID
AMIDE DERIVATIVES FOR
STIMULATING NEURITE
GROWTH
[22]
[31]
[87]
[51]
13. 11.1997
748447
[32] 13. 11.1996
[33] US
WO 98/20891
Int. Cl.7 A61K 31/16, 31/33; A61P 25/00 // C07C 235/78, 309/14, 309/45, 417/24,
317/26, 323/22, 323/23; C07D 207/32, 207/34, 209/18, 209/30, 209/44, 213/241,
213/72, 415/12, 215/22, 217/12, 217/22, 231/02, 231/06, 231/96, 233/66, 233/88,
235/06, 235/24, 237/36, 237/26 317/48, 333/08, 333/36, 341/00, 401/00, 403/00,
405/00, 409/00
Vertex Pharmaceuticals Incorporated,
Cambridge, Mass., U.S.A.
Wolff, Bregman and Goller,
,‫ ברגמן וגולר‬,‫וולף‬
P.O.B. 1352, Jerusalem
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[71]
[74]
August 31, 2005– ‫כ"ו באב התשס"ה‬
990
[57] A pharmaceutically acceptable
composition comprising:
(a) a neurotrophic amount of a compound
of the formula
and pharmaceutically acceptable
derivatives thereof, wherein:
R1, B and D are independently: hydrogen,
Ar, (C1-C6) straight or branched alkyl, (C2C6) straight or branched alkenyl or alkynyl,
(C5-C7) cycloalkyl substituted (C1-C6)
straight or branched alkyl, (C5-C7)
cycloalkyl substituted (C3-C6) straight or
branched alkenyl or alkynyl, (C5-C7)
cycloalkenyl substituted (C1-C6) straight or
branched alkyl, (C5-C7) cycloalkenyl
substituted (C3-C6) straight or branched
alkenyl or alknyl, Ar-substituted (C1-C6)
straight or branched alkyl, Ar-substituted
(C3-C6) straight or branched alkenyl or
alkynyl;
provided that R1 is not hydrogen or (C1-C6)
straight or branched alkyl; and wherein
any one of the CH2 groups of said alkyl
chains in R1, B and D is optionally
replaced by O, S, SO, SO2 or NR;
wherein R is hydrogen, (C1-C6) straight or
branched alkyl, (C3-C4) straight or
branched alkenyl or alkynyl, or (C1-C4)
bridging-alkyl wherein a bridge is formed
between the nitrogen and a carbon atom of
said alkyl chain to form a ring, and
wherein said ring is optionally fused to Ar;
wherein each Ar is independently selected
from phenyl, 1-naphthyl, 2-naphthyl,
indenyl, azulenyl, fluorenyl, anthracenyl,
2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl,
oxazolyl, thiazolyl, imidazolyl, pyrazolyl,
2-pyrazolinyl, pyrazolidinyl, isoxazolyl,
isotraizolyl, 1, 2, 3-oxadiazolyl, 1, 2, 3triazolyl, 1, 3, 4-thiadiazolyl, pyridazinyl,
pyrimidinyl, pyrazinyl, 1, 3, 5-triazinyl, 1,
3, 5-trithianyl, indolizinyl, indolyl,
isoindolyl, 3H-indolyl, indolinyl, benzo[b]
furanyl, benzo[b] thiophenyl, 1Hindazolyl, benzimidazolyl, benzthiazolyl,
pyrinyl, 4H-quinolizinyl, quinolinyl, 1, 2,
3, 4-tetrahydroisoquinolinyl, isoquinolinyl,
1, 2, 3, 4-tetrahydroquinolinyl, cinnolinyl,
phthalazinyl, quinazolinyl, quinoxalinyl,
1,8-naphthyridinyl, pteridinyl, carbazolyl,
acridinyl, phenazinyl, phenothiazinyl and
phenoxazinyl; and wherein each Ar is
optionally and independently substituted
with one to three substituents
independently selected from hydrogen,
halogen, hydroxyl, nitro, -SO3H,
trifluoromethyl, trifluoromethoxy, (C1-C6)
straight or branched alkyl, O-((C1-C6)
straight or branched alkyl), O-benzyl, Ophenyl, 1, 2-methylenedioxy, -NR5R6,
carboxyl, N-(C1-C6 straight or branched
alkyl or C3-C5 straight or branched
alkenyl) carboxamide, N,N-di-((C1-C6)
straight or branched alkyl or (C3-C5)
straight or branched alkenyl) carboxamide,
morpholinyl, piperidinyl, O-M, CH2(CH2)q-M, O-(CH2)q- M, (CH2)q-O-M, and
CH-CH-M;
wherein R5 and R6 are independently
selected from the group consisting of
hydrogen, (C1-C6) straight or branched
alkyl, (C2-C6) straight or branched alkenyl
or alkynyl, benzyl or R5 and R6 are taken
together to form a 5-7 membered
heterocyclic ring;
M is selected from the group consisting of
4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4pyridyl, pyrazyl, quinolyl, 3, 5dimethylisoxazolyl, 2-methylthioazolyl,
991
August 31, 2005– ‫כ"ו באב התשס"ה‬
thiazolyl, 2-thienyl, 3-thienyl, 4-thienyl
and pyrimidyl; and
q is 0-2;
J is selected from the group consisting of
(C1-C6) straight or branched alkyl, (C3-C6)
straight or branched alkenyl or alkynyl,
Ar-substituted (C1-C6) straight of branched
alkyl, and Ar-subsituted (C3-C6) straight or
branched alkenyl or alkynyl, and
cyclohexylmethyl;
K is selected from the group consisting of
(C1-C6) straight or branched alkyl, Ar substituted (C1-C6) straight or branched
alkyl, (C2-C6) straight or branched alkenyl
or alkynyl, and Ar-substituted (C3-C6)
straight or branched alkenyl or alkynyl,
and Ar-substituted (C3-C6) straight or
branched alkenyl or alknyl; or
J and K are taken together with the
nitrogen and carbon atoms to which they
are respectively bound to form a 5-7
membered heterocyclic ring which may
contain a heteroatom selected from O, S,
SO and SO2;
X is selected from the group consisting of
Ar, -OR2, and-N(R3)R4;
wherein R2 has the same definition as R1;
R3 and R4 independently have the same
definitiona as B and D; or R3 and R4 are
taken together to form a 5-7 membered
heterocyclic aliphatic or aromatic ring; and
m is 0 or 1;
(b) a neurotrophic factor; and
(c) a pharmaceutically suitable carrier.
__________
[11] [21] 130041
‫או אצטט ברזלי לבקרה‬/‫ציטרט ברזלי ו‬
‫בעצירת זרחה בחולי היפרפוספטמיה‬
[54]
FERRIC CITRATE AND/OR
FERRIC ACETATE FOR
CONTROLLING PHOSPHATE
RETENTION IN
HYPERPHOSPHATEMIA
PATIENTS
[22]
[31]
14. 11.1997
60/032745
[32] 16. 12.1996
[33] US
794328
3.2.1997
"
WO 98/26776
Int. Cl.7 A61K 31/19; A61P 12/13//C07C 53/10, 5 9/265
Chen Hsing Hsu, Ann Arbor, Mich.,
U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[87]
[51]
[71]
[74]
[57] A compound selected from the group
consisting of ferric citrate and ferric
acetate and combinations thereof, for use
in therapeutic composition in an oral
dosage form for controlling phosphate
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
retention in patients having need for
reduced absorption of dietary phosphate,
wherein said composition comprises on a
per dose basis from about 500 mg to about
1000 mg of said compound.
_________
August 31, 2005– ‫כ"ו באב התשס"ה‬
992
[11] [21] 130133
‫ ותכשירי‬,‫תולדות של אינדן או דיהידרואינדול‬
‫רוקחות המכילים אותן‬
[54]
INDANE OR DIHYDROINDOLE
DERIVATIVES AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
[22]
[31]
[87]
[51]
[71]
19. 12.1997
1514/96
[32] 20. 12.1996
[33] DK
WO 98/28293
Int. Cl.7 C07D 401/04, 401/14, 403/04, 403/14, 491/02; A61K 31/445; A61P 25/00
H. Lundbeck A/S, Valby Copenhagen,
Denmark
Dr. Yitzhak Hess & Partners,
,‫ד"ר יצחק הס ושותפיו‬
P.O.B. 6451, Tel-Aviv
‫אביב‬-‫ תל‬,6451 .‫ד‬.‫ת‬
[74]
[57] A substituted indane or
dihydroindole compound of the formula
wherein A is a group
Y is hydrocarbon group completing an
indane ring, a group NR1 completing a
dihydroindole ring or a group N
completing a dihydroindole ring linked via
the 1-position;
W is a bond, and n+m is 1, 2, 3, 4, 5, or 6;
993
W is CO, SO, or SO2, n is 2, 3, 4, or 5 and
m is 0, 1, 2, or 3, provided that n+m is not
more the 6; or
W is O, S, n is 2, 3, 4, or 5 and m is 0, 1, 2,
or 3, provided that n+m is not more than 6,
and provided that if Y is N completing a
August 31, 2005– ‫כ"ו באב התשס"ה‬
dihydroindole ring attached via the 1position then m is 2, or 3; and if Y is NR1
completing a dihydroindole ring linked via
the 2-position then m is 1, 2, or 3;
the dotted line, emanating from X,
indicates an optional bond; when it does
not indicate a bond, N, CH or COH; and
when it indicates a bond, X is C;
R1 is
hydrogen, C1-6-alk (en/yn)yl, C3-8cycloalk(en)yl, C3-8-cycloalk)en)yl-C1-6alk(en/yn)yl, aryl,
heteroaryl, aryl-C1-6-alkyl, heteroaryl-C1-6alkyl, acyl, thioacyl, C1-6-alkylsulfonyl,
trifuoromethylsulfonyl, arylsulfonyl, or
heteroarylsulfonyl;
R15VOC – wherein v is O or S and R15 is
C1-6-alk (en/yn)yl, C3-8-cycloalk (en) yl, C38-cycloalk(en)yl-C1-6-alk (en/yn)yl, aryl, or
heteroaryl; or
group R16R17NCO-or R16R17NCS- wherein
R16 and R17 are independently hydrogen,
C1-6alk (en/yn)yl, C3-8-cycloalk(en)yl, C3-8cycloak(en)yl-C1-6-alk(en/yn)yl,
heteroaryl, or aryl, or R16 and R17 together
with the N-atom to which they are linked,
form a pyrrolidinyl, piperidinyl or
perhydroazepin group; and
R2-R5 are independently selected from
hydrogen, halogen, cyano, nitro, C1-
6(alk(en/yn)/yl,
C1-6 alkoxy, C1-6 alkylthio,
hydroxy, C3-8-cycloalk(en) yl, C3-8cycloalk(en)yl- C1-6-alk(en/yn)yl, C1-6alkylcarbonyl, trifluoromethyl,
trifluoromethylsulfonyloxy and R1-6
alkylsulfonyl, one of R2-R5 alternatively
being a group –NR13R14 wherein R13 is as
defined for R1 and R14 is hydrogen, C1-6alk(en/yn)yl, C3-8-cycloalk(en)yl, C3-8cycloalk(en)yl-C1-6 alk(en/yn)yl, or two
adjacent groups taken from R2 – R5 may be
joined and designate a – (CH2)3-,
or – CH=CH-NH-, thereby forming a
fused 5 membered ring;
R6 – R9 and R12 are independently
hydrogen, halogen, cyano, nitro, C1-6alk(en/yn)yl, C1-6-alkoxy, C1-6-alkylthio,
hydroxy, C3-8-cycloalk (en) yl, C3-8cycloalk(en)yl – C1-6 alk (en/yn)yl,
trifluoromethyl, or C1-6 alkylsulfonyl, or
two adjacent groups taken from R6 – R9
may together form a methylenedioxy
group; R10 is as defined for R1 above;
with the proviso that the substituent R3 or
R4 in position 6 may not be –NR13R14
when Y is CH2, W is a bond, n+m is 1 and
the ring is linked via the 1-position; or a
pharmaceutically acceptable acid addition
salt thereof.
____________
August 31, 2005– ‫כ"ו באב התשס"ה‬
994
[11] [21] 130178
‫חומר מורכב בעל יכולת ספיגה גבוהה‬
‫ יריעות סופגות המכילות‬,‫ושיטות להכנתו‬
‫אותו והתקנים להכנת יריעות אלה‬
[54]
HIGHLY ABSORBENT
COMPOSITE AND METHODS
FOR MAKING THE SAME,
ABSORBENT SHEETS
INCORPORATING THE SAME
AND APPARATUS FOR MAKING
SUCH SHEETS
[22]
[31]
15. 12.1997
8-333520
[32] 13. 12.1996
[33] JP
9-124623
15.5.1997
"
9-192159
17.7.1997
"
9-213222
7.8.1997
"
9-313368
14.11.1997
"
9-329830
1.12.1997
"
WO 98/25999
Int. Cl.7 C08L 1/00; A61F 13/15; A61L 15/28, 15/60; D06M 15/05
Japan Absorbent Technology Institute,
Tokyo, Japan
Wolff, Bregman and Goller,
,‫ ברגמן וגולר‬,‫וולף‬
P.O.B. 1352, Jerusalem
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[87]
[51]
[71]
[74]
[57] A highly absorbent composite
comprising hydratable fine fibers in the
form of microfibril obtained from cellulose
or a derivative thereof, and water-
swellable solid particles, at least part of the
surface of each of said water-swellable
solid particles being covered with said fine
fibers in the form of microfibril.
__________
[11] [21] 130295
[54]
SCLERAL PROSTHESIS FOR
TREATMENT OF PRESBYOPIA
AND OTHER EYE DISORDERS
[22]
[31]
[87]
[51]
[71]
21. 5.1998
946975
[32] 8. 10.1997
WO 99/17691
Int. Cl.7 A61F 2/14, 9/007
RAS Holding Corporation, Dallas,
Tex., U.S.A.
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[74]
995
‫פרותזה סקלרלית לטיפול בפרסביופיה‬
‫והפרעות עיניים אחרות‬
[33] US
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] An ocular scleral prosthesis (200)
adapted for insertion into the sclera (102)
of an eye in the region of the ciliary body
comprising: a base member (202) having
an elongated planform with a major
dimension, a minor dimension, an inner
major surface and an outer major surface,
said outer major surface being generally
smooth and adapted to contact ocular
tissue within a pocket surgically formed
within scleral tissue of the eye, and a ridge
member (214) on said base member that
applies an outward force to the pocket to
thereby elevate the sclera in the region of
the ciliary body.
__________
[11] [21] 130486
[54]
OPTICAL SYSTEM
[22]
[51]
[71]
[72]
15.6.1999
Int. Cl.7 G02B 13/18
Given Imaging Ltd., Yoqneam
Hanoch Kislev, Arkady Glukhovsky,
Gavriel Iddan and Gavriel Merom
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
[74]
[57] An optical system comprising an
illumination element (11) and a receiving
means (13), the illumination element and
the receiving means disposed behind a
single optical window (14), wherein: said
optical window is configured such that it
defines a shape having a focal curve; and
wherein said illumination element and said
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫מערכת אופטית‬
‫ יקנעם‬,‫גיוון אימג'ינג בע"מ‬
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
receiving means are positioned in
proximity of a focal curve plane of said
focal curve, such that, when illuminating,
rays from the illumination element, that are
internally reflected from the optical
window, will not be incident on the
receiving means.
996
__________
[11] [21] 130524
,‫פורמולציות נוזליות ויציבות של אינטרפיון‬
‫ערכת המכילה אותן ותהליך ייצובן‬
[54]
STABLE LIQUID INTERFERON
FORMULATIONS, A KIT
CONTAINING THE SAME AND A
PROCESS FOR STABILIZING
THE SAME
[22]
[31]
[87]
[51]
[71]
23.12.1997
60/034353
[32] 24. 12.1996
WO 98/28007
Int. Cl.7 A61K 38/21, 9/08, 47/18
Biogen Idec MA Inc., Cambridge,
Mass., U.S.A.
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[74]
[57] A liquid composition comprising an
interferon and an amino acid stabilizing
agent selected from the group consisting of
acidic amino acids, arginine and glycine;
wherein the amino acid stabilizing agent is
[33] US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
present at between 0.3% and 5% w/v;
wherein the liquid composition has not
been reconstituted from lyophilized
interferon; and wherein the liquid
composition is not further lyophilized.
_________
997
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 130831
‫ תהליך‬,‫אנתרסיקלינון‬-‫אזא‬-‫תולדות אמינו‬
‫להכנתן ותכשירי רוקחות המכילים אותן‬
‫לטיפול באמילואידוזה‬
[54]
IMINO-AZA-ANTHRAYCLINONE
DERIVATIVES, PROCESS FOR
THEIR PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM FOR THE TREATMENT
OF AMYLOIDOSIS
[22]
[31]
[87]
[51]
[71]
9.1.1998
9701628.1
[32] 27. 1.1997
[33] GB
WO 98/32754
Int. Cl.7 C07D 471/08; A61K 31/436; A61P 25/00
Pharmacia & Upjohn S.p.A., Milan,
Italy
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A compound of the formula
wherein:
R1 is selected from:
hydrogen,
hydroxyl,
C1-16 alkyl,
C1-16 alkoxyl,
C3-8 cycloalkoxyl,
halogen,
amino which may be unsubsituted or
mono-or disubsituted by acyl,
trifluoroacyl, aryl which is a monocyclic or
bicylic aromatic group containing from 6
to 10 carbons in the ring portion,
optionally substituted by one or more
substituents, said substituents being
selected from C1-6 alkyl, C1-6 alkoxy,
trifluoromethyl, halogen, hydroxy and
August 31, 2005– ‫כ"ו באב התשס"ה‬
aryloxy group, in which aryl is as above
defined and it is linked to an oxygen atom,
aralkyl, in which a C1-6 alkyl is substituted
by an aryl group as defined above,
OSO2(R4) wherein R4 is alkyl or aryl as
above defined;
R2 is selected from
hydrogen,
RB-CH2-wherein RB represents an aryl
group as defined above, a heterocyclyl
group which is is a 3-, 4-, 5- or 6membered, saturated or unsaturated
heterocyclic ring containing at least one
heteroatom selected from O, S and N,
which is optionally fused to a second 5- or
6-membered, saturated or unsaturated
heterocyclyl group as defined above or to a
998
C3-8 cycloalkyl or aryl group as defined
hydrogen,
above, or a group of formula RC-CH=CHC1-16 alkyl,
wherein RC is hydrogen, C1-16 alkyl, C2-8
C2-16 alkenyl,
alkenyl or C3-8 cycloalkyl,
C3-8 cycloalkyl,
C1-16 alkyl,
aryl as defined above,
C3-8 cycloalkyl,
a group of formula NR7R8 wherein R7 and
aryl-C1-C16-alkyl,
R8, which can be the same or different,
aryloxy-C1-C16-alkyl, in which aryl is as
represent hydrogen, C1-16 alkyl,
defined above, acyl of formula –C(R5)=O
aralkyl as above defined,
wherein R5 is selected from
C2-16 alkenyl,
hydrogen,
C3-8 cycloalkyl,
C1-16 alkyl,
heterocyclyl as above defined,
C2-16 alkenyl,
4-methylpiperazinyl,
C3-8 cycloalkyl,
acyl of formula –C(R5)=O wherein R5 is as
aryl as defined above,
above defined, or R7 and R8, together with
heterocyclyl as defined above,
the N atom to which they are attached,
an acyl residue of an amino acid selected
represent heterocyclyl as above defined,
from glycine, alanine, cysteine,
with the proviso that when R1 is a
phenylalanine, tyrosine,
methoxyl group and R3 is a hydroxyl group
R3 is selected from:
then R2 is not 4-pyridinmethyl,
a group of formula OR6 wherein R6
or a pharmaceutically acceptable salt
represents
thereof.
__________
[11] [21] 130869
[54]
ENDOSCOPIC INFUSION
NEEDLE HAVING DUAL DISTAL
STOPPING POSITIONS
[22]
[31]
[87]
[51]
[71]
7.1.1998
778243
[32] 8. 1.1997
WO 98/30259
Int. Cl.7 A61M 5/162
Symbiosis Corporation, Miami, Fla.,
U.S.A.
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[74]
[57] An endoscopic infusion needle
device, comprising:
(a) a catheter (12) having a proximal end
(14), a distal end (16), and defining a first
lumen (18);
(b) an injection tube (22) having a
proximal end (24), a distal end (26), and
defining a second lumen (28), said
999
‫מחט החדרה לבדיקת פנים בעלת שני‬
‫מרווחי עצירה מרוחקים‬
[33] US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
injection tube extending at least partially
through said first lumen and defining an
annular space between said injection tube
and said catheter;
(c) an injection needle (30) coupled to said
distal end of said injection tube, said
injection needle having an injection lumen
in fluid communication with said second
lumen;
August 31, 2005– ‫כ"ו באב התשס"ה‬
(d) a proximal actuating means (32)
coupled to said proximal end of said
catheter and to said proximal end of said
injection tube for axially displacing said
catheter and said injection tvbe relative to
one another;
(e) injection fluid port means (52) coupled
to said second lumen for introducing an
injection fluid into said injection lumen;
(f) a first distal stopping structure (66a)
coupled to a distal portion of said catheter,
wherein at least a portion of the first distal
stopping structure extends within the
catheter lumen; and
(g) a second distal stopping structure (62)
coupled to at least one of said injection
tube and said injection needle, wherein at
least a portion of said second distal
stopping structure is moveable with the
injection tube and needle within the
catheter lumen, and
wherein said first and second distal
stopping structures cooperate with one
another to provide a positive well-defined
proximal stopping location wherein said
injection needle is shrouded by said
catheter, and to provide a positive welldefined distal stopping location wherein
said injection needle is shrouded by said
catheter, and to provide a positive welldefined distal stopping location wherein
said injection needle extends out of said
catheter.
__________
[11] [21] 130917
[54]
UNIVERSAL T-CELL EPITOPES
FOR ANTI-MALARIAL
VACCINES
[22]
[31]
[87]
[51]
[71]
21.1.1998
60/033916
[32] 21. 1.1997
WO 98/31382
Int. Cl.7 A61K 39/002, 39/015
New York University, New York,
N.Y., U.S.A.
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
[74]
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫ לחיסונים‬T-‫אפיטופים אונירסליים של תאי‬
‫מלריים‬-‫אנטי‬
[33] US
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
1000
[57] An immunogenic composition which
NO:3) or (ii) corresponding in length and
comprises a first peptide comprising a
alignment to SEQ ID NO:3 as present in P.
universal T-cell epitope, wherein said
falciparum NF54 strain CS protein;
universal T-cell epitope:
(b) is not contiguous in the first peptide
(a) is sequence of contiguous amino acids
with any amino acid sequence which is
as present in a sequence of a
immediately adjacent to the sequence of
circumsporozoite (CS) protein of a
the epitope in the sequence of the CS
plasmodila species, said epitope sequence
protein of the plasmodial species; and
(i) having a length and alignment of a
(c) binds many diverse major
motif of aliphatic and aromatic amino acid
histocompatability complex (MHC) class
residues which are identical to the length
II molecules; wherein said composition
and alignment of the motif of amino acid
elicits an anti-CS parasite-specific T-cell
residues in positions corresponding to
response in humans of diverse human
residues 2, 3, 6, 10 and 14 of a sequence
leukocyte antigen (HLA) genetic
EYLNKIQNSLSTEWSPCSVT (SEQ ID
backgrounds.
__________
[11] [21] 130986
‫תהליך ליצור דשנים לשחרור מושהה‬
‫המוכמסים בתכשירי איזוציאנט מכילי‬
‫גופרית‬
[54]
PROCESS FOR PRODUCTION OF
ENCAPSULATED SLOW
RELEASE FERTILIZER IN
SULFUR CONTAINING
ISOCYANATE COMPOSITIONS
[22]
[31]
[51]
[71]
20.7.1999
121374
[32] 23. 7.1998
[33] US
Int. Cl.7 C05C 9/00; A01N 25/00, 27/00, 31/00 // C07C 265/14
Bayer Corporation, Pittsburgh, Pa.,
U.S.A.
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[74]
[57] A process for the production of an
isocyanate coated fertilizer particles from
encapsulated, slow release fertilizer
step (1) to yield polyurethane and/or
composition comprising:
polyurea encapsulated fertilizer articles,
(1) applying an isocyanate composition to
and optionally,
fertilizer particles which contain at least
(3) repeating steps (1) through (2) as
one water soluble plant nutrient to form
many times as necessary, wherein the
isocyanate coated fertilizer particles,
encapsulated fertilizer particles from step
wherein said isocyanate composition
(2) are substituted for the fertilizer
comprises an aromatic di-or
particles in step (1) above, thereby forming
polyisocyanate containing from 1 to 50%
encapsulated fertilizer particles which
by weight of sulfur, based on 100% by
contain from about 2% to about 20% by
weight of isocyanate,
weight of polyurethane and/or polyurea,
(2) applying an isocyanate-reactive
based on the total weight of the
composition which contains at least two
encapsulated fertilizer particles.
isocyanate-reactive groups to the
__________
1001
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 131177
‫תהליך להכנת חומצות ואסטרים של‬
‫ניקוטין‬
[54]
PROCESS FOR THE
PREPARATION OF NICOTINIC
ACIDS AND ESTERS
[22]
[31]
[87]
[51]
[71]
18. 2.1998
811087
[32] 3. 3.1997
[33] US
WO 98/39298
Int. Cl.7 C07D 213/79
Abbott Laboratories, Abbott Park, Ill.,
U.S.A.
Dr. Shlomo Cohen & Co.,
P.O.B. 11490, Tel-Aviv
[74]
,'‫ד"ר שלמה כהן ושות‬
‫אביב‬-‫ תל‬,11490 .‫ד‬.‫ת‬
[57] A process for the preparation of
compounds of the formula
said process comprising reacting a
compound of the formula
under acidic conditions with a nitrite salt;
wherein R1, R2 and R3, are independently
selected from the group consisting of
hydrogen, and halogen atoms and R4 is
selected from the group consisting of
hydrogen, lower alkyl, and aryl.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1002
[11] [21] 131543
‫שיטות קוסמטיות ותכשירים למניעה וטיפול‬
‫בהזדקנות כרונולוגית של עור אנושי‬
[54]
COSMETIC METHODS AND
COMPOSITIONS FOR
PREVENTING AND TREATING
CHRONOLOGICAL AGING IN
HUMAN SKIN
[22]
[31]
23.2.1998
60/040594
[32] 25. 2.1997
60/042976
7.4.1997
WO 98/36742
Int. Cl.7 A61K 7/00, 7/42, 7/44
The Regents of the University of
Michigan, Ann Arbor, Mich., U.S.A.
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[87]
[51]
[71]
[74]
[33] US
"
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[57] A cosmetic method of reducing the
said chronologically-aged skin ot an
natural, chronological, age-related
effective, non-toxic amount of at least one
elevation of collagen-degrading MMP
active non-retinoid ingredient that inhibits
enzymes present in chronologically-aged
MMPs.
skin, comprising the topical application to
__________
[11] [21] 131627
‫שיטה לקידוד אינפורמציה רבת מילים‬
[54]
METHOD FOR ENCODING
MULTIWORD INFORMATION
[22]
[31]
[51]
[87]
[71]
21.12.1998
97204130.5
[32] 29. 12.1997
Int. Cl.7 H03M 13/00
WO 99/34271
Koninklijke Philips Electronics N.V.,
Eindhoven, The Netherlands
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] A method of encoding multiword
information, wherein said method includes
encoding said information as multibit
symbols in relative contiguity with respect
to a medium, with wordwise interleaving
1003
[33] EP
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
and wordwise error protection coding, and
provides error locative clues across
multiword groups, characterized in that the
method comprises: splitting said
multiword information into clue words and
August 31, 2005– ‫כ"ו באב התשס"ה‬
target words, providing a high level of
said target words, and using detected errors
error protection coding for said clue words,
in said clue words to identify target word
and a lower level of protection coding for
portions having a high likelihood of errors.
__________
[11] [21] 131660
‫תהליך להכנת חומרי ביניים לחומרי הדברה‬
‫וחומרי ביניים חדשים לתהליך זה‬
[54]
PROCESS FOR PREPARATION
OF PESTICIDAL
INTERMEDIATES AND NOVEL
INTERMEDIATES THEREFOR
[22]
[31]
25. 2.1998
60/039516
[32] 3. 3.1997
[33] US
9705316.9
14.3.1997
GB
WO 98/39302
Int. Cl.7 C07C 255/66; C07D 213/76, 231/14, 401/04
Rhone-Poulenc Agro, Lyon, France
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[87]
[51]
[71]
[74]
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] Process for the preparation of a
compound of the formula
wherein W is nitrogen or –CR4;
R2, R4, R5 and R6 are independnently
selected from hydrogen, halogen, C1-6
alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6
haloalkoxy, R7S(O)n-, nitro, cyano and –
SF5;
and R3 is hydrogen, halogen, C1-6 alkyl, C16 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy,
R7S(O)n-, nitro, cyano, -SF5, or phenyl
substituted by one to five members of the
August 31, 2005– ‫כ"ו באב התשס"ה‬
group consisting of halogen, C1-6 alkyl, C16 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy,
R7S(O)n-, nitro, cyano and –SF5, which
may be the same or different;
R7 is C1-6 alkyl or C1-6 haloalkyl; and
n is 0, 1 or 2;
which comprises the cyclization, in the
presence of a base, of a compound of the
formula
1004
The compounds of formula (II) are
claimed as novel.
__________
[11] [21] 132003
‫שיטה לטיפול בנגיף הכשל החיסוני האנושי‬
‫אנושיים ע"י מתן הרכבים‬-‫ביונקים לא‬
‫המכילים כימיקאלים מצמחים‬
[54]
METHOD FOR TREATING
HUMAN IMMUNODEFICIENCY
VIRUS (HIV) IN NON-HUMAN
MAMMALS BY
ADMINISTRATION OF
PHYTOCHEMICAL
COMPOSITIONS
[22]
[31]
[51]
[71]
24.3.1998
824041
[32] 26.3.1997
[33] US
Int. Cl.7 A61K 35/78, 45/06
Meryl J. Squires, Barrington Hills, Ill.,
U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[74]
[57] A method for use in treating HIV
(human immunedeficiency virus)
comprising the steps of: systemically
applying an antimicrobial compound with
a syringe into a rectal canal or vagina of a
non-human mammal infected with human
immundedeficiency virus; said
antimicrobial compound comprising by
weight: from about 40% to about 60% of a
phytochemical concentrate of herbaceous
botanicals consisting of Commiphora
myrrha and Echinacea purpurea; said
phytochemical concentrate of commiphora
myrhha and Echinacea purpurea providing
1005
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
antimicrobial isolates; from about 20% to
about 60% sterile water providing a diluent
and carrier for said phytochemical
concentrate; from about 0.02% to about
0.30% ammonium salt surfactant
comprising benzalkonium chloride; from
about 2% to about 12% folic acid
providing a nutrient; and said folic acid
cooperating with said Commiphora myrrha
and said Echinacea purpurea to treat
human immunedeficiency virus; applying
said antimicrobial compound in sufficient
concentration and a sufficient period of
time to decrease human immunedeficiency
August 31, 2005– ‫כ"ו באב התשס"ה‬
virus in the non-human mammal;
comprising tussilagine and isotussilagine;
controlling viral load; and said
from about 0.003% to about 0.009%
antimicrobial isolates of said
isomeric dodeca isobutalamides and
phytochemical concentrate, comprises by
tetroenoic acid; and Commophora myrrha
weight based upon the total weight of the
phytochemicals comprising members
medical composition: from about 0.3% to
selected from the group consisting of:
about 9% echincoside; from about 0.1% to
caryophylenes, sequiterpenes, curzerenone,
about 7% PSI (4-Odihydro fuanodien-6-one; 2methylgulcoronoarabinoxylan, Mr 35 kD)
methoxyfuradine, elemol, lyndesterene,
and PSI (acid rhamnoarabinogalactan, Mr
acetic acid, alpha-amyrone, arabinose,
450 kD); from about 0.1% to about 10%
alpha-bisabolene, gamma-bisabolene,
cynarin (1, 5-di-o-caffeoylquinic acid) and
cadinene, campesterol, cinnamaldehyde,
chioric acid (2, 3-O-di-caffeoyltartaric
commiferin, alpha-commiphoric acid,
acid) and derivatives thereof; from about
beta-commiphoric acid, gama0.2% to about 4% echinolone; from about
commiphoric acid, commiphorinic acid,
0.2% to about 8% echinacin B; from about
m-cresol, cumic alcohol, cuminaldehyde,
0.1 to about 6% echinaceine; from about
dipentene, 3-epi-alpha-amyrin, eugenol,
2% to about 7% anthonocyanins
furanodiene, furanodienone, galactose,
comprising cyananidin 3-O-B-Dgum, heerabolene, alpha-heerabomyrrhol,
glucopyranoside and 3-O-(6-O-malonyl)beta-heerabomyrrhol, heeraboresene,
B-D-glucopyranoside; from about 0.01%
limonene, 4-O-methyl-glucuronic acid, nto about 0.06% pyrrolizidine alkaloids
nonacesane, beta-sitosterol, xylose.
__________
[11] [21] 132159
[54]
[22]
[31]
[87]
[51]
[71]
[74]
PLANT EXTRACTS FOR THE
TREATMENT OF INCREASED
BONE RESORPTION
4. 5.1998
9709082.3
[32] 6. 5.1997
WO 98/50054
Int. Cl.7 A61K 35/78; A61P 19/08
Roman Conrad Muhlbauer,
Rapperswil, Switzerland
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[57] Use of a plant extract or concentrate
selected from the group consisting of
allium, petroselinum, brassica and eruca
extracts and concentrates or mixtures
thereof in the preparation of a medicament
or nutritional formulation for the treatment
‫תמציות צמחים לטיפול בהחלשות מוגברת‬
‫של העצם‬
[33] GB
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
or prophylaxis of a disease or condition
which is characterized by increased bone
resorption, such as Paget's disease, tumorinduced bone disease or particularly
osteoporosis.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1006
[11] [21] 132607
‫רצף דנא המקודד לחלבון הגורם לדגרדציה‬
‫של תחליף סוכר שאינו גורם לנקב שיניים‬
[54]
DNA SEQUENCE CODING FOR A
PROTEIN CAUSING
DEGRADATION OF A NONCARIOGENIC SUGAR
SUBSTITUTE
[22]
[31]
13.1.1995
P4401451.1
[32] 19. 1.1994
P4414185.8
22.4.1994
Int. Cl.7 C12N 15/61, 9/90, 15/63, 1/21
Division from 112329
Sudzucker Aktiengesellschaft,
Mannheim, Germany
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[51]
[62]
[71]
[74]
[33] DE
"
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[57] DNA sequence characterized in that
(a) one of the nucleotide sequences shown
it codes for a protein having activity that
in SEQ ID NO. 7 or SEQ ID NO. 15, and
causes degradation of a non-cariogenic
(b) a nucleotide sequence characterized in
sugar substitute selected from the group
that it corresponds to the sequence from (a)
consisting of palatinose and trehalulose
within the scope of the degeneracy of the
and comprises:
genetic code.
__________
[11] [21] 132609
[54]
RADIOACTIVE STENTS
[22]
[31]
29.4.1998
19718342.5
[32] 30. 4.1997
19718341.7
30.4.1997
19718340.9
30.4.1997
19724223.5
3.6.1997
19724229.4
3.6.1997
19724230.8
3.6.1997
Int. Cl.7 A61L 31/00; A61F 2/06; A61M 29/00
WO 98/48851
Schering Aktiengesellschaft, Berlin,
Germany
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[51]
[87]
[71]
[74]
1007
‫סטנטים רדיואקטיבים‬
[33] DE
"
"
"
"
"
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] Radioactive stents, wherein the
radioactive isotope is fixed on the surface
of the stent by means of at least one
adhesive.
__________
[11] [21] 132688
[54]
METHOD AND SYSTEM FOR
DETERMINATION OF
PARTICLES IN A LIQUID
SAMPLE
[22]
[31]
5.5.1998
0509/97
[32] 5. 5.1997
1431/97
9.12.1997
WO 98/50777
Int. Cl.7 G01N 15/14
Chemometec A/S, Allerod, Denmark
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[87]
[51]
[71]
[74]
[57] A method for the assessment of at
least one parameter of a species of
biological particles in a liquid analyte
material, comprising applying a volume of
a liquid sample representing the analyte
material and comprising a plurality of
particles, or a plurality of particles isolated
from a volume of liquid sample
representing the analyte material, to a
sample compartment from which sample
compartment electromagnetic signals from
the sample in the compartment can pass to
the exterior, the size of the volume
allowing identification of at least 10 of the
biological particles, transmitting light onto
the sample from a light source,
transmitting light onto the sample from a
light source,
performing one exposure of
electromagnetic signals from the sample
onto an array of active detection elements
forming an image of the plurality of
‫שיטה ומערכת לקביעת חלקיקים בדוגמא‬
‫נוזלית‬
[33] DK
"
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
particles, the ratio of a linear dimension of
the image on the array of detection
elements to the original linear dimension
in the sample compartment being from
40:1 to 1:10, when the size of the particles
is between 1/3 μm and 3 μm, and from 3:1
to 1:100, when the size of the particles is
between 3 μm and 100 μm, detecting the
image as intensities by individual active
detection elements, processing the
intensities detected by the individual active
detection elements in order to identify the
image of electromagnetic signals, from the
species of biological particles as distinct
from representations of electromagnetic
signals from background signals
correlating the results of the processing to
the at least one parameter of the species of
biological particles in the liquid analyte
material, and assessing the at least one
parameter with a repeatability error of at
most 33%.
_________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1008
[11] [21] 132704
[54]
COMPOUNDS AND METHOD
FOR THE INACTIVATION OF A
VIRUS IN A BIOLOGICAL
COMPOSITION
[22]
[31]
[87]
[51]
[71]
13.5.1998
855378
[32] 13. 5.1997
WO 98/51660
Int. Cl.7 C07C 211/02; A61P 31/12
V.I. Technologies, Inc., Melville, N.Y.,
U.S.A.
Seligsohn Gabrieli Levit & Co.,
P.O.B. 1426, Tel-Aviv
[74]
[57] A compound having the formula βHal-(CH2CH2CH2-NH)nH, wherein n is an
integer between 2 and 5, inclusive, and
‫תרכובות ושיטה לאבטול של נגיף בהרכב‬
‫ביולוגי‬
[33] US
,'‫זליגסון גבריאלי לויט ושות‬
‫אביב‬-‫ תל‬,1426 .‫ד‬.‫ת‬
(HX)3 salts thereof, when n is 3, where X
is Br or C1.
__________
[11] [21] 132759
[54]
INFORMATION
RECORDING/PROCESSING
DEVICES AND
MACHINE/SYSTEM
CONTROLLING DEVICES
EQUIPPED WITH FINGERPRINT
SENSORS
[22]
[87]
[51]
[71]
[74]
30.3.1998
WO 99/50794
Int. Cl.7 G06K 9/20
BMF Corporation, Kanagawa, Japan
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[57] A flat information
recording/processing device having a thin
pressure-based fingerprint pattern sensor
(13) for sensing a pattern of ridges and
valleys of a fingerprint by surface pressure
1009
‫עיבוד מידע והתקני בקרת‬/‫התקני הקלטת‬
‫מערכות המצויידים בחיישני טביעות‬/‫מכונות‬
‫אצבעות‬
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
distribution, comprising: a plurality of first
linear scanning electrodes (200c) generally
aligned in a first direction, a plurality of
second linear scanning electrodes (200d)
generally aligned in a second direction, the
August 31, 2005– ‫כ"ו באב התשס"ה‬
first and second plurality of the scanning
electrodes intersecting at spaced apart
intersection points, a plurality of active
elements (200e) operatively associated
with intersection points of the first and
second plurality of electrodes, and
conversion means (27) for converting
fingerprint pattern data detected by the
fingerprint sensor into digital electrical
signals.
__________
[11] [21] 133363
[54]
PROCESS FOR THE
PRODUCTION OF HEPARIN
[22]
[31]
[87]
[51]
[71]
9.7.1998
97202213.1
[32] 16. 7.1997
WO 99/03893
Int. Cl.7 C08B 37/10; C12P 19/04
Akzo Nobel N.V., Arnhem, The
Netherlands
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
‫תהליך להכנת הפרין‬
[33] EP
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A method for producing heparin
to 8 hours; raising the temperature of the
from mammalian mucosa tissue,
mixture to approximately 50-75oC; and
comprising adding a proteolytic enzyme to
incubating the mixture within that
mucosa tissue; mixing the enzyme and
temperature range for approximately 1 to 6
mucosa tissue at ambient temperature for 2
hours and further recovering said heparin.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1010
[11] [21] 134131
‫ שיטות הפרדה‬,‫אורגניות‬-‫תרכובות מימן לא‬
‫ושימושים לשם דלק‬
[54]
INORGANIC HYDROGEN
COMPOUNDS, SEPARATION
METHODS AND FUEL
APPLICATIONS
[22]
[31]
7.7.1998
60/053378
[32] 22. 7.1997
60/068913
29.12.1997
009294
20.1.1998
60/074006
9.2.1998
60/080647
3.4.1998
WO 99/05735
Int. Cl.7 C01B 6/24; H01M 4/58
Black Light Power, Inc., Malvern, Pa.,
U.S.A.
Randell L. Mills
Jeremy M. Ben-David & Co. Ltd.,
P.O.B. 45087, Jerusalem
[87]
[51]
[71]
[72]
[74]
[33] US
"
"
"
"
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,45087 .‫ד‬.‫ת‬
[57] A compound comprising (a) at least
for which the corresponding ordinary
one neutral, positive, or negative increased
hydrogen species is unstable or is not
binding energy hydrogen species having a
observed because the ordinary hydrogen
binding energy (i) greater than the binding
species binding energy is less than thermal
energy of the corresponding ordinary
energies or is negative; and (b) at least one
hydrogen species, or (ii) greater than the
other element.
binding energy of any hydrogen species
__________
[11] [21] 134166
– ‫תכשירי רוקחות המכילים צמד חומצה‬
‫בסיס מבעבע‬
[54]
PHARMACEUTICAL
COMPOSITIONS CONTAINING
AN EFFERVESCENT ACID-BASE
COUPLE
[22]
[31]
[87]
[51]
[71]
23.7.1998
MI97A001746
[32] 23. 7.1997
WO 99/04765
Int. Cl.7 A61K 9/46
Chiesi Farmaceutici S.p.A., Parma,
Italy
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
1011
[33] IT
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] Pharmaceutical composition in form
of effervescent tablet comprising an active
ingredient and an effervescent couple, the
couple comprising an acidic component
and an alkaline component, characterized
in that the alkaline component is sodium
glycine carbonate and the acid is selected
from fumaric acid, maleic acid, their salts
and mixtures thereof.
__________
[11] [21] 134395
[54]
COMPRESSED
NITROGYLYCERIN TABLET
AND ITS METHOD OF
MANUFACTURE
[22]
[31]
[87]
[51]
[71]
16.9.1998
60/061105
[32] 3. 10.1997
WO 99/17766
Int. Cl.7 A61K 9/00, 9/20
Warner-Lambert Company, Morris
Plains, N.J., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
‫גלולת ניטרוגליצרין דחוסה ושיטה ליצורה‬
[33] US
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A stable composition comprising
lubricant, wherein nitroglycerin is the sole
effective amount of nitroglycerin, lactose,
pharmacologically active agent.
silica, starch, glycerol monostearate and
__________
[11] [21] 134568
[54]
SUSTAINED RELEASE DRUG
DELIVERY DEVICES
[22]
[31]
[87]
[51]
[71]
28.8.1998
919221
[32] 28. 8.1997
WO 99/11244
Int. Cl.7 A61K 9/22, 9/32
Control Delivery Systems, Inc.,
Watertown, Mass., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] A sustained release drug delivery
system, said drug delivery system
comprising:
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫מתקן לחלוקת תרופות בשחרור מושהה‬
[33] US
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
(1) an inner core or reservoir comprising
an effective amount of an agent to obtain a
desired local or systemic physiological or
1012
pharmacological effect,
impermeable disc being different material
(2) a first coating layer permeable to the
from or having substantially greater
passage of said agent, wherein said first
hardness, thickness, malleability or
coating layer covers at least a portion of
response to heat curing than said
said inner core, which provides control and
impermeable film, and
sustained release of the agent,
(4) a third coating layer permeable to the
(3) a second coating layer, said second
passage of said agent, wherein said third
coating layer essentially impermeable to
coating layer essentially completely covers
the passage of said agent, and said second
said second coating layer and the uncoated
coating layer covering at least 50% of the
portion of the first coating layer or inner
inner core and/or the first coating layer,
core, whereby said agent is able to pass
wherein at least a small portion of the
through said third coating layer in a
inner core or first coating layer is not
controlled manner; for use in obtaining a
coated with said second coating layer and
desired local or systemic physiological or
said second coating layer comprises an
pharmacological effect in a mammalian
impermeable film and at least one
organism.
.
__________
[11] [21] 134571
[54]
ROTORS UTILIZING A STEPPED
SKEW
[22]
[31]
[87]
[51]
[71]
25.6.1999
60/090773
[32] 26. 6.1997
WO 00/01058
Int. Cl.7 H02K 21/14
General Electric Company,
Schenectady, N.Y., U.S.A.
Seligsohn Gabrieli Levit & Co.,
P.O.B. 1426, Tel-Aviv
[74]
[57] A rotor core comprising a plurality
of rotor laminations, each of said
laminations having an outer periphery, a
first set of rotor laminations comprising a
plurality of slots (22) having skew portions
(26) extending in a first direction, a second
set of said rotor laminations comprising a
1013
‫רוטורים המשתמשים בהסטה מדורגת‬
[33] US
,'‫זליגסון גבריאלי לויט ושות‬
‫אביב‬-‫ תל‬,1426 .‫ד‬.‫ת‬
plurality of slots having skew portions (28)
extending in a second direction, and a
plurality of notches (38) having an open
end at said outer periphery and
substantially aligned radially and
coextensive radially with at least one of the
skew portions.
August 31, 2005– ‫כ"ו באב התשס"ה‬
__________
[11] [21] 134635
– 3 ,1 ‫תהליך להכנת תרכובות אציל ציקלי‬
‫דיקרבוניל וחומרי ביניים של התהליך‬
[54]
PROCESS FOR THE
PREPARATION OF ACYLATED
CYCLIC 1, 3-DICARBONYL AND
INTERMEDIATES FOR THE
PROCESS
[22]
[31]
[87]
[51]
17.11.1998
9725135.9
[32] 27. 11.1997
[33] GB
WO 98/28282
Int. Cl.7 C07C 45/54, 49/385, 49/417, 49 /792, 49/86, 205/42, 225/22, 233/30, 255/56,
311/15, 315/04, 317/24, 323/22; C07D 249/08, 249/18
Syngenta Limited, Fernhurst,
Haslemere, Surrey, England
S. Horowitz & Co.,
,'‫ הורוביץ ושות‬.‫ש‬
P.O.B. 2499, Tel-Aviv
‫אביב‬-‫ תל‬,2499 .‫ד‬.‫ת‬
[71]
[74]
[57] A process for preparing a compound
of the formula
August 31, 2005– ‫כ"ו באב התשס"ה‬
1014
where Q completes an optionally
substituted 5- or 6- member saturated
carbocylic ring and R is optionally
substituted phenyl or optionally substituted
C3-C6 cycloalkyl which process comprises
the rearrangement of a compound of the
formul
where Q and R are as defined in relation to
formula (I) in a polar aprotic, dipolar
aprotic or aromatic hydrocarbon solvent in
the presence of a moderate base and an
azole compound of the formula
in which A is N or CR22; B is N or CR23
and R21, R22 and R23 are independently H,
alkyl, or aryl or when B is CR23, R21 and
R23 together with the carbon atoms to
which they are attached form a 6membered carbocylic ring and salts thereof
and a compound of the formula
where Y is a 1, 2, 4-triazolyl or a 1,2,3benzotriazolyl group, R7 is halogen, cyano,
NO2, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy
or RaS in which Ra is C1-4 alkyl; R8, R9 and
R10 independently are hydrogen, halogen,
C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4
haloalkoxy, CN, NO2, phenoxy,
halophenoxy, C1-4 haloalkylphenoxy;
RbS(O)n Om in which m is 0 or 1, n is 0, 1
or 2 and Rb is C1-4 alkyl, C1-4 haloalkyl,
phenyl or benzyl, NHCORc in which Rc is
C1-4 alkyl, NRdRe in which Rd and Re
independently are hydrogen or C1-4 alkyl;
RfC(O)- in which Rf is hydrogen, C1-4
alkyl, C1-4 haloalkyl or C1-4 alkoxy;
SO2NRgRh in which Rg and Rh
1015
August 31, 2005– ‫כ"ו באב התשס"ה‬
independently are hydrogen or C1-4 alkyl;
or any two of R8, R9 and R10 together with
the carbon atoms to which they are
attached form a 5 or 6 membered
heterocyclic ring containing up to three
heteroatoms selected from O, N or S and
which may be optionally substituted by
=NO C1-4 alkyl, C1-4 alkyl, C1-4 haloalkyl,
C1-4 alkoxy or halogen, provided that when
Y is 1, 2, 4- triazolyl and R7 is halo, C1-4
alkyl, C1-4 haloalkyl, C14 alkoxy, nitro or
cyano, then none of R8, R9 or R10 may be
halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy,
nitro or cyano at the 6-position of the
phenyl ring.
__________
[11] [21] 134703
[54]
PROCESS FOR CONTROLLING
THE LOADING OF A
BIOLOGICALLY ACTIVE
AGENT INTO A LIPOSOME
[22]
[31]
[87]
[51]
[71]
8.9.1998
925532
[32] 8. 9.1997
WO 99/12523
Int. Cl.7 A61K 9/127
SkyePharma Inc., San Diego, Calif.,
U.S.A.
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[74]
[57] An in-vitro process for controlling
loading of at least one biologically active
agent into liposomes comprising:
(a) preparing a standard by dissolving at
least one biologically active agent in an
aqueous solution, wherein the resulting
osmolarity of the aqueous solution is
measured;
(b) forming liposomes by mixing the
product of (a) with a lipid component,
thereby encapsulating said biological
agent;
‫תהליך לויסות טעינה של גורם בעל פעילות‬
‫ביולוגית לתוך ליפוזום‬
[33] US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
(c) measuring the amount of active agent
encapsulated; and
(d) preparing modified liposomes by
repeating steps (a) and (b) except that in
(a) the osmolarity is either further
increased relative to the standard
osmolarity, thereby decreasing loading of
the agent; or further decreased relative to
the standard osmolarity, thereby increasing
loading of the agent.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1016
[11] [21] 134729
[54]
METHODS OF SYNTHESIZING
POLYNUCLEOTIDES BY
LIGATION OF MULTIPLE
OLIGOMERS
[22]
[31]
22.7.1999
121887
[32] 24. 7.1998
241353
2.2.1999
241979
2.2.1999
245984
5.2.1999
WO 00/05412
Int. Cl.7 C12Q 1/68
Lumigen, Inc., Southfield, Mich.,
U.S.A.
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[87]
[51]
[71]
[74]
‫ידי‬-‫שיטה לסינתזה של פולינוקלאוטידים על‬
‫ליגציה של רבוי אוליגומרים‬
[33] US
"
"
"
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[57] A method for synthesizing a strand
(c) contacting the primer-template hybrid
of a nucleic acid complementary to at least
with a plurality of oligonucleotide 5'a portion of a target singel stranded nucleic
monophosphates;
acid template comprising:
(d) ligating to the primer-template hybrid
(a) providing a primer which is
in sequence at least some of the plurality
complementary to a portion of the target
of oligonucleotide 5'-monophosphates to
single stranded nucleic acid template;
extend the double stranded region and
(b) hybridizing the primer with the
thereby synthesize a nucleic acid strand
template to form a primer-template hybrid
which is complementary to the portion of
having a single stranded region and a
the template.
double stranded region;
__________
[11] [21] 134762
[54]
8a-AZALIDES FOR TREATMENT
OF BACTERIAL RESPIRATORY
OR ENTERIC INFECTION IN A
LIVESTOCK ANIMAL
[22]
[31]
4.9.1998
60/058329
[32] 10. 9.1997
9806029.6
20.3.1998
WO 99/12542
Int. Cl.7 A61K 31/7052 // C07H 17/08
Merck & Co. Inc., Rahway, N.J.,
U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[87]
[51]
[71]
[74]
1017
‫ – אזאלידים לטיפול בזיהום בקטריאלי‬8a
‫נשימתי או של המעי בבעלי חיים של משק‬
‫החי‬
[33] US
GB
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] A method for the treatment or
prophylactically effective amount of an 8aprevention of bacterial respiratory or
azalide wherein the respiratory or enteric
enteric infection in a livestock animal
infecting organism is Pasteurella spp.,
which comprises administering to a
Actinobacillus spp., Haemophilus spp.,
livestock animal in need of such treatment
Mycoplasma spp., Treponema spp., or
or prevention a therapeutically or
Salmonella spp.
__________
[11] [21] 134798
‫דבקים רגישי לחץ הסופגים נוזלים ביולוגיים‬
[54]
BIOLOGICAL FLUID
ABSORBING PRESSURE
SENSITIVE ADHESIVES
[22]
[31]
14.7.1998
9718289.3
[32] 29. 8.1997
9813771.4
25.6.1998
WO 99/11728
Int. Cl.7 C09J 153/02
Avery Denisson Corporation,
Pasadena, Calif., U.S.A.
Dr. Mark Friedman Ltd.,
7 Haomanim St., Tel Aviv
[87]
[51]
[71]
[74]
[57] A pressure-sensitive adhesive
material comprising a mixture of:
(a) a continuous phase formed from a
physically cross-linked solid rubber, a
compatible liquid rubber, other than
polyisobutylene and 0 to 9.37 wt. % of
tackifiers other than said rubbers, based on
the total composition, wherein the weight
[33] GB
"
,‫ד"ר מרק פרידמן בע"מ‬
‫ תל אביב‬,7 ‫רח' האומנים‬
ratio of said liquid rubber to said solid
rubber is from 3:2 to 7:1; and
(b) 10 to 70% by weight, based on the total
adhesive material, of a discontinuous
phase comprising one or more hydrophilic
polymers that are soluble and/or swellable
in water.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1018
[11] [21] 134946
‫מתקן חשמלי לחימום‬
[54]
ELECTRICAL HEATING
APPARATUS
[22]
[51]
[71]
8.3.2000
Int. Cl.7 F24H 1/10; A47J 31/00
Atmor Industries (1973) Ltd., Bnei
Brak
G.E. Ehrlich (1995) Ltd.,
28 Bezalel St., Ramat Gan
[74]
[57] Electrical heating apparatus for
automatically heating water passing
therethrough from a cold water supply pipe
to a hot water delivery pipe, comprising: a
water heater housing (2) including an
electrical heater (3) therein, an inlet
coupling (8), and an outlet coupling (9); an
electrical control device controlling said
electrical heater; an inlet conduit (4)
connectable between the water supply pipe
and the inlet coupling of the electrical
heater housing for inletting cold water; an
outlet conduit (5) connectable between the
‫ בני ברק‬,‫) בע"מ‬1973( ‫אטמור תעשיות‬
,‫) בע"מ‬1995( ‫ ארליך‬.‫א‬.‫ג‬
‫ רמת גן‬,28 ‫רח' בצלאל‬
outlet coupling of the water heater housing
and the water delivery pipe for outletting
hot water thereto; and a pressureresponsive device (7) cooperable with said
electrical control device to control the
electrical heater; characterized in that said
pressure-responsive device is connected to
one of said conduits in parallel to said
electrical heater housing, and in that said
pressure-responsive device includes an
inlet (7a) integrally formed with said one
conduit and the respective coupling of the
heater housing.
__________
1019
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 135138
[54]
METHOD AND EQUIPMENT
FOR PREPARING A HIGH
PRESSURE HYPERPOLARIZED
HELIUM GAS AND USE OF SAID
METHOD
[22]
[31]
[87]
[51]
[71]
17.9.1998
9711553
[32] 17. 9.1997
WO 99/14582
Int. Cl.7 G01N 24/00
Centre National de la Recherche
Scientifique (CNRS), Paris, France
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[74]
[57] Process for preparation of a
hyperpolarized high pressure helium gas
using an optical pumping step at a resonant
wavelength of close to 1083 nanometers in
a helium gas formed from the pure helium3 isotope or a mixture of the helium-3 and
‫שיטה וציוד להכנת גז הליום היפרפולרי‬
‫ ושימוש בשיטה זו‬,‫בלחץ גבוה‬
[33] FR
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
helium-4 iso-topes, characterized in that a
magnetic field of 0.1 to 1 Tesla is applied
to the said helium gas during the optical
pumping steps and is held at a pressure of
more than 1000 Pa.
__________
[11] [21] 135218
[54]
SELF-ROLLING BANNER
[22]
[51]
[71]
[72]
[74]
22.3.2000
Int. G09F 17/00
Argo Ltd., Ra'anana
Moshe Harel
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[57] A self-rolling banner (10)
for two-handed vertical and horizontal
display comprising an elongated sheet (14)
of self-rolling material having two ends
(16, 18) and two side edges (20, 22) and at
least one handle (28) having ends
bracketing the side edges of said sheet
adjacent one of said ends, wherein said
material is capable of alternating between
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫סרט הצגה מתגלגל בעצמו‬
‫ רעננה‬,‫ארגו בע"מ‬
‫משה הראל‬
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
a relaxed and tensioned state and of
independently assuming a rolled-up
configuration in said relaxed state around
at least one end of said sheet, said end
being attached to an axle means (32)
around which said sheet assumes its rolledup configuration, characterized in that said
axle is freely attached to said ends of said
handle, enabling the free rotation of said
1020
axle relative thereto and in that said banner
further comprises a second handle and a
secnd axle means to which a second end of
said sheet is attached, wherein said second
end of said sheet and the sheet material
adjacent thereto assumes a rolled-up
configuration around said second axle and
said second axle is freely attached to the
ends of said second handle, enabling the
free rotation of said second axle relative to
said second handle.
__________
[11] [21] 135231
[54]
CONNECTING DEVICE FOR
MEDICAL PURPOSES
[22]
[31]
[87]
[51]
[71]
[74]
20.10.1998
9703839-2
[32] 21. 10.1997
WO 99/20338
Int. Cl.7 A61M 39/10
Hemapure AB, Uppsala, Sweden
Seligsohn Gabrieli Levit & Co.,
P.O.B. 1426, Tel-Aviv
1021
‫התקן חיבור למטרות רפואיות‬
[33] SE
,'‫זליגסון גבריאלי לויט ושות‬
‫אביב‬-‫ תל‬,1426 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] Device for external connection of the
bloodstream of a patient to an external
circuit or a fluidum source for medical
purposes, said device comprising:
a main body (1) with at least a first
opening (8) surrounded by a first sealing
surface (9) and communicating with an
outward coupling means (2) for connection
to the bloodstream, wherein in a nonconnected position, the first sealing surface
being adapted to be protected by a
removable protective member (24), and a
connecting member (10) with at least one
second opening (12) surrounded by a
second sealing surface (22) and for
communicating with said external circuit
or fluidum source, which in a nonconnected position is arranged to be
protected by a protective body which is
removable with respect to the connecting
member, the connecting member being
connectable to the main body under
simulataneous removal of the protective
member from the first sealing surface and
the protective body from the second
sealing surface in order to obtain cooperation between the first and second
sealing surfaces and obtaining a leakproof
connection between said openings, the
main body being provided with holding
elements (6) for the co-operation with
holding means (17) on the protective body
and the connecting member, respectively,
said holding elements forming a guide
open at two ends for the protective
member and the connecting member,
respectively.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1022
[11] [21] 135331
‫ של פולימורף גבישי נגד פטריות‬I ‫צורה‬
‫והרכבים רוקחיים המכילים אותה‬
[54]
CRYSTALLINE ANTIFUNGAL
POLYMORPH FORM I AND
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THE SAME
[22]
[31]
[87]
[51]
[71]
5.10.1998
946183
[32] 7. 10.1997
[33] US
WO 99/18097
Int. Cl.7 C07D 405/06; A61K 31/4196; A61P 31/10
Schering Corporation, Kenilworth,
N.J., U.S.A.
Dr. Shlomo Cohen & Co.,
P.O.B. 11490, Tel-Aviv
[74]
,'‫ד"ר שלמה כהן ושות‬
‫אביב‬-‫ תל‬,11490 .‫ד‬.‫ת‬
[57] A crystalline polymorph from I of
(-)-4-[4-[4-[4-[[(2R-cis)-5-(2,4difluorophenyl) tetrahydro-5-(1H- 1, 2, 4triazol-1-ylmethyl) furan-3-yl]- methoxy]
phenyl] -1-piperazinyl] phenyl-2, 4dihydro-2-[(S)-1-ethyl-2(S)hydroxylpropyl]-3H-1, 2, 4-triazol-3-one
of the formula
and characterized by the following x-ray
powder diffraction pattern expressed in
terms of "d" spacing and relative
intensities "(RI"):
dspacing (±0.04)
6.10
4.63
4.10
3.69
3.05
RI
Medium
Medium
Wide
Wide
Wide
__________
1023
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 135404
‫מחליף לחץ‬
[54]
PRESSURE EXCHANGER
[22]
[31]
[87]
[51]
[71]
30.9.1998
974542
[32] 1. 10.1997
WO 99/17028
Int. Cl.7 F04F 11/00; F15D 1/14; F15B 3/00
Energy Recovery, Inc., Chesapeake,
Va., U.S.A.
Seligsohn Gabrieli Levit & Co.,
P.O.B. 1426, Tel-Aviv
[74]
[57] A pressure exchanger for
transferring pressure from a first fluid at
high pressure to a second fluid at a lower
pressure, comprising a pressure housing;
(1) and a pressure exchanger assembly
disposed within the pressure housing; the
pressure exchanger assembly comprising a
generally cylindrically-shaped liner having
first and second end covers (13, 14)
located thereon, each end cover having one
or more fluid passageways for fluid
communication with an interior of the
cylindrical liner; and a rotor (11) disposed
withing the interior of the liner for rotation
about a longitudinal axis, the rotor having
a plurality of channels (25) therethrough
[33] NO
,'‫זליגסון גבריאלי לויט ושות‬
‫אביב‬-‫ תל‬,1426 .‫ד‬.‫ת‬
positioned for fluid communication with
said passageways within said end covers
during rotation of the rotor; the pressure
housing having a first inlet (7) for
communicating the first high pressure fluid
to a passageway in the first end cover and
having a second inlet (3) for
communicating the second lower pressure
fluid to a passageway in the second end
cover; and a sealing ring (22) disposed
about the second end cover for sealing
engagement with the pressure housing, the
sealing ring defining a high pressure area
between the exterior of the liner and the
pressure housing and a low pressure area
adjacent to the second end cover.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1024
[11] [21] 135562
‫ – דיאולים‬3 ,1–‫תהליך לסינטזה של ציס‬
‫ותצריף סינרגיסטי של תלתאלקילבורן‬
‫ודיאלקילאלקוקסיבורן לתהליך זה‬
[54]
PROCESS FOR THE SYNTHESIS
OF CIS-1, 3-DIOLS AND A
SYNERGISTIC COMBINATION
OF TRIALKYLBORANE AND
DIALKYLALKOXYBORANE FOR
SUCH SYNTHESIS
[22]
[31]
[87]
[51]
2.12.1998
60/068193
[32] 19. 12.1997
[33] US
WO 99/32434
Int. Cl.7 C07B 31/00, 41/02; C07C 33/28, 35/08, 69/675, 253/30, 255/12, 271/38;
C07D 207/416, 209/10, 213/26, 215/12, 23/12, 239/26, 257/04, 311/96; C07F 5/04
Warner–Lambert Export Limited, Dun
Laoghaire, County Dublin, Ireland
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[71]
[74]
[57] A process for the preparation of a
compound of the formula
wherein R is alkyl,
NC-CH2-,
PG-O-CH2-wherein PG is a protecting group,
1025
August 31, 2005– ‫כ"ו באב התשס"ה‬
wherein R2 is (H3C)2 CH- or
cyclopropyl,
wherein R3 is C6H5, (H3C)2-N-or
(H3C)2CH- and
R4 is hydrogen,
H3C-O-CH2-,
H3C-CH2-C(CH3)2-CO2CH2-, or
H3C-O2C-CH2-CH(OH)-CH2CH(OH)-CH=CH,
R6 is hydrogen or CH3,
R7 is hydrogen or CH3,
R8 is hydrogen,
OH,
CH3, or
H5C6-NHCO-O, and
R9 is hydrogen or CH3,
August 31, 2005– ‫כ"ו באב התשס"ה‬
1026
R1 is alkyl, or
-CH2-CO2R6 wherein R6 is alkyl;
which comprises:
step (a) treating a compound of the
formula
or a compound of the formula
wherein R and R1 are as defined above
with a trialkylborane or
dialkylalkoxyborane or a mixture of a
trialkylborane and a dialkylalkoxyborane
in a solvent; step (b) adding an alkali metal
hydride at about -110oC to about -50oC;
step (c) concentrating the reaction mixture
by distillation to afford a compound of
formula I and a distillate containing
alkylborane species;
step (d) treating additional compound of
formula II or III with the distillate from
step (c) containing recovered alkylborane
species, and repeating steps (b) and (c) as
desired to afford additional compound of
formula I.
__________
1027
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 135641
‫שיטה להכנת ציטאלופרם‬
[54]
METHOD FOR THE
PREPARATION OF
CITALOPRAM
[22]
[87]
[51]
[71]
11.11.1997
WO 98/19512
Int. Cl.7 C07C 225/22; C07D 307/87; A61K 31/34
H. Lundbeck A/S, Valby-Copenhagen,
Denmark
Dr. Shlomo Cohen & Co.,
P.O.B. 11490, Tel-Aviv
[74]
,'‫ד"ר שלמה כהן ושות‬
‫אביב‬-‫ תל‬,11490 .‫ד‬.‫ת‬
[57] A method for the preparation of
citalopram comprising the steps of
(a) reacting a compound of the formula
wherein R1 is H or C1-6 alkylcarbonyl with
a Grignard reagent of 4-halogenfluorophenyl;
(b) reacting the resulting compound of the
formula
with a Grignard reagent of 3-halogen –
N,N-dimethylpropyl-amine;
(c) effecting ring closure of the resulting
compound of the formula
August 31, 2005– ‫כ"ו באב התשס"ה‬
1028
and (d) converting the resulting
compound of the formula
wherein R1 is as defined above, into the
corresponding 5-cyano derivative, i.e.
Claimed as novel is the compound of the formula
citalopram, which is isolated as the base or
a pharmaceutically acceptable salt thereof.
wherein R1 is H or C1-6 alkylcarbonyl.
__________
1029
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 135773
‫משאבות עבור מזרק‬
[54]
SYRINGE PUMPS
[22]
[31]
[51]
[71]
[74]
19.4.2000
9910985.2
[32] 12. 5.1999
Int. Cl.7 A61M 5/145
Smiths Group plc, London, England
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[57] A syringe pump adapted to receive a
syringe (3) of the kind having a plunger
(35) movable along a barrel (30) with a
nose outlet at its forward end and a rear
end, characterized in that the pump
includes a movable member (44, 56)
movable in a first direction towards
[33] GB
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
engagement with a portion at the rear end
of the barrel projecting radially outwardly,
and a sensor (54) for sensing the position
of the movable member to detect whether
or not the projecting portion and hence the
syringe is correctly positioned in the pump.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1030
[11] [21] 135789
[54]
METHOD AND APPARATUS FOR
MEASURING PULMONARY
BLOOD FLOW BY PULMONARY
EXCHANGE OF OXYGEN AND
AN INERT GAS WITH THE
BLOOD
[22]
[87]
[51]
[71]
24.10.1997
WO 98/18383
Int. Cl.7 A61B 5/02, 5/08
Gavin Joseph Brian Robinson,
Burwood, Vic., Australia
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
‫שיטה והתקן למדידת זרימת דם ריאתית‬
‫ידי החלפת חמצן וגז אינרטי ריאתי עם‬-‫על‬
‫הדם‬
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A method for measuring the
pulmonary bloodflow in a subject
including:
isolating two or more division of the
respiratory system, said divisions
comprising the complete gas exchanging
part of said respiratory system, ventilating
each said division with a separate gas
mixture, at least one of said gas mixtures
including an inert soluble gas, determining
uptake of inert soluble gas in at least two
of said divisions, determining relative
pulmonary blood flow of said divisions,
determining end tidal concentration of
inert soluble gas in at least two of said
divisions, and calculating pulmonary blood
flow from determined values of uptake and
end tidal concentration of inert soluble gas,
and relative pulmonary blood flow.
__________
[11] [21] 135884
[54]
METHOD FOR MEASURING
NON-TRANSFERRIN BOUND
IRON
[22]
[51]
[71]
30.4.2000
Int. Cl.7 G01N 33/50, 33/90
Yissum Research Development
Company of the Hebrew University of
Jerusalem, Jerusalem
William Breuer and Zvi Yoav
Cabantchik
G.E. Ehrlich (1995) Ltd.,
11 Menachem Begin St., Ramat Gan
[72]
[74]
1031
‫תהליך למדידת ברזל שאינו קשור‬
‫לטרנספרין‬
‫יישום חברה לפתוח המחקר של‬
‫ ירושלים‬,‫האוניברסיטה העברית בירושלים‬
‫וויליאם ברוייר וצבי יואב קבנצ'יק‬
,‫) בע"מ‬1995( ‫ ארליך‬.‫א‬.‫ג‬
‫ רמת גן‬,11 ‫רח' מנחם בגין‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] A method of determining the content
of non-transferrin-bound iron (NTBI)
and/or chelator accessible iron in samples
the method comprising
(a) contacting a sample with:
(i) a first reagent including a fluorescent
marker-conjugated Fe chelator; and
(ii) a second reagent including said
fluorescent marker-conjugated Fe chelator
and non-conjugated fe chelator
(b) calculting ratio of fluorescence
resulatant from contacting said sample
with said first reagent and said second
reagent, said ratio being indicative of
content of non-transferrin-bound iron
(NTBI) and/or chelator accessible iron in
said sample.
__________
[11] [21] 135898
‫תהליך להכנת נגזרות של תיאזולידינדיאון‬
[54]
PROCESS FOR THE
PREPARATION OF
THIAZOLIDINEDIONE
DERIVATIVES
[22]
[31]
[87]
[51]
[71]
27. 10.1998
9723295.3
[32] 4. 11.1997
WO 99/23095
Int. Cl.7 C07D 277/34, 417/12
SmithKline Beecham Plc, Brentford,
Middlesex, England
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[74]
[57] A process for preparing 5-{4-[2-(Nmethyl-N-(2-pyridyl) amino) ethoxy]
benzyl}- 2, 4-thiazolidinedione, or a
tautomeric form thereof or a salt thereof,
or a solvate thereof, which process
comprises catalytically reducing 5-{4-[2(N-methyl-N-(2-pyridyl} amino) ethoxy]
[33] GB
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
benzylidene}- 2,4-thiazolidinedione, or a
tautomeric form thereof or a salt thereof,
or a solvate thereof, characterized in that
the reduction reaction is carried out using a
hydrogen pressure above 1.379x105Pa
(20psi); and thereafter if required forming
a pharmaceutically acceptable salt and/or a
pharmaceutically acceptable solvate.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1032
[11] [21] 135921
‫תולדות חומצות הידרוקסאמית‬
‫וקארבוקסילית בעלות פעילות מעכבת‬
TNF-‫ ו‬MMP
[54]
HYDROXAMIC AND
CARBOXYLIC ACID
DERIVATIVES HAVING MMP
AND TNF INHIBITORY
ACTIVITY
[22]
[31]
12. 11.1998
9723906.5
[32] 12. 11.1997
[33] GB
9802618.0
6.2.1998
"
9813933.0
26.6.1998
"
WO 99/24399
Int. Cl.7 C07C 311/04, 317/26, 323/23, 325 /50, 313/06; C07D 211/92, 233/72, 401/12,
405/12; A61K 31/10, 31/16, 31/335, 31/395;, A61P 3/04, 7/02, 9/00, 25/06, 29/00,
17/00, 31/12, 35/00
Darwin Discovery Limited, Cambridge,
England
Dr. Yitzhak Hess & Partners,
,‫ד"ר יצחק הס ושותפיו‬
P.O.B. 6451, Tel-Aviv
‫אביב‬-‫ תל‬,6451 .‫ד‬.‫ת‬
[87]
[51]
[71]
[74]
[57] Compounds for therapeutic
use, of the formula
wherein
m is 0-2;
X is S(O)1-2;
Y is OH or NHOH;
R1 is H or a group (optionally substituted
with R7) selected from C1-6 alkyl, C2-6
alkenyl, aryl, C1-6 alkyl-aryl, heteroaryl,
C1-6 alkyl-heteroaryl, heterocycloalkyl, C16 alkyl-heterocycloalkyl, cycloalkyl and
C1-6 alkyl-cycloalkyl, and R2 is H or C1-6
alkyl; or CR1R2 is a cycloalkyl or
heterocycloalkyl ring optionally
substituted with R7 or a group (optionally
substituted with R7) selected from C1-6
alkyl, aryl, C1-6 alkyl-aryl, heteroaryl and
C1-6 alkyl-heteroaryl;
1033
each B is the same or different and is H or
a group selected from C1-6 alkyl-aryl, C1-6
alkyl, cycloalkyl, C1-6 alkyl-cycloalkyl,
cycloalkenyl, heterocycloalkenyl, C1-6
alkyl- heteroaryl, heterocycloalkyl, C1-6
alkyl-heterocycloalkyl, aryl or heteroaryl,
any of which groups is optionally
substituted by a substituent selected from
R3, C1-6 alkyl-R3, C2-6 alkenyl-R3, aryl
(optionally substituted with R3), aryl-C1-6
alkyl-R3, C1-6 alkyl-aryl (optionally
substituted with R3), C1-6 alkyl-heteroaryl
(optionally substituted with R3), aryl- C2-6
alkenyl-R5, heteroaryl (optionally
substituted with R3), heteroaryl-C1-6 alkylR3, cycloalkyl (optionally substituted with
August 31, 2005– ‫כ"ו באב התשס"ה‬
R3) and heterocycloalkyl (optionally
heteroaryl, cycloalkyl, C1-6 alkylsubstituted with R3), provided that NB2 is
cycloalkyl, heterocycloalkyl and C1-6
not NH2,
alkyl-heterocycloalkyl, wherein said group
or B-N-B is a heterocycloalkyl ring
is optionally substituted with R6, COR6,
substituted with =O or =NOR4, or, when
SO0-2R6, CO2R6, OR6, CONR8R6, NR8R6,
1
2
neither R nor R is H, B-N-B is a
halogen, CN, SO2NR8R6 or NO2, and for
heterocycloalkyl or heterocycloalkenyl
each case of N(R4)2 the R4 groups are the
ring optionally substituted by a substitutent
same or different or N(R4)2 is
3
3
selected from R , C1-6 alkyl-R , C2-6
heterocycloalkyl optionally substituted
alkenyl-R3, aryl (optionally substituted
with R6, COR6, SO0-2R6, CO2R6, OR6,
3
3
with R ), aryl-C1-6 alkyl-R , C1-6 alkyl-aryl)
CONR8R6, NR8R6, halogen, CN,
optionally substituted with R3), C1-6 alkylSO2NR8R6 or NO2;
heteroaryl (optionally substituted with R3),
R5 is COR4, CON(R4)2, CO2R6 or SO2R6;
5
aryl – C2-6 alkenyl-R , heteroaryl
R6 is C1-6 alkyl, aryl, C1-6 alkyl-aryl,
3
(optionally substituted with R ),
heteroaryl or C1-6 alkyl-heteroaryl; and
heteroaryl-C1-6 alkyl-R3, cycloalkyl
R7 is OR4, COR4, CO2R8, CON(R4)2,
3
(optionally subisutted with R ), and
NR4R5, S(O)0-2R6, SO2N(R4)2M halogen,
heterocycloalkyl) optionally substituted
CN or cycloimidyl (optionally substituted
with R3); R3 is C1-6 alkyl, C2-6 alkenyl-R5,
with R8); and
halogen, CN, NO2, N(R4)2, OR4,
R8 is H or C1-6 alkyl;
C(=NOR6)R4, CON (R4)2, COR4, CO2R8,
and the salts, solvates, hydrates, N-oxides,
NR4R5, S(O)0-2R6 or SO2N(R4)2;
protected amino, protected carboxy, or
R4 is H or a group selected from C1-6 alkyl,
protected hydroxamic acid derivatives
aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkylthereof.
__________
[11] [21] 135946
[54]
PESTICIDE AGAINST PLANT –
PATHOGENIC
MICROORGANISMS
[22]
[31]
[87]
[51]
[71]
5. 11.1998
1007457
[32] 5. 11.1997
WO 99/22597
Int. Cl.7 A01N 63/00
Campina Melkunie B.V., Veghel and
Koppert B.V., Berkel en Rodenrijs,
both of the Netherlands
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
[74]
‫קוטלי מזיקים כנגד מיקרואורגניזמים‬
‫צמחים‬-‫הגורמים למחלות‬
[33] NL
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
[57] Composition comprising
and glucose, and an oil base for use in the
lactoperoxidase, thiocyanate (SCN-)
control of plant-pathogenic organisms,
and/or iodide (I-), a hydrogen peroxide
particularly fungi and bacteria.
donor system, in particular glucose oxidase
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1034
[11] [21] 135960
[54]
SYSTEM AND METHOD FOR
THE DELIVERY OF DIGITAL
VIDEO AND DATA OVER A
COMMUNICAITON CHANNEL
[22]
[87]
[51]
[71]
4.11.1998
WO 99/23825
Int. Cl.7 H04N 7/08, 7/173
Georgia Tech Research Corporation,
Atlanta, Ga., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] A system for delivering digital video
and data over a single communication
channel, comprising: a programming
center configured to receive a plurality of
video signals representing a plurality of
video programs, said programming center
also configured to process at least one bidirectional data signal;
a central office in communication with
said programming center, said central
office configured to receive said plurality
of video signals representing said plurality
of video programs and place said plurality
of video signals simultaneously on a bus,
1035
‫מערכת ושיטה להעברת וידאו דיגיטלי‬
‫ונתונים דרך ערוץ תקשורת‬
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
said central office also configured to
process said at least one bi-directional data
signal, said at least one bidirectional data
signal including a telephone channel; and
means located in said central office for
simultaneously delivering and terminating
any of said plurality of video signals
representing said plurality of video
programs to any of a plurality of end user
locations and supporting communication
of said at least one bidirectional data signal
to said any of said plurality of end user
locations over a single communications
channel.
August 31, 2005– ‫כ"ו באב התשס"ה‬
_________
[11] [21] 135975
[54]
FLASHOVER PROTECTION
COVER FOR ELECTRICAL
POWER LINES
[22]
[31]
[87]
[51]
[71]
8.12.1998
988000
[32] 10. 12.1997
WO 99/30399
Int. Cl.7 H02G 7/00
Tyco Electronics Corporation,
Middletown, Pa., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
‫מכסה להגנה מפני קצר בקוי מתח חשמלי‬
[33] US
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] A flashover protection cover (10) for
an electrical power line, comprising: a
flexible panel (12) having an inner surface
(12a) and generally parallel opposite edge
portions (14a, 14b) said edge portions
being configured to be joined together to
form a first longitudinally extending
chamber (16); and a longitudinally
extending first wall (18) connected along
an edge portion (18a) of said first wall to
said inner surface and having an opposite
free edge portion, wherein said first wall is
longitudinally coextensive with said first
longitudinally extending chamber, said
first wall configured to form a second
longitudinally extending chamber (20)
within said first chamber when said panel
edge portions are joined together, wherein
said second longitudinally extending
chamber is configured to enclose an
electrical power line (22), and wherein said
second longitudinally extending chamber
is longitudinally coextensive with said first
longitudinally extending chamber; and a
second wall (24) connected along an edge
portion of said second wall to said inner
surface and having an opposite free edge
portion (24b), wherein said second wall is
longitudinally coextensive with said first
longitudinally extending chamber.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1036
[11] [21] 136044
‫–אמינואצטאמיד ותכשירי רוקחות‬2 ‫תולדות‬
‫המכילים אותן‬
[54]
2-AMINOACETAMIDE
DERIVATIVES AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
[22]
[31]
[87]
[51]
20.11.1998
60/066707
[32] 21. 11.1997
[33] US
WO 99/26614
Int. Cl.7 C07C 237/04, 237/14, 237/16, 237/20, 237/28, 237/48, 317/26, 323/23; C07D
211/36, 213/62, 215/16, 309/12, 313/48; A61K 31/165, 31/35, 31/36, 31/395; A61P
29/00
Euro-Celtique S.A., Luxembourg
Wolff, Bregman and Goller,
,‫ ברגמן וגולר‬,‫וולף‬
P.O.B. 1352, Jerusalem
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[71]
[74]
[57] A pharmaceutical composition for
treating or ameliorating pain in a mammal,
comprising an effective amount of a
compound having the formula
or a pharmaceutically acceptable salt or
prodrug thereof, wherein: R1 R2, R3 and R4
are independently hydrogen, alkyl,
cycloalkyl, alkenyl, alkynyl, haloalkyl,
aryl, aminoalkyl, hydroxyalkyl,
alkoxyalkyl or carboxyalkyl; R5, R6 and R7
are independently hydrogen, alkyl,
cycloalkyl, alkenyl, alkynyl, haloalkyl,
aryl, aminoalkyl, hydroxyalkyl,
alkoxyalkyl or carboxyalkyl, or R5, is
defined as above, and R6 and R7 together
with the nitrogen atom to which they are
attached form a heterocycle;
A1 and A2 are independently aryl,
heteroaryl, saturated or partially
unsaturated carbocycle or saturated or
partially unsaturated heterocycle, any of
which is optionally substituted;
X is O, S, NR8, CH2, NR8C(O), C(O)NR8,
SO, SO2 or a covalent bond; where
R8 is hydrogen, alkyl, cycloalkyl, alkenyl,
alkynyl, haloalkyl, aryl, aminoalkyl,
hydroxyalkyl, alkoxyalkyl or
carboxyalkyl; and n is 0, 1, 2 or 3,
as active ingredient therein in combination
with a pharmaceutically acceptable carrier.
__________
1037
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 136057
‫תהליך רציף למיצוי של פוליאמידים‬
[54]
CONTINUOUS POLYAMIDE
EXTRACTION PROCESS
[22]
[31]
[87]
[51]
[71]
24.11.1998
19752182.7
[32] 25. 11.1997
WO 99/26998
Int. Cl.7 C08F 69/16, 69/46
BASF Aktiengesellschaft,
Ludwigshafen, Germany
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] A process for continuous extraction
of polyamide particles in an essentially
vertical extraction column using an
aqueous extractant, which comprises using
an extraction column that is divided into
two zones and performing an extraction
with a recirculating 15-40% strength by
weight aqueous ε-caprolactam solution in
[33] DE
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
the first zone and then with countercurrent
water in the second zone, the diameter of
the extraction column in the first zone
being greater than that in the second zone
and the transition from the first to the
second zone being equipped with a flow
barrier.
__________
[11] [21] 136067
[54]
ROAD INTERSECTION
SYSTEMS ON DIFFERENT
LEVELS
[22]
[31]
[87]
[51]
[71]
[74]
17.11.1998
1997/61140
[32] 19. 11.1997
WO 99/26211
Int. Cl.7 E01C 1/04
Lee Jang Hee, Seoul, Korea
Dr. Mark Friedman Ltd.,
7 Haomanim St., Tel Aviv
[57] An intersection system, comprising:
a plate-shaped road, on each of upper (P1)
and lower (P2) levels, respectively, at a
central section of an intersection, each
having left and right turns for opposing
traffic onto entrance roads; half-mainroads (55, 57) in two respective directions,
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫מערכות צומת כבישים במפלסים שונים‬
[33] KR
,‫ד"ר מרק פרידמן בע"מ‬
‫ תל אביב‬,7 ‫רח' האומנים‬
and in two other directions (61, 62) being
connected to edges of the plate-shaped
roads of said upper level and lower level,
respectively; said half-main-road on the
upper level and those of the lower level,
being in different directions with respect to
each other in a plane, and said entrance
1038
road of the upper level and those of the
lower level, being in different directions as
well; one or more one-way roads (51, 53)
constituting half-main-roads or entrance
roads (63, 64) having a sloping section;
said entrance roads being connected to
either of the one-way roads of the upper or
lower level, traffic moving in a same
direction of said entrance roads; traffic
lights at said plate-shaped roads of the
upper and lower levels, and at the
respective one-way road entrance roads,
for the benefit of the traffic entering from
respective directions therein.
__________
[11] [21] 136101
‫תכשירי רוקחות המכילים חומצה אזילאית‬
[54]
PHARMACEUTICAL
COMPOSITIONS CONTAINING
ZAELAIC ACID
[22]
[31]
18.11.1998
19753044.3
[32] 19.11.1997
[33] DE
60/074850
12.2.1998
US
19808086.7
20.2.1998
DE
WO 99/25332
Int. Cl.7 A61K 31/23, 47/00; A61P 17/00, 17/10// C07C 55/18
Schering Aktiengesellschaft, Berlin,
Germany
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[87]
[51]
[71]
[74]
[57] Composition that comprises the
following features:
(i) azelaic acid as a therapeutic active
ingredient,
(iii) triacylglycerides,
(iv) propylene glycol, and
(v) polysorbates
(vii) in an aqueous phase that comprises
water and salts,
1039
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
characterized in that the composition
comprises
(ii) polyacrylic acid, and
(vi) lecithin
as further additives, wherein the lecithin is
present in the composition at a
concentration of up to 4% by weight, and
that the composition is a hydrogel.
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 136268
[54]
METHOD AND APPARATUS FOR
OBTAINING TRANSMIT
DIVERSITY USING SWITCHED
ANTENNAS
[22]
[31]
30.11.1998
60/067247
[32] 7.12.1997
114036
10.7.1998
WO 99/29050
Int. Cl.7 H04B 7/02, 7/06
Qualcomm Incorporated, San Diego,
Calif., U.S.A.
Sanford T. Colb & Co.,
P.O.B. 2273, Rehovot
[87]
[51]
[71]
[74]
[57] A communication apparatus with
transmit diversity, comprising: a bit stream
signal generator (20) that generates bit
stream signals (Q), punctures power
control symbols (22) into message symbols
in the bit stream signals, and errorcorrection encodes the message symbols;
an orthogonal code generator (25) coupled
to the bit stream signal generator to
generate coded signals in a plurality of
code channels and a control signal to
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫שיטה והתקן להשגת שידור מגוון באמצעות‬
‫אנטנות ממותגות‬
[33] US
"
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ת‬
indicate a boundary of a code sequence; at
least one switch coupled to the orthogonal
code generator to switch the coded signals
between at least two output signal paths in
response to the control signal; and at least
two antennas (34, 36) disposed on said at
least two output signal paths to transmit
the coded signals alternately in a plurality
of time intervals, each of the time intervals
being an integral multiple of a time period
of the code sequence.
1040
__________
[11] [21] 136282
[54]
OXIME DERIVATIVES AND
PESTICIDAL COMPOSITIONS
CONTAINING THE SAME
[22]
[31]
[87]
[51]
[71]
9.12.1998
9/339790
[32] 10.12.1997
WO 99/29689
Int. Cl.7 C07D 413/12, A01N 43/82, 417/12
Dainippon Ink and Chemicals, Inc.,
Tokyo and Sagami Chemical Research
Center, Kanagawa, both of Japan
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[74]
‫תולדות אוקסים ותכשירים קולטי חרקים‬
‫המכילים אותן‬
[33] JP
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
[57] Oxime derivatives of the formula
wherein, R1 represents a hydrogen atom or
a lower alkyl group; X represents a
halogen atom, a nitro group, a hydroxyl
group, a cyano group, a carboxyl group, an
alkoxy-carbonyl group, a lower alkyl
group which may be substituted with
halogen atoms; a lower alkoxy group
which may be substituted with halogen
atoms; a lower alkylthio group which may
be substituted with halogen atoms; a lower
alkylsulfonyl group which may be
substituted with a halogen atom; an aryl
group which may be substituted with a
halogen atom or a lower alkyl group; an
aryloxy group which may be substituted
with a halogen atom or a lower alkyl
group; or an amino group which may be
1041
substituted with a lower alkyl group; and
n represents an integer from 0 to 3; and
Het A represents a 6-membered aromatic
nitrogen-containing ring which contains
one or two nitrogen atoms or its benzocondensation ring-type nitrogen containing
aromatic ring which may be substituted
with one or two substitutable groups
selected from the group consisting of a
halogen atom, a lower alkyl grup, a lower
alkylthio group, a lower alkylsulfonyl
group, a lower alkoxy group, a lower
alkoxy group, a trifluoromethyl group, and
a cyano group; and Het B represents oxime
derivatives, each ring structure, expressed
by the following formulas:
August 31, 2005– ‫כ"ו באב התשס"ה‬
wherein, Y represents a hydrogen atom, a
halogen atom or a lower alkyl group which
may be substituted with a halogen atom.
___________
[11] [21] 136313
[54]
LONG ACTING INJECTABLE
FORMULATIONS CONTAINING
HYDROGENATED CASTOR OIL
[22]
[31]
14.9.1998
60/067374
[32] 3.12.1997
9809792.6
7.5.1998
WO 99/27906
Int. Cl.7 A61K 9/08, 47/14, 47/44
Merck & Co. Inc., Rahway and Merial
LLC, Iselin, both of N.J., U.S.A.
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[87]
[51]
[71]
[74]
[57] A long-acting injectable formulation
comprising:
(a) a therapeutic agent selected from the
group consisting of insecticides,
acaricides, parasiticides, growth enhancers
and oil-soluble NASIDS,
(b) hydrogenated castor oil, and
‫הרכבים להזרקה עמידים לאורך זמן‬
‫המכילים שמן קיק רווי‬
[33] US
GB
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
(c) a hydrophobic carrier comprising:
(i) triacetin, benzyl benzoate or ethyl
oleate or a combination thereof; and
(ii) acylated monoglycerides, propyl
dicaprylates/dicaprates, caprylic/capric
acid triglycerides, or a combination
thereof.
_________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1042
[11] [21] 136350
[54]
METHOD AND SYSTEM FOR
BILLING IN A NETWORK
[22]
[51]
[71]
25.5.2000
Int. Cl.7 G06F 17/60; H04M 17/00
Lead IP Systems Ltd., Teradion
Industrial Park
[72]
[74]
Shlomo Inbar and Eldad Caspi
G.E. Ehrlich (1995) Ltd.,
11 Menachem Begin St., Ramat Gan
[57] A network billing method for users,
each user having a local area network and
a connection device (3) for connecting said
local area network in peer-to-peer
connections to nodes external to said local
area network, comprising the following
steps:
‫שיטה ומערכת לחיובים ברשת‬
‫ אזור תעשייה‬,‫ליד אי פי סיסטמנס בע"מ‬
‫תרדיון‬
‫שלמה ענבר ואלדד כספי‬
,‫) בע"מ‬1995( ‫ ארליך‬.‫א‬.‫ג‬
‫ רמת גן‬,11 ‫רח' מנחם בגין‬
(a) installing a monitoring device (5, 6) in
said connection device for monitoring
peer-to-peer usage information;
(b) configuring said monitoring device to
connect to a remotely located billing server
(7) in the network; and
(c) reporting said peer-to-peer usage
information to said billing server.
__________
1043
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 136422
‫בקבוק לתינוק‬
[54]
BABY BOTTLE
[22]
[31]
[51]
[71]
29.5.2000
9903000011
[32] 1. 6.1999
Int. Cl.7 A61J 9/00
Thawee Eksuwancharoen, Bangkok,
Thailand
Anupongse Tantiroongrojchai
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[72]
[74]
[57] A baby bottle comprising: a
cylindrically shaped main body (1, 3)
whose top end in open and bottom end (4)
is closed;
a cylindrically shaped linking wall whose
ends are both open; a cylindrically shaped
neck whose ends are both open; wherein
the angle that is formed when the axis (8)
that passes the center of the diameter of
said main body is connected with the axis
that passes the center of the diameter of
[33] TH
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
said linking wall of said bottle is equal to
the angle that is formed when the top part
of the axis that passes the center of the
diameter of said linking wall is connected
with the axis that passes the center of the
diameter of said neck of said bottle; and,
wherein the top part of said neck of said
bottle is used for filling milk or liquid food
and for assembling with the nipple (6) and
the screw cover (5).
__________
[11] [21] 136591
[54]
NASAL PHARMACEUTICAL
SOLUTIONS
[22]
[31]
[87]
[51]
[71]
28.1.1999
98810069.9
[32] 30. 1.1998
WO 99/38492
Int. Cl.7 A61K 9/00
Novartis Consumer Health S.A., Nyon,
Switzerland
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[74]
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫תמיסות תרופתיות לאף‬
[33] EP
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
1044
[57] A liquid nasal pharmaceutical
composition, and which is selected from
composition which comprises
water and mixtures of water with
(a) one or more active substances suitable
propylene glycol, water with glycerol and
for nasal administration and selected from
water with both propylene glycol and
the group consisting of vasoconstrictors,
glycerol, whereby in all said mixtures
antiallergic agents and corticosteroids;
water is present in an amount of at least
(b) sorbitol;
95% (m/V); and
(c) a water-soluble C1-C4-alkyl-cellulose
(e) optionally one or more nasally
derivative;
acceptable excipients.
(d) a vehicle which is present in an amount
of at least 90% (m/V) of the total
__________
[11] [21] 136823
‫צורת מינון פרמצבטית למתן דרך הפה‬
‫בעלת שחרור פועם‬
[54]
ORAL PHARMACEUTICAL
PULSED RELEASE DOSAGE
FORM
[22]
[31]
[87]
[51]
[71]
[72]
[74]
17.12.1998
9704870-6
[32] 22. 12.1997
[33] SE
WO 99/32093
Int. Cl.7 A61K 9/26, 26/54//C07D 401/12, 405/14, 495/02, 235/22
AstraZeneca AB, Sodertalje, Sweden
Per Johan Lundberg and Brita Sjoblom
Luzzatto & Luzzatto,
,‫לוצאטו את לוצאטו‬
P.O.B. 5352, Beersheba
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
[57] An enteric coated pharmaceutical
dosage form giving a discontinuous release
of a H+, K+-ATP ase inhibitor,
characterized in that the release of the
H+,K+ATP ase inhibitor is in the form of at
least two consecutive pulses separated in
time by form 0.5 and up to 12 hours, and at
least one fraction of the dosage form has a
1045
pulsed delayed release and another fraction
has instant release, and the H+, K+-ATP
ase inhibitor is a compound with the
formula I, an alkaline salt of compound I, a
single enantiomer of compound I or an
alkaline salt of the single enantiomer of
compound I
August 31, 2005– ‫כ"ו באב התשס"ה‬
wherein
N in the benzimidazole moiety means that
one of the ring carbon atoms substituted by
R6-R9 optionally may be exchanged for a
nitrogen atom without any substituents;
R1, R2 and R3 are the same or different and
selected from hydrogen, alkyl, alkoxy
optionally substituted by fluorine,
alkylthio, alkoxyalkoxy, dialkylamino,
piperidino, morphilino, halogen, phenyl
and phenylalkoxy;
R4 and R5 are the same or different and
selected from hydrogen, alkyl and
arylalkyl;
R6' is hydrogen, halogen, trifluoromethyl,
alkyl or alkoxy;
R6-R9 are the same or different and
selected from hydrogen, alkyl, alkoxy,
halogen, halo-alkoxy, alkylcarbonyl,
alkoxycarbonyl, oxazolinyl, and
trifluoroalkyl, or adjacent groups
R6-R9 form ring structures which may be
further substituted;
R10 is hydrogen or forms an alkylene chain
together with R3 and R11 and R12 are the
same or different and selected from
hydrogen, halogen or alkyl.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1046
[11] [21] 136828
‫צורה פולימורפית גבישית של אסטר‬
– p – 5 – ‫ – מתיל‬1 ‫גואיאציל של חומצת‬
‫ – אצטאמידואצטית‬2 – ‫טולואילפירול‬
(MED 15)
[54]
CRYSTALLINE POLYMORPHIC
FORM OF 1-METHYL-5-pTOLUOYLPYRROLE-2ACETAMIDOACETIC ACID
GUAIACYL ESTER (MED 15)
[22]
[31]
[87]
[51]
[71]
16.12.1998
RM97A000811
[32] 24. 12.1997
[33] IT
WO 99/33797
Int. Cl.7 C07D 207/37; A61K 31/40; A61P 25/04, 29/00
Sigma-Tau Industrie Farmaceutiche
Riunite S.p.A., Rome and Medosan
Industrie Biochimiche Riunite S.R.L.,
Cecchina di Albano, both of Italy
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[74]
[57] 1-Methyl-5-p-toluoylpyrrole-2acetamidoacetic acid guaiacyl ester in new
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
crystalline form (MED 15, form 2) of the
formula
characterised by the following physicochemical characteristics: melting point:
133-136oC;
DSC
Peak
136.2C
136.7oC
o
Onset
132.5 C
133.7oC
Delta H
97.3.J/g
98.3 J/g
IR spectrum (presenting characteristic
signals at the following wave numbers in
cm-1)
3302.98
3092.37
2948.24
2842.00
1785.85
1762.26
1646.73
1626.80
1607.82
1564.93
1550.27
1501.85
1480.85
1458.18
1377.94
1310.86
1262.66
1202.46
1179.67
1162.83
1113.95
1037.43
1022.34
976.95
885.21
833.34
788.30
769.16
749.21
729.28
699.06
620.38
576.81 cm -1
__________
1047
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 137165
‫שיטה להכנת פוליאמידים מאמינוניטרילים‬
[54]
METHOD FOR PRODUCING
POLYAMIDES FROM
AMINONITRILES
[22]
[31]
[87]
[51]
[71]
2. 2.1999
19804020.2
[32] 2. 2.1998
[33] DE
WO 99/38907
Int. Cl.7 C08G 69/04, 69/08, 69/16, 69/18; C08J 11/04
BASF Aktiengesellschaft,
Ludwigshafen, Germany
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] A process for producing polyamides
by reacting at least one aminonitrile with
aqueous monomer and oligomer extracts
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
obtained from polyamide production by
extraction of the polymer with water.
__________
[11] [21] 137305
[54]
METHOD AND SYSTEM FOR
SHARING KNOWLEDGE
[22]
[51]
[71]
13. 7.2000
Int. Cl.7 G06N 5/02; G06F 17/30
ClickSoftware Technologies Ld., Tel
Aviv
Israel Beniaminy and Moshe Benbassat
Luzzatto & Luzzatto,
P.O.B. 5352, Beersheba
[72]
[74]
[57] A method for sharing knowledge
among a pluraliuty of individuals,
comprising:
(a) providing a dynamically updated
knowledge base system that can be
accessed over a network;
(b) allowing an individual encountering a
problem the solution of which is not
known, to query said knowledge base
system to determine whether the problem
and its solution are found in it;
(c) if the solution to the problem is not
available in said knowledge base system,
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫שיטה ומערכת לשיתוף בידע‬
‫אביב‬-‫ תל‬,‫קליקסופטוור טכנולוגיות בע"מ‬
‫ישראל בנימיני ומשה בן בסט‬
,‫לוצאטו את לוצאטו‬
‫שבע‬-‫ באר‬,5352 .‫ד‬.‫ת‬
allowing said individual to prepare a query
including the details of the problem;
(d) broadcasting said query described in
step (c) over said network;
(e) allowing the experts who "listen in"
said network to answer the query by
filling-in their reply to the query form, and
if desired, also by additional person-toperson communication;
(f) conveying the answer to the query via
the network to the individual who queried
the system;
1048
(g) optionally, once the problem has been
solved, or when the suggestions have
produced no positive result, reporting by
said individual the outocome of the query
to the system, thereby to complete the
dialogue between the individual and the
system;
(h) adding to the knowledge base system,
and making part of it, the dialogue, the
problem, and information on the
suggestion that led to the solution of the
problem;
(i) reusing the knowledge contributed in
steps (a) to (g) when similar problems
subsequently arise, so that they are
completely solved at steps (b); and
(j) keeping track of the knowledge
contributed by each expert, and subsequent
cases solved by such knowledge, as a tool
for performance monitoring and incentive
generation.
__________
[11] [21] 137342
[54]
RETICLE DEVICE FOR
OPTICAL SIGHTING SYSTEM
[22]
[31]
[51]
[71]
18. 7.2000
9909512
[32] 22. 7.1999
Int. Cl.7 F41G 3/00; G02B 7/32
Aerospatiale Matra Missiles, Paris,
France
Seligsohn Gabrieli Levit & Co.,
P.O.B. 1426, Tel-Aviv
[74]
1049
‫התקן של רשתית עבור מערכת ראייה‬
‫אופטית‬
[33] FR
,'‫זליגסון גבריאלי לויט ושות‬
‫אביב‬-‫ תל‬,1426 .‫ד‬.‫ת‬
August 31, 2005– ‫כ"ו באב התשס"ה‬
[57] An optical sighting system (1)
comprising: at least one optical channel
(21); and at least one reticle (3) associated
with said at least one optical channel,
wherein said at least one reticle comprises
at least one mark (4A) which is visible to
an observer using said optical sighting
system and which is centered
approximately about a centering point (P)
situated substantially at a distance (D)
which is representative of a sighting angle
of between 13o and 18o, with respect to a
predetermined direction of observation
(O), according to a first direction, said first
direction being representative on said
optical sighting system of a direction
passing substantially by the centers of the
eyes of an observer who is using said
optical sighting system, and wherein said
at least one mark exhibits a shape of an
ellipse whose minor axis is oriented along
said first direction and exhibits a length
(L1) representative of a sighting angle of
7o and whose major axis is oriented along
a second direction orthogonal both to said
first direction and to said direction of
observation (O) and exhibits a length (L2)
representative of a sighting angle of 8o.
__________
[11] [21] 137364
[54]
PROCESS FOR THE
PREPARATION OF 6,6DIMETHYLHEPT-1-EN-4-YN-3OL
[22]
[51]
[71]
[72]
18. 7.2000
Int. Cl.7 C07C 29/42, 33/048
Chemagis Ltd., Tel-Aviv
Joseph Kaspi, Oded Friedman and
Edna Danon
Wolff, Bregman and Goller,
P.O.B. 1352, Jerusalem
[74]
August 31, 2005– ‫כ"ו באב התשס"ה‬
–4–‫–אן‬1–‫–דימתילהפט‬6,6 ‫תהליך להכנת‬
‫–אול‬3–‫אין‬
‫אביב‬-‫ תל‬,‫כימאגיס בע"מ‬
‫ עודד פרידמן ועדנה דנון‬,‫יוסף כספי‬
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ת‬
1050
[57] A process for the preparation of 6,6dimethylhet-1-en-4-yn-3-ol comprising
(i) reacting t-butylacetylene with a protonextracting agent selected from the group
consisting of an organometallic compound
and metallic lithium to form a tbutylacetylide, wherein said
organometallic compound has the formula
R2Li where R2 is an alkyl or aryl group;
(ii) reacting said acetylide with acrolein at
temperatures between -40oC to +20oC;
(iii) quenching the reaction mixture; and
(iv) isolating the product.
_______________
[11] [21] 137472
[54]
MICROPARTICLE INHALATION
FORMULATIONS
[22]
[31]
[87]
[51]
[71]
30. 12.1998
016265
[32] 30. 1.1998
WO 99/38493
Int. Cl.7 A61K 9/50, 9/127, 47/06
Skyepharma Canada Inc., Verdun,
P.Q., Canada
Iskandar Moussa and Indu Parikh
Jeremy M. Ben-David & Co. Ltd.,
P.O.B. 45087, Jerusalem
[72]
[74]
‫תכשירים לשאיפה המכילים חלקיקים‬
[33] US
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,45087 .‫ד‬.‫ת‬
[57] A dry suspension aerosol
tetrafluoroethane HFA134a or
formulation having a density in the range
1,1,1,2,3,3,3-heptafluoropropane HFA 227
of from 1.0 to 1.5 g/ml consisting
propellant, wherein the density of the
essentially of stabilized drug microcrystals
coated drug microparticles substantially
in a mean size range of 0.1 to 10 microns
matches the density of the propellant and
as a core coated with an envelope of one or
the amount of phospholipids coating on the
more membrane-forming phospholipids
drug microparticles is more than 0.1% and
and at least one surfactant surrounding the
less than 200% of the weight of the drug.
drug core and dispersed in 1,1,1,2__________
1051
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 137477
[54]
BUNDLED CONDUCTOR FOR
ELECTRICAL LINE
[22]
[51]
[71]
24. 7.2000
Int. Cl.7 H02G 7/20
The Israel Electric Corporation Ltd.,
Haifa
Arie-Leib Tukachinsky and Felix
Kaidanov
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[72]
[74]
[57] A bundled phase conductor for an
overhead high voltage power line, said
bundled phase conductor comprising at
least two electrically interconnected
subconductors; characterized in that: said
at least two electrically interconnected
subconductors include one or more main
subconductors (11) having sufficient
electrical conductivity and combined
cross-section for conducting rated current
and at least one weight-bearing
‫מוליך אלום עבור קו חשמלי‬
‫ חיפה‬,‫חברת החשמל לישראל בע"מ‬
‫לייב טוקצ'ינסקי ופליקס קיידנוב‬-‫אריה‬
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
subconductor (10) having significantly
lower electrical conductivity than the main
subconductors; said main and weightbearing subconductors being mechanically
configured so that a sag of the bundled
phase conductor owing to heating caused
by current flowing through said
subconductors is substantially limited to
the sag of the at least one weight-bearing
subconductor.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1052
[11] [21] 137534
‫תהליך להכנת תרכובות סטילבן‬
[54]
PROCESS FOR THE
PREPARATION OF STILBENE
COMPOUNDS
[22]
[31]
[87]
[51]
[71]
13 2.1999
98810140.8
[32] 20. 2.1998
[33] EP
WO 99/42454
Int. Cl.7 C07D 251/68, 401/02, 403/02, 413/02; D06L 3/12
Ciba Specialty Chemicals Holding Inc.,
Basle, Switzerland
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] Process for the preparation of a 4,4'bis-(triazinylamino)-stilbene-2,2'disulphonic acid of the formula
characterized in that
(a) in a first reaction step cyanuric chloride
is reacted with the disodium salt of 4,4'-
diaminostilbene-2,2'-disulfonic acid to
give the intermediate of the formula
(b) in a second reaction step the compound
of formula (2) is reacted with a compound
of formula R1H and R2-H to give the
compound of the formula
1053
August 31, 2005– ‫כ"ו באב התשס"ה‬
(c) in a third step the compound of formula
(3) is reacted with the compound of the
formula R3H, and reaction step (a) and/or
(c) are carried out in a medium consisting
of a mixture of water and polyglycol to
give the compound of formula (1),
wherein R1, R2 and R3, independently, are
phenylamino; phenylamino substituted by
C1-C3 alkyl, halogen, cyano, COOR or
COR; CONH-R; SO2NH-R; NH-COR;
mono-or disulphonated phenylamino;
morpholino; piperidino; pyrrolidino;-NH2;
-NH(C2-C4 hydroxyalkyl); -N(C2-C4
hydroxyalkyl)2; -N(C1-C4 alkyl) (C2-C4
hydroxyalkyl); NHC2-C4 alkylsulphonic
acid; -OC1-C4 alkyl; an aminoacid or
aminoacid amide residue from which a
hydrogen atom on the amino group has
been removed; or a polyethyleneglycol
from which a hydrogen atom of the –OHgroup was removed;
R is hydrogen; or C1-C3 alkyl; and
M is H or Na.
__________
[11] [21] 137586
[54]
DSP FOR TWO CLOCK CYCLE
CODEBOOK SEARCH
[22]
[31]
[51]
[71]
[72]
[74]
30.7.2000
368317
[32] 3. 8.1999
Int. Cl.7 G10L 19/12; H03M 7/00
Ceva D.S.P. Ltd., Herzlia Pituach
Gil Vinitzki
Eitan, Pearl, Latzer & CohenZedek, 7 Shenkar St., Herzliya
[57] A device for performing a search for
the optimum code vector in a codebook
having N code vectors indexed by i, the
device comprising: a general purpose
processor; and
August 31, 2005– ‫כ"ו באב התשס"ה‬
‫עבוד אות דיגיטלי עבור חיפוש במערך‬
‫דגימות בשני מחזורי מכונה‬
[33] US
‫ הרצליה פיתוח‬,‫פי בע"מ‬.‫אס‬.‫סיוה די‬
‫גיל ויניצקי‬
,‫צדק‬-‫ לצר וכהן‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,7 ‫רח' שנקר‬
a controller which provides each ith code
vector to said processor, wherein said
processor determines in two clock cycles
whether said ith code vector is a current
optimal code vector.
1054
__________
[11] [21] 137675
‫שיטה לייצור פוליאמידים‬
[54]
METHOD FOR PRODUCING
POLYAMIDES
[22]
[31]
[87]
[51]
[71]
22.2.1999
19808190.1
[32] 26. 2.1998
WO 99/43735
Int. Cl.7 C08G 69/14, 69/28
BASF Aktiengesellschaft,
Ludwigshafen, Germany
Reinhold Cohn and Partners,
P.O.B. 4060, Tel-Aviv
[74]
[57] A process for producing polyamides
by polymerization of lactams in the
presence of metal oxides as heterogeneous
catalysts, wherein the metal oxide catalysts
are used in the form of pellets, extrudates,
fixed beds or catalyst-coated packing
elements or internals, which permits
[33] DE
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
mechanical removal from the reaction
mixture and being removed from the
reaction mixture in the course of or on
completion of the polymerization, wherein
the reaction is carried out in the presence
of less than 10% by weight of water, based
on the entire reaction mixture.
__________
1055
August 31, 2005– ‫כ"ו באב התשס"ה‬
[11] [21] 137677
‫ תהליך‬,‫תולדות אמינו אנתראציקלינון‬
‫להכנתן והשימוש בהן להכנת תרופה‬
‫לטיפול בעמילואידוזיס‬
[54]
AMINO ANTHRACYCLINONE
DERIVATIVES, A PROCESS FOR
THEIR PREPARATION AND
THEIR USE IN THE
PREPARATION OF A
MEDICAMENT FOR THE
TREATMENT OF AMYLOIDOSIS
[22]
[31]
[87]
[51]
[71]
[74]
25 2.1999
9805080.0
[32] 10. 3.1998
[33] GB
WO 99/46254
Int. Cl.7 C07D 211/70, 401/10, 405/06, 413/10; A61K 31/65; A61P 25/28
Pharmacia & Upjohn SpA, Milan, Italy
Reinhold Cohn and Partners,
,‫ריינהולד כהן ושותפיו‬
P.O.B. 4060, Tel-Aviv
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
[57] Compounds of the formul
wherein R1 represents:
hydrogen, hydroxy,
a group of formula OR7 wherein R7 is C1C6 alkyl, C2-C6 alkenyl;
R2 represents:
hydrogen, hydroxy,
diethylamino, piperidino,
tetrahydropyridino or morpholino;
and either R3, taken alone, represents
hydrogen or hydroxy, and R4 and R5, when
taken alone, independently represent
hydrogen, hydroxy or, taken together with
the carbon atom, represent a carbonyl
group; or R3 and R4, taken together,
represent a group of formula
wherein R8 and R9 represent a C1-C6 alkyl
acceptable salts thereof; with the proviso
and R5 represents hydrogen;
that in case R6 is a phenyl group
R6 represents:
substituted by halogen, fluorine is
hydrogen or a phenyl group, optionally
excluded and further when R4 and R5 are H
substituted by methyl, methoxy or
and OH or when both are H, R6 may not be
halogen; and the pharmaceutically
H.
__________
August 31, 2005– ‫כ"ו באב התשס"ה‬
1056
Download